0001079973-22-001425.txt : 20221114 0001079973-22-001425.hdr.sgml : 20221114 20221114081033 ACCESSION NUMBER: 0001079973-22-001425 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BION ENVIRONMENTAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000875729 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 841176672 STATE OF INCORPORATION: CO FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19333 FILM NUMBER: 221380493 BUSINESS ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 BUSINESS PHONE: (212) 758-6622 MAIL ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 FORMER COMPANY: FORMER CONFORMED NAME: RSTS CORP DATE OF NAME CHANGE: 19930328 10-Q 1 bion_10q-093022.htm FORM 10-Q
0000875729 false --06-30 2023 Q1 0000875729 2022-07-01 2022-09-30 0000875729 2022-11-01 0000875729 2022-09-30 0000875729 2022-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2022-09-30 0000875729 us-gaap:SeriesBPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-09-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-09-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-06-30 0000875729 2021-07-01 2021-09-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-06-30 0000875729 us-gaap:CommonStockMember 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-06-30 0000875729 2021-06-30 0000875729 us-gaap:CommonStockMember 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-07-01 2021-09-30 0000875729 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000875729 bnet:SubscriptionsReceivableMember 2021-07-01 2021-09-30 0000875729 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-07-01 2022-09-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-07-01 2022-09-30 0000875729 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000875729 bnet:SubscriptionsReceivableMember 2022-07-01 2022-09-30 0000875729 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-09-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-09-30 0000875729 us-gaap:CommonStockMember 2021-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000875729 bnet:SubscriptionsReceivableMember 2021-09-30 0000875729 us-gaap:RetainedEarningsMember 2021-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-09-30 0000875729 2021-09-30 0000875729 us-gaap:CommonStockMember 2022-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000875729 bnet:SubscriptionsReceivableMember 2022-09-30 0000875729 us-gaap:RetainedEarningsMember 2022-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-09-30 0000875729 bnet:RibbonwireMember 2022-07-01 2022-09-30 0000875729 2020-07-01 2021-06-30 0000875729 2021-07-01 2022-06-30 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2022-09-30 0000875729 srt:MaximumMember 2022-09-30 0000875729 bnet:CenterpointMember 2022-09-30 0000875729 us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 us-gaap:WarrantMember 2021-07-01 2021-09-30 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2022-09-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2021-09-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2022-07-01 2022-09-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2021-07-01 2021-09-30 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2022-07-01 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2021-09-30 0000875729 bnet:BassaniMember 2021-09-30 0000875729 bnet:SmithMember 2021-09-30 0000875729 bnet:ConsultantsMember 2022-09-30 0000875729 bnet:ConsultantsMember 2021-09-30 0000875729 bnet:SmithMember 2022-09-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-07-01 2022-09-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-07-01 2021-09-30 0000875729 bnet:PennvestLoanMember 2022-09-30 0000875729 2021-12-29 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2022-07-01 2022-09-30 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2022-07-01 2022-09-30 0000875729 bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2020-07-01 2021-06-30 0000875729 bnet:PA1Member 2014-09-25 0000875729 bnet:PA1Member 2022-06-01 2022-06-15 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember srt:ChiefExecutiveOfficerMember 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember srt:PresidentMember 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember bnet:ExecutiveViceChairmanMember 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember srt:ChiefExecutiveOfficerMember 2021-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember srt:PresidentMember 2021-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember bnet:ExecutiveViceChairmanMember 2021-09-30 0000875729 bnet:The2020ConvertibleObligationsMember 2022-07-01 2022-09-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2022-09-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:CommonSharesMember 2022-07-01 2022-09-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2022-07-01 2022-09-30 0000875729 bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2022-09-30 0000875729 bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member bnet:CommonSharesMember 2022-07-01 2022-09-30 0000875729 bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2022-09-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2022-09-30 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2022-09-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2021-09-30 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2021-09-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2021-09-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-02 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-03 0000875729 us-gaap:SeriesBPreferredStockMember 2014-06-25 2014-07-01 0000875729 us-gaap:SeriesBPreferredStockMember 2022-07-01 2022-09-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-07-01 2021-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember bnet:PrincipalMember 2022-07-01 2022-09-30 0000875729 us-gaap:ConvertibleDebtMember bnet:AccruedInterestMember bnet:The2020ConvertibleObligationsMember 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000875729 us-gaap:ConvertibleDebtMember bnet:The2020ConvertibleObligationsMember 2022-09-30 0000875729 srt:PresidentMember 2022-09-30 0000875729 bnet:WarrantsMember 2022-09-30 0000875729 bnet:WarrantsMember 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember bnet:PrincipalMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 bnet:AccruedInterestMember us-gaap:WarrantMember bnet:The2020ConvertibleObligationsMember 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 us-gaap:ConvertibleDebtMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2022-09-30 0000875729 us-gaap:WarrantMember 2022-09-30 0000875729 bnet:TwoConsultantsMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 bnet:TwoConsultantsMember us-gaap:WarrantMember srt:MinimumMember 2022-09-30 0000875729 bnet:TwoConsultantsMember us-gaap:WarrantMember srt:MaximumMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-05-01 0000875729 us-gaap:EmployeeStockOptionMember bnet:EquityIncentivePlanMember 2022-09-30 0000875729 us-gaap:EmployeeStockOptionMember 2022-09-30 0000875729 bnet:Plan2006Member 2022-02-01 2022-02-11 0000875729 2022-04-01 2022-04-29 0000875729 bnet:SchaferMember 2022-04-01 2022-04-29 0000875729 bnet:NorthropMember 2022-04-01 2022-04-29 0000875729 bnet:BassaniMember 2022-04-01 2022-04-29 0000875729 bnet:SmithMember 2022-04-01 2022-04-29 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000875729 us-gaap:OptionMember 2022-07-01 2022-09-30 0000875729 us-gaap:OptionMember 2021-07-01 2021-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-09-30 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-09-30 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-09-30 0000875729 bnet:SmithsMember bnet:SecuredPromissoryNoteMember 2022-09-30 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2022-09-30 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-09-30 0000875729 srt:PresidentMember 2016-10-01 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2021-12-31 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2022-09-30 0000875729 2022-04-30 2022-05-01 0000875729 bnet:SmithMember 2022-07-01 2022-09-30 0000875729 bnet:SmithMember 2021-07-01 2021-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 bnet:BassaniMember srt:ScenarioForecastMember 2023-03-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-07-01 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-07-01 2021-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-07-01 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2021-07-01 2021-09-30 0000875729 2022-01-01 2022-01-28 0000875729 2022-03-02 2022-03-21 0000875729 2022-07-01 2022-07-05 0000875729 2022-03-02 2022-03-23 0000875729 bnet:PennvestLoanMember 2022-07-01 2022-09-30 0000875729 bnet:PennvestLoanMember 2021-07-01 2021-09-30 0000875729 us-gaap:SubsequentEventMember 2022-10-01 2022-10-28 0000875729 us-gaap:SubsequentEventMember 2022-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure bnet:Decimal

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2022

 

o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______ to _________

 

Commission File No. 000-19333

 

Bion Environmental Technologies, Inc.

(Name of registrant in its charter)

 

Colorado   84-1176672
(State or other jurisdiction of incorporation or formation)   (I.R.S. employer identification number)

 

9 East Park Court

Old Bethpage, New York 11804

(Address of principal executive offices)

 

516-586-5643

(Registrant’s telephone number, including area code) 

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Securities Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock BNET OTCQB

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x Yes o No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes o No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

    Large accelerated filer  o   Accelerated filer  o  
    Non-accelerated filer   Smaller reporting company  x  
    Emerging growth company   o      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes x No

 

 
 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS: Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Not applicable.

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

On November 1, 2022, there were 44,329,884 Common Shares issued and 43,625,575 Common Shares outstanding.

 

 

 

 

 

 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC.

 

FORM 10-Q

 

TABLE OF CONTENTS

 

PART I.  FINANCIAL INFORMATION   Page
       
Item 1.

Consolidated Financial Statements

 

  4
  Consolidated financial statements (unaudited):    
    Balance sheets   4
    Statements of operations   5
    Statement of changes in equity (deficit)   6
    Statements of cash flows   7
    Notes to unaudited consolidated financial statements   8-34
       
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations   35
       
Item 3. Quantitative and Qualitative Disclosures about Market Risk   43
       
Item 4. Controls and Procedures   43
       
PART II.  OTHER INFORMATION    
       
Item 1. Legal Proceedings   44
       
Item 1A. Risk Factors   46
       
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   46
       
Item 3. Defaults Upon Senior Securities   46
       
Item 4. Mine Safety Disclosures   46
       
Item 5. Other Information   46
       
Item 6. Exhibits   46
       
  Signatures   47

 

 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "project," "predict," "plan," "believe" or "continue" or the negative thereof or variations thereon or similar terminology. The expectations reflected in forward-looking statements may prove to be incorrect.

3 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

           
   September 30,   June 30, 
   2022   2022 
    (unaudited)      
           
ASSETS
           
 Current assets:          
 Cash  $1,897,981   $3,160,442 
 Prepaid expenses   134,253    157,550 
 Deposits and other assets   1,000    1,000 
           
 Total current assets   2,033,234    3,318,992 
           
 Operating lease right-of-use asset   132,881    145,787 
 Property and equipment, net (Note 3)   3,248,610    2,895,558 
           
 Total assets  $5,414,725   $6,360,337 
           
 LIABILITIES AND EQUITY (DEFICIT)
           
 Current liabilities:          
Accounts payable and accrued expenses  $549,425   $1,360,644 
Series B Redeemable Convertible Preferred stock, $0.01 par value, 50,000 shares authorized; 0 and 200 shares issued and outstanding, liquidation preference of $0 and $40,000, respectively (Note 7)            
 Deferred compensation (Note 4)   654,349    594,798 
 Loan payable and accrued interest (Note 5)            
           
 Total current liabilities   1,203,774    1,955,442 
           
 Operating lease liability   132,113    128,864 
 Convertible notes payable - affiliates (Note 6)   5,212,286    5,170,610 
           
 Total liabilities   6,548,173    7,254,916 
           
           
 Deficit:          
Bion's stockholders' equity (deficit):          
Series A Preferred stock, $0.01 par value, 50,000 shares authorized, no shares issued and outstanding            
Series C Convertible Preferred stock, $0.01 par value, 60,000 shares authorized; no shares issued and outstanding            
Common stock, no par value, 250,000,000 shares authorized, 44,303,654 and 43,758,820 shares issued, respectively; 43,599,345 and 43,054,511 shares outstanding, respectively            
Additional paid-in capital   124,300,604    123,620,046 
Subscription receivable - affiliates (Note 8)   (504,650)   (504,650)
Accumulated deficit   (124,966,975)   (124,047,548)
           
Total Bion's stockholders’ deficit   (1,171,021)   (932,152)
           
Noncontrolling interest   37,573    37,573 
           
Total deficit   (1,133,448)   (894,579)
           
Total liabilities and deficit  $5,414,725   $6,360,337 

 

See notes to consolidated financial statements

 

4 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021
(UNAUDITED)

         
   2022   2021 
         
Revenue  $      $    
         
Operating expenses:        
General and administrative (including stock-based compensation)   866,494    491,133 
Depreciation   330    248 
Research and development (including stock-based compensation)   28,443    61,809 
           
Total operating expenses   895,267    553,190 
           
Loss from operations   (895,267)   (553,190)
           
Other (income) expense:          
Interest income   (1,935)   (1,494)
Interest expense   26,095    112,180 
           
Total other expense   24,160    110,686 
           
Net loss   (919,427)   (663,876)
           
Net loss attributable to the noncontrolling interest         506 
           
Net loss applicable to Bion's common stockholders  $(919,427)  $(663,370)
           
Net loss applicable to Bion's common stockholders per basic and diluted common share  $(0.02)  $(0.02)
           
Weighted-average number of common shares outstanding:          
Basic and diluted   43,451,846    40,719,692 

 

See notes to consolidated financial statements

 

5 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
                                                               
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) 
                                                               
THREE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021
                                                               
(UNAUDITED)

 

                                             
Three months ended September 30, 2021  Bion's Stockholders'         
   Series A Preferred Stock   Series C Preferred Stock   Common Stock   Additional paid-in   Subscription Receivables for   Accumulated   Noncontrolling   Total 
   Shares   Amount   Shares   Amount   Shares   Amount   capital   Shares   deficit   interest   equity/(deficit) 
                                             
Balances, July 1, 2021        $           $      41,315,986   $      121,399,067   $(504,650)  $(132,339,873)  $39,117   $(11,406,339)
Warrants exercised for common shares   —            —            139,334          104,500                      104,500 
Commissions on warrant exercises   —            —            10,000          (1,000)                     (1,000)
Conversion of debt and liabilities   —            —            10,253          5,126                      5,126 
Net loss   —            —            —                        (663,370)   (506)   (663,876)
Balances, September 30, 2021        $           $      41,475,573   $     $121,507,693   $(504,650)  $(133,003,243)  $38,611   $(11,961,589)

 

                                             
Three months ended September 30, 2022  Bion's Stockholders'         
   Series A Preferred Stock   Series C Preferred Stock   Common Stock   Additional paid-in   Subscription Receivables for   Accumulated   Noncontrolling   Total 
   Shares   Amount   Shares   Amount   Shares   Amount   capital   Shares   deficit   interest   equity/(deficit) 
Balances, July 1, 2022        $           $      43,758,820   $     $123,620,046   $(504,650)  $(124,047,548)  $37,573   $(894,579)
Sale of units   —            —            320,000          320,000                      320,000 
Warrants exercised for common shares   —            —            74,834          56,125                      56,125 
Issuance of units for services   —            —            50,000          80,000                      80,000 
Issuance of warrants for services   —            —            —            15,000                      15,000 
Conversion of debt and liabilities   —            —            100,000          50,000                      50,000 
Modification of warrants   —            —            —            159,433                      159,433 
Net loss   —            —            —                        (919,427)         (919,427)
Balances, September 30, 2022        $           $      44,303,654   $     $124,300,604   $(504,650)  $(124,966,975)  $37,573   $(1,133,448)

 

 

See notes to consolidated financial statements

 

6 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
                     
CONSOLIDATED STATEMENTS OF CASH FLOWS
                     
THREE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021
                     
(UNAUDITED)

 

         
   2022   2021 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss   $(919,427)  $(663,876)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation expense   330    248 
Accrued interest on loans payable, deferred compensation and other   26,096    121,111 
Stock-based compensation   154,933       
Stock-based compensation for services   95,000       
Decrease (increase) in prepaid expenses   23,297    33,753 
Increase (decrease) in accounts payable and accrued expenses   (787,276)   59,367 
Decrease in operating lease assets and liabilities   16,155       
Increase in deferred compensation   75,000    99,400 
           
Net cash used in operating activities   (1,315,892)   (349,997)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment   (322,694)   (7,490)
           
Net cash used in investing activities   (322,694)   (7,490)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from exercise of warrants   56,125    104,500 
Commissions on exercise of warrants         (1,000)
Proceeds from sale of units   320,000       
           
Net cash provided by financing activities   376,125    103,500 
           
Net decrease in cash   (1,262,461)   (253,987)
           
Cash at beginning of year   3,160,442    4,216,321 
           
Cash at end of year  $1,897,981   $3,962,334 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $     $   
           
Non-cash investing and financing transactions:          
Conversion of debt and liabilities into notes payable  $23,943   $   
Conversion of deferred compensation to notes payable  $20,000   $   
Conversion of notes payable into shares  $50,000      
Capitalized interest in property and equipment  $30,688      
Shares issued for warrant exercise commissions  $     $7,500 
Shares issued for accounts payable  $     $5,126 
Purchase of property and equipment for accounts payable  $     $54,800 

 

See notes to consolidated financial statements

 

7 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

THREE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021

 

 

1.  ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to create extraordinary value for our shareholders and employees (all of whom own securities in the Company) while delivering premium, sustainable products to our customers through ventures developing profitable, transparent, and sustainable solutions for livestock agriculture. 

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third-generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste stream ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures s (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3 Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of 2022 Bion began marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2023, Bion announced a letter of intent (“Ribbonwire LOI”) to develop its first large-scale commercial project, a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). The Dalhart Project will be developed to produce blockchain-verified, sustainable beef (with reduced the stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) while remediating the environmental impacts associated usually associated with cattle CAFOs. Bion’s patented technology will refine the waste stream into valuable coproducts that include clean water, renewable natural gas (RNG), photovoltaic solar electricity and organic fertilizer products. We anticipate converting the Ribbonwire LOI into a definitive joint venture agreement with Ribbonwire Ranch and creating distribution agreements with key retailers and food service distributors during the next six months.

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef joint venture projects over the next twelve months while moving forward with the Initial Project (see below) and the Dalhart Project (and/or other Gen3Tech beef joint venture projects) and pursuing other opportunities in the livestock industry enabled by our Gen3 Tech business model.  The Ribbonwire LOI announcement has generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment.

 

 

8 
 

During the next six months, the Company intends to construct and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial setting by the end of the 2nd quarter in 2023 and supports development of the Dalhart Project (and/or other Gen3Tech beef joint venture projects) during 2023.  We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion is now focused primarily on: i) development/construction of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) development/construction of the Dalhart Project (and/or other Gen3Tech beef joint venture projects), iii) developing applications and markets for its low carbon organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product while raising sustainable livestock.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

 

9 
 

During July 2022, the Company entered into a letter of intent with Ribbonwire Ranch (Dalhart, Texas) (“Ribbonwire LOI”) setting forth the parties’ intention to negotiate a joint venture agreement and enter into a joint venture to develop and operate an initial 15,000 head integrated, sustainable beef facility on RWR property (“Dalhart Project”) including:

 

a)innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,
b)‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,
c)a Bion GEN3 Tech module (which will utilize the recycled CO2 to increase ammonium bicarbonate recovery) for the production of ammonium bicarbonate fertilizer for use in organic crop production (plus residual organic solids and clean water),
d)which will produce verifiably sustainable beef products with USDA certified branding.

The Dalhart Project will include expansion capability up to 60,000 head of cattle, in aggregate, located at/around/contiguous to the initial facilities on Ribbonwire property.

The opportunity presented by the Ribbonwire LOI to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation in Dalhart, TX a reality as soon as possible.

 

To place the Ribbonwire LOI and the Dalhart Project in the context of Company’s business plan (and our prior public disclosure), if the contemplated venture moves forward on the timelines set forth in the Ribbonwire LOI, active development of the Dalhart Project will commence early in the second quarter of 2023.

 

Prior to such activity, the Company intends to construct and operate the initial phase of the previously announced Gen3 Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion 3G Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the Dalhart Project). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, intends to utilize anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Construction and related activities of this demonstration project have commenced with main module assembly on site targeted to commence during January 2023 (somewhat delayed due to supply chain constraints) followed by operations through the first half of 2023 to generate the required information. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Company anticipates that it will negotiate additional letters of intent and enter into additional joint ventures related to the development of further commercial-scale sustainable beef projects over the next 6-18 months in addition to the Dalhart Project.

 

As previously disclosed, during late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility will be large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs have delayed likely delivery dates for core modules of the Bion system to the site until sometime during January 2023. 3G1 has been moving forward with the development process of the Initial Project. See Note 3 “Property and Equipment” and Note 10 “Subsequent Events” (for activities since the start of the second quarter of the 2023 fiscal year).

 

 

10 
 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

Specifically, the Initial Project is being developed to provide and/or accomplish the following:

 

  i. Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

  ii. Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

  iii. Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.

 

  iv. Produce sustainable beef products for initial test marketing efforts.

 

The Initial Project will be carried out in stages with phase one focused on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project, (coupled with obtaining organic certifications(s) for our for our solid ammonium bicarbonate fertilizer product line), Bion expects to be ready to move forward with its plans for development of much larger facilities including the Dalhart Project. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 6-12 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the development/construction of the Initial Project with a 2023 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the core modules may be re-located to a subsequent more permanent location to be determined at a later date. The Company is in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3 Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) including innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company is also considering re-locating the core modules of the Initial Project to Dalhart, Texas, where they may be integrated into the first phases of the Dalhart Project. 

 

 

11 
 

The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI, the California Department of Food & Agriculture (“CDFA”) and the Iowa Organic Program (“IOP”) and are in the review processes (which are likely to require an extended period of time and multiple procedural steps, in part due to the novel nature of our Gen3Tech in the context of organic certifications). See “Organic Fertilizer Listing/Certification Process” below.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project’ below as an example) in the swine, dairy and poultry industries utilizing our Gen3 Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/ dairy/ egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a certain segment of consumers are choosing seemingly sustainable offering, and are also willing to pay a premium for it. Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef is 63% more expensive today, while pork and chicken, which are now primarily raised in covered barns, at CAFOs with highly integrated supply chains, are 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and have enjoyed steady sales growth. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the only ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy.

 

 

12 
 

It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy these concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be first to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in appropriate geographical locations) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

 

Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

 

13 
 

Sustainable Organic Beef

 

Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Organic Fertilizer Listing/Certification Process

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of organically listed ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products.

 

14 
 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line have been filed with OMRI (filed during May 2021), the Iowa Organic Program (“IOP”)(filed during March 2022) and the California Department of Food & Agriculture (“CDFA”)(filed during May 2022) and are each in the review process. The review processes are likely to require an extended period of time and multiple procedural steps with each entity in part due to the novel nature of Bion’s Gen3 Tech and our solid ammonium bicarbonate product in the context of organic certifications. The OMRI application has proceeded through multiple stages of review and rebuttal/appeal without receiving a positive result to date. The Company’s has recently filed responses to the CDFA’s initial set of questions and comments regarding our solid ammonium bicarbonate product line. The Company’s product line is novel in part due to the fact that there is not a formal listing category for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this matter with one or more listings/certifications of this product line well prior to operational dates for the Company’s initial large scale JV Gen3 Tech projects.

 

 Gen3 Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3 Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company has commenced discussions with Kreider Farms regarding updating the JVA to reflect the capabilities of our Gen3 Tech platform and anticipates executing an amended (or new) JVA during the current fiscal year. The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3 Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

15 
 

Technology Deployment: Bion Gen3Tech

 

Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage, and the Company has additional applications pending and/or planned.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2023 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

 The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

16 
 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

 Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

 

17 
 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

Going concern and management’s plans:

 

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses of approximately $3,451,000 during the year ended June 30, 2021 and a net income of $8,292,000 for the year ended June 30, 2022. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of PA-1 resulting in a gain of approximately $10,235,000 as well as a one-time gain of $902,490 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. The Company incurred a net loss of $919,000 and $663,000 for the three months ended September 30, 2022 and 2021, respectively. At September 30, 2022, the Company has working capital and a stockholders’ deficit of approximately $1,171,000 and $829,000, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the years ended June 30, 2022 and 2021, the Company received gross proceeds of approximately $1,737,000 and $5,209,000, respectively, from the sale of its debt and equity securities.

 

During the three months ended September 30, 2022, the Company received total proceeds of approximately $376,000 from the sale of its equity securities.

 

 

18 
 

During fiscal years 2022 and 2021, the Company has faced less difficulty in raising equity funding (but substantial equity dilution has gone along with the larger amounts of equity financing during the periods) than was experienced in the prior 3 years except that during the first three months of the current fiscal year, the Company has raised equity funds at a rate materially lower than the average rate during fiscal years 2021 and 2022. The Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) portions of their cash compensation and/or are accepting compensation in part in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent relative success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart Project), Integrated Projects and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

 

19 
 

 

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at September 30, 2022, and the results of operations and cash flows of the Company for the three months ended September 30, 2022 and 2021. Operating results for the three months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of September 30, 2022 and June 30, 2022 there are no cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

 

20 
 

 

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

 

21 
 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three months ended September 30, 2022 and 2021, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

        
   September 30,
2022
   September 30,
2021
 
Warrants   19,873,801    21,802,822 
Options   11,201,600    10,471,600 
Convertible debt   10,793,421    10,462,498 
Convertible preferred stock         20,250 

 

 

22 
 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three months ended September 30, 2022 and 2021:

 

        
   Three months
ended
September 30,
2022
   Three months
Ended
September 30,
2021
 
Shares issued – beginning of period   43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,054,511    40,611,677 
Weighted average shares issued
    during the period
   397,335    108,015 
Diluted weighted average shares –
    end of period
   43,451,846    40,719,692 

 

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change

 

3.  PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

 

        
   September 30,
2022
   June 30,
2022
 
Machinery and equipment  $     $   
Buildings and structures            
Computers and office equipment   13,598    13,598 
3G project construction in process   3,245,604    2,892,222 
 Property and equipment, gross    3,259,202    2,905,820 
Less accumulated depreciation   (10,592)   (10,262))
 Property and equipment, net   $3,248,610   $2,895,558 

 

The 3G project began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for 3G construction in process includes $62,688 for capitalized interest and $135,648 in non-cash compensation as of September 30, 2022.

 

Management has reviewed the remaining property and equipment for impairment as of September 30, 2022 and believes that no impairment exists.

 

Depreciation expense was $330 and $248 for the three months ended September 30, 2022 and 2021, respectively.

 

23 
 

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $654,349 and $528,640 as of September 30, 2022 and 2021, respectively. Included in the deferred compensation balances as of September 30, 2022, are $459,627 and $5,000 owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of September 30, 2021 was $436,920 and nil, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $117,222 and $19,220 as of September 30, 2022 and 2021, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 0% to 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing.

Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election.

During the three months ended September 30, 2022, Smith elected to convert $20,000 of deferred compensation into the 2020 Convertible Note.

The Company recorded interest expense of $4,551 ($4,119 with related parties) and $4,032 ($3,949 with related parties) for the three months ended September 30, 2022 and 2021, respectively, related to deferred compensation.

  

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

 

24 
 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

 

25 
 

 

6.       CONVERTIBLE NOTES PAYABLE - AFFILIATES:

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations, which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”.

 

As of September 30, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees), Smith and Edward Schafer (“Schafer”), a director of the Company, were $2,620,941, $1,335,199 and $503,813, respectively. As of September 30, 2021, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $2,526,492, $1,253,335 and $485,658, respectively.

 

During the three months ended September 30, 2022, Smith elected to add $20,000 of his salary to his 2020 Convertible Obligations.

 

During the three months ended September 30, 2022, Smith elected to convert $30,000 in principal of the 2020 Convertible Obligation to 60,000 units (60,000 common shares and 60,000 warrants) and $20,000 of accrued interest of the 2020 Convertible Obligation to 40,000 units (40,000 common shares and 40,000 warrants).

 

The Company recorded interest expense of $41,367 and $40,560 for the three months ended September 30, 2022 and 2021, respectively. The Company capitalized $30,688 and nil related to the 3G project for the three months ended September 30, 2022 and 2021, respectively.

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani (now owned by Bassani Family Trusts), Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of September 30, 2022, including accrued interest owed Bassani Family Trusts, Schafer and Shareholder, are $281,789, $21,009 and $449,535, respectively. The balances of the September 2015 Convertible Notes as of September 30, 2021, including accrued interest, were $172,765, $20,354 and $434,419, respectively.

 

The Company recorded interest expense of $6,366 and $5,366 for the years ended September 30, 2022 and 2021, respectively, on the September 2015 Convertible Notes.

 

 

26 
 

 

7.       STOCKHOLDERS' EQUITY:

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

During the years ended June 30, 2022, and 2021, the Company declared dividends of $1,000 and $2,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is no liability at September 30, 2022.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

During the three months ended September 30, 2022, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

During the three months ended September 30, 2022, 74,834 warrants were exercised to purchase 74,834 shares of the Company’s common stock at $0.75 per share for total proceeds of $56,125.

During the three months ended September 30, 2022, the Company issued 50,000 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.60 per share for a total value of $80,000.

During the three months ended September 30, 2022, the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 320,000 units for total proceeds of $320,000.

 

Warrants:

 

As of September 30, 2022, the Company had approximately 20.6 million warrants outstanding, with exercise prices from $0.60 to $1.60 and expiring on various dates through November 9, 2026.

 

The weighted-average exercise price for the outstanding warrants is $0.76, and the weighted-average remaining contractual life as of September 30, 2022 is 2.2 years.

 

 

27 
 

During the three months ended September 30, 2022, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until three years after the date of conversion.

 

During the three months ended September 30, 2022, the Company approved the issuance of 150,000 warrants, in aggregate, to three new members of its Advisory Group for advisory and/or consulting services of $15,000, in aggregate. The warrants are exercisable at $1.50 to $1.60 and expire in August 2025.

During the three months ended September 30, 2022, the Company approved the modification of existing warrants held by one former consultant and four investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $154,933 and interest expenses of $4,500.

During the three months ended September 30, 2022, 74,834 warrants were exercised to purchase 74,834 shares of the Company’s common stock at $0.75 per share for total proceeds of $56,126.

 

Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

Stock options:

 

On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “Equity Plan”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,

 

On February 11, 2022, the Company granted 10,000 options under the 2006 Plan to one consultant.

 

On April 29, 2022, the Company granted an aggregate of 720,000 options under the 2006 Plan to seven employees/consultants/directors including: i) 50,000 options each to Schafer and Northrop for service as directors, ii) 200,000 options to Bassani (now COO of the Company and formerly CEO) and iii) 200,000 options to Smith, the Company’s President, which new option grants are included in the presentation below.

 

The Company recorded compensation expense related to employee stock options of nil and nil for the three months ended 2022 and 2021, respectively. The Company granted nil options during the three months ended September 30, 2022 and 2021, respectively.

 

28 
 

A summary of option activity under the 2006 Plan for the three months ended September 30, 2022 is as follows:

                 
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2022    11,201,600   $0.80    2.7   $4,429,263 
   Granted                       
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at September 30, 2022    11,201,600   $0.80    2.48   $5,757,755 

 

 

The total fair value of stock options that vested during the three months ended September 30, 2022 and 2021 was nil. As of September 30, 2022, the Company had no unrecognized compensation cost related to stock options.

 

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of September 30, 2022, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($504,741, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum and are secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

As of September 30, 2022, the Company has an interest bearing, secured promissory note for $30,000 ($34,987 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at 4% per annum, and is secured by $30,000 ($35,361, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

As of September 30, 2022 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($55,472 including interest) from two former employees as consideration to purchase warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.

9.       COMMITMENTS AND CONTINGENCIES:

 

Employment and consulting agreements:

 

Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $18,000 until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2022, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $25,000 per month of which $5,000 a month is deferred. For the three months ended September 30, 2022 and 2021, Smith was paid $60,000 and $54,000, respectively, of cash compensation.

 

 

29 
 

Since March 31, 2005, the Company has had various agreements with Bassani (and/or Brightcap which provided his services during some of the initial years), now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’), (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which will continue to be accrued in part until there is adequate cash available. Additionally, the Company has agreed to pay him $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of September 30, 2022, the principal and accrued interest was $351,812. For the three months ended September 30, 2022 and 2021, Brightcap was paid $75,000 and $60,000, respectively, of cash compensation.

 

William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s GEN3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13th month) with compensation of $25,000 cash and $10,000 deferred compensation per month. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.  For the three months ended September 30, 2022 and 2021, O’Neill was paid $45,500 and nil, respectively, of cash compensation.

 

Execution/exercise bonuses:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant. These exercise bonuses were subsequently increased to 75%.

 

During the year ended June 30, 2021, the Company added a 75% execution/exercise bonus to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of September 30, 2022, the execution/exercise bonuses ranging from 50-90% were applicable to 10,966,600 of the Company’s outstanding options and 17,612,151 of the Company’s outstanding warrants.

 

Effective May 1, 2022, an entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

 

30 
 

Purchase Order Agreement:

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375)) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. On March 21, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next 25% payment ($666,375).  On June 6, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next 25% payment ($666,375) which was paid on July 5, 2022 bringing the aggregate payments to $1,999,125 as of the date of this report. No invoices were received in the quarter ended September 30, 2022. Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete and procurement/fabrication has now been initiated.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, etc.) for work related to the Initial Project.

 

Litigation:

 

A: Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations werebeen subject disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

 

31 
 

 

B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

 

32 
 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

The Company currently is not involved in any other material litigation or similar events.

 

Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of September 30, 2022:

 

     
Year ended June 30, 2023  $43,750 
Year ended June 30, 2024   75,000 
Year ended June 30, 2025   31,250 
Undiscounted cash flow   150,000 
Less imputed interest   (17,888)
Total  $132,112 

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of September 30, 2022 were 2.33 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

 

 

33 
 

 

10.        SUBSEQUENT EVENTS:

 

The Company has evaluated events that occurred subsequent to September 30, 2022 for recognition and disclosure in the financial statements and notes to the financial statements.

 

On October 28, 2022 the Company entered into a subscription agreement to sell 26,230 units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024 for total proceeds of $26,230.

 

 

 

34 
 

 

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

 

Statements made in this Form 10-Q that are not historical or current facts, which represent the Company's expectations or beliefs including, but not limited to, statements concerning the Company's operations, performance, financial condition, business strategies, and other information, involve substantial risks and uncertainties. The Company's actual results of operations, most of which are beyond the Company's control, could differ materially. These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," anticipate," "estimate," or "continue" or the negative thereof. We wish to caution readers not to place undue reliance on any such forward looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected.

 

These factors include adverse economic conditions, entry of new and stronger competitors, inadequate capital and limited ability to obtain financing, unexpected costs, failure (or delay) to gain product certifications and/or regulatory approvals in the United States (or particular states) or foreign countries, loss (permanently or for any extended period of time) of the services of members of the Company’s small core management team (many of whom are age 70 or older) and failure to capitalize upon access to new markets. Additional risks and uncertainties that may affect forward looking statements about Bion's business and prospects include: i) delays and/or costs exceeding expectations relating to Bion's development of the Initial Project, JVs and/or Projects, ii) the possibility that markets for nutrient reduction credits (discussed below) and/or other ways to monetize nutrient reductions and other environmental benefits will be slow to develop (or not develop at all), iii) PA1’s dissolution and its effect on how the Company is viewed, (if any), iv) the possibility that competitors will develop more comprehensive and/or less expensive environmental solutions, v) delays in market awareness of Bion and our Systems, vi) uncertainties and costs increases related to research and development efforts to update and improve Bion’s technologies and applications thereof, and/or vii) failure of marketing strategies, each of which could have both immediate and long term material adverse effects by placing us behind our competitors and requiring expenditures of our limited resources.

 

THESE RISKS, UNCERTAINTIES AND FACTORS BEYOND OUR CONTROL ARE MAGNIFIED DURING THE CURRENT UNCERTAIN PERIOD RELATED TO THE COVID-19 PANDEMIC AND THE UNIQUE ECONOMIC, FINANCIAL, GOVERNMENTAL AND HEALTH-RELATED CONDITIONS IN WHICH THE COMPANY, THE ENTIRE COUNTRY AND THE ENTIRE WORLD NOW RESIDE.  TO DATE THE COMPANY HAS EXPERIENCED DIRECT IMPACTS  IN VARIOUS AREAS INCLUDING WITHOUT LIMITATION: I) GOVERNMENT-ORDERED  SHUTDOWNS WHICH HAVE SLOWED THE COMPANY’S RESEARCH AND DEVELOPMENT PROJECTS AND OTHER INITIATIVES, II) SHIFTED FOCUS OF STATE AND FEDERAL GOVERNMENT WHICH IS LIKELY TO NEGATIVELY IMPACT THE COMPANY’S LEGISLATIVE INITIATIVES IN PENNSYLVANIA AND WASHINGTON DC, III) STRAINS AND UNCERTAINTIES IN BOTH THE EQUITY AND DEBT MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS WITH INVESTMENT BANKERS, BANKS AND POTENTIAL STRATEGIC PARTNERS MORE TENUOUS, IV) STRAINS AND UNCERTAINTIES IN THE AGRICULTURAL SECTOR AND MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS MORE DIFFICULT AS FUTURE INDUSTRY CONDITIONS ARE NOW MORE DIFFICULT TO ASSESS/PREDICT, V) CONSTRAINTS DUE TO PROBLEMS EXPERIENCED IN THE GLOBAL INDUSTRIAL SUPPLY CHAIN WHICH HAVE INCREASED ANTICIPATED PROJECT DEVELOPMENT COSTS, VI) DUE TO THE AGE AND HEALTH OF OUR CORE MANAGEMENT TEAM, MOST OF WHOM ARE AGE 70 OR OLDER AND HAVE HAD ONE OR MORE EXISTING HEALTH ISSUES, THE COVID-19 PANDEMIC PLACES THE COMPANY AT GREATER RISK THAN WAS PREVIOUSLY THE CASE (TO A HIGHER DEGREE THAN WOULD BE THE CASE IF THE COMPANY HAD A LARGER, DEEPER AND/OR YOUNGER CORE MANAGEMENT TEAM), AND VII) THERE ALMOST CERTAINLY WILL BE OTHER UNANTICIPATED CONSEQUENCES FOR THE COMPANY AS A RESULT OF THE CURRENT PANDEMIC EMERGENCY AND ITS AFTERMATH.

 

 

35 
 

Bion disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and Notes to Consolidated Financial Statements filed with this Report.

 

 

BUSINESS OVERVIEW AND PLAN

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to create extraordinary value for our shareholders and employees (all of whom own securities in the Company) while delivering premium, sustainable products to our customers through ventures developing profitable, transparent, and sustainable solutions for livestock agriculture. 

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste stream ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures s (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3 Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of 2022 Bion began marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop its first large-scale commercial project, a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). The Dalhart Project (and/or other Gen3Tech beef joint venture projects) will be developed to produce blockchain-verified, sustainable beef (with reduced the stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) while remediating the environmental impacts associated usually associated with cattle CAFOs. Bion’s patented technology will refine the waste stream into valuable coproducts that include clean water, renewable natural gas (RNG), photovoltaic solar electricity and organic fertilizer products. We anticipate converting the Ribbonwire LOI into a definitive joint venture agreement with Ribbonwire Ranch and creating distribution agreements with key retailers and food service distributors during the next six months.

 

36 
 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and, in some cases, Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

Bion’s Gen3Tech was designed to capture and stabilize the assets contained in the livestock waste stream and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

Our business plan is focused on executing multiple agreements and letters of intent related to the “Bion Beef Opportunity” and commencing development of multiple sustainable beef joint venture projects over the next twelve-eighteen (12-18) months while moving forward with the Initial Project (see below) and the Dalhart Project (and/or other Gen3Tech beef joint venture projects). Bion also intends to pursue other opportunities in the livestock industry enabled by our Gen3Tech business model. The Ribbonwire LOI announcement has generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and the growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, provides Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment.

 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their harvest and production techniques, meat industry leaders have also announced their willingness to move forward with initiatives in this area. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2025) and 25% in five (5) years (end of 2027) (approximately 2,000,000 cattle annually) (and more thereafter). If Bion can successfully execute on its sustainable beef business plan, facilities utilizing Bion’s Gen3Tech platform will provide one-third (1/3) or more of that premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of 2023. Our first commercial project is likely to be the Dalhart Project but we anticipate commencing additional sustainable beef projects during 2023 as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development/under construction during 2023 in three (3) different JVs with the initial barns being populated with livestock by fall/winter 2024-25. Further expansion in the number of distinct JVs is projected through 2025 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2025 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and populated by 2027-28 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

During this five (5) year period, the Company also anticipates having additional Gen3Tech projects underway in the pork/dairy/egg sectors of the US animal protein market.

 

 

 

37 
 

During the next six months, the Company intends to construct and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial setting by the end of the 2nd quarter in 2023 and supports development of the Dalhart Project (and/or other Gen3Tech beef joint venture projects) during 2023.  We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion is now focused primarily on: i) development/construction of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) development/construction of the Dalhart Project (and/or other Gen3Tech beef joint venture projects), iii) developing applications and markets for its low carbon organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

For additional information regarding our ‘HISTORY, BACKGROUND AND CURRENT ACTIVITIES’,  see discussion in Notes to the Financial Statements (particularly Notes 1,3,5,and 9) included in this report and Item 1 in our annual report on Form 10-K.

 

COVID-19 PANDEMIC RELATED MATTERS:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

 

38 
 

CRITICAL ACCOUNTING POLICIES

 

Revenue Recognition

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of Accounting Standards Codification (“ASC”) 606 “Revenue from Contracts with Customers”.

Stock-based compensation

 

The Company follows the provisions of ASC 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of income based upon their grant date fair values.

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. As of September 30, 2022 and 2021, there are no derivative financial instruments.

 

Options:

 

The Company has issued options to employees and consultants under its 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

39 
 

THREE MONTHS ENDED SEPTEMBER 30, 2022 COMPARED TO THE THREE MONTHS ENDED SEPTEMBER 30, 2021

Revenue

Total revenues were nil for both the three months ended September 30, 2022 and 2021.

General and Administrative

Total general and administrative expenses were $866,000 and $491,000 for the three months ended September 30, 2022 and 2021, respectively.

Salaries and related payroll tax expenses were $171,000 and $97,000, for the three months ended September 30, 2022 and 2021, respectively, representing a $74,000 increase. Consulting costs were $118,000 and $152,000 for the three months ended September 30, 2022 and 2021, respectively. The $34,000 decrease in consulting costs is due to the capitalization of Brightcap’s consulting expense to the 3G Project. Investor relations expenses were $249,000 and $86,000 for the three months ended September 30, 2022 and 2021, respectively, and the $163,000 increase is due to a new contract with an investor relations firm and increased activity during the three months ended September 30, 2022 due to the resumption of investor conferences and other matters. Legal costs were $8,000 and $25,000 for the three months ended September 30, 2022 and 2021, respectively due to less outside legal activities in the quarter.

Depreciation

Total depreciation expense was $330 and $248 for the three months ended September 30, 2022 and 2021, respectively.

Research and Development

Total research and development expenses were $28,000 and $62,000 for the three months ended September 30, 2022 and 2021, respectively, representing a $34,000 decrease due to less legal and consulting costs allocated to research and development.

Salaries and related payroll tax expenses were $3,000 and $7,000 for the three months ended September 30, 2022 and 2021, respectively, as more salary expense was allocated to administrative expense for the three months ended September 30, 2022. Consulting costs were $17,000 and $32,000 for the three months ended September 30, 2022 and 2021, respectively. The decrease in consulting is due to capitalizing costs on the 3G project.   The Company also incurred $3,000 and $21,000 for the three months ended September 30, 2022 and 2021, respectively in legal costs related to patent applications and renewals.

Loss from Operations

As a result of the factors described above, the loss from operations was $895,000 and $553,000 for the three months ended September 30, 2022 and 2021, respectively.

Other (Income) Expense

Other expense was $24,000 and $111,000 for the three months ended September 30, 2022 and 2021, respectively and was all attributed to interest expense for both periods. The decrease in interest expense is largely due to there being no interest expense related to the Pennvest loan during the three months ended September 30, 2022 and capitalizing interest of $31,000 to the 3G project.

 

Interest expense related to deferred compensation, loan payable and convertible notes prior to capitalization was $52,000 and $112,000 for the three months ended September 30, 2022 and 2021, respectively. Interest expense related to investor warrant modifications was $4,500 and nil for the three months ended September 30, 2022 and 2021.

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was nil and $506 for the three months ended September 30, 2022 and 2021, respectively.

Net Loss Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net loss attributable to Bion’s stockholders was $919,000 and $663,000 for the three months ended September 30, 2022 and 2021, respectively, and the net loss per basic common share was $.02 and $.02 for the three months ended September 30, 2022 and 2021, respectively.

 

40 
 

LIQUIDITY AND CAPITAL RESOURCES

 

The Company's consolidated financial statements for the three months ended September 30, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Report of our Independent Registered Public Accounting Firm on the Company's consolidated financial statements as of and for the year ended June 30, 2022 includes a "going concern" explanatory paragraph which means that the auditors stated that conditions exist that raise substantial doubt about the Company's ability to continue as a going concern.

 

Operating Activities

 

As of September 30,2022, the Company had cash of approximately $1,898,000. During the three months ended September 30, 2022, net cash used in operating activities was $1,316,000, primarily consisting of cash operating expenses related to salaries and benefits, and other general and administrative costs such as insurance, legal, accounting, consulting and investor relations expenses as well as the purchase of property and equipment. Cash expenditures were offset by proceeds from financing activities, primarily the exercise of warrants. As previously noted, the Company is currently not generating significant revenue and accordingly has not generated cash flows from operations. The Company does not anticipate generating sufficient revenues to offset operating and capital costs for a minimum of two to five years. While there are no assurances that the Company will be successful in its efforts to develop and construct its Projects and market its Systems, it is certain that the Company will require substantial funding from external sources. Given the unsettled state of the current credit and capital markets for companies such as Bion, there is no assurance the Company will be able to raise the funds it needs on reasonable terms.

 

Investing Activities

 

During the three months ended September 30, 2022, the Company invested $323,000 in the purchase of property and equipment, primarily related to project construction in process.

 

Financing Activities

During the three months ended September 30, 2022, the Company received gross cash proceeds of $56,125 from the exercise of 74,834 warrants into shares of the Company’s common stock.

During the three months ended September 30, 2022, the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 320,000 units for total proceeds of $320,000.

 

As of September 30, 2022, the Company has debt obligations consisting of: a) deferred compensation of $654,000 and b) convertible notes payable – affiliates of $5,212,000.

 

Plan of Operations and Outlook

 

As of September 30, 2022, the Company had cash of approximately $1,898,000.

 

The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues. During fiscal years 2022 and 2021, the Company has faced progressively less difficulty in raising equity funding (but substantial equity dilution has resulted from the larger amounts of equity financing during the periods). However, the Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring all or part of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 5 and 7 to Financial Statements) and members of the Company's senior management have from time to time made loans to the Company. During the year ended June 30, 2018 senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. As of June 30 2022, such deferrals/loans totaled approximately $5,765,000 (including accrued interest and deferred compensation converted into convertible obligations and convertible promissory notes but excluding conversions of deferred compensation into the Company's common stock by officers, employees and consultants that have already been completed). The extended constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company's effort to develop its business. The Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again in 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent increased success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

 

41 
 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop the Initial Project, JVs, Projects (including Integrated Projects) and CAFO Retrofit waste remediation systems (potentially including the Kreider 2 facility. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more (debt and equity) during the next twelve months. However, as discussed above, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

 

The Company is not currently generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing projects, JVs and proposed projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. During the year ended June 30, 2021 the Company raised gross proceeds of approximately $5,209,000 through the sale of its securities and paid commissions of approximately $165,000, and anticipates raising additional funds from such sales and transactions. During the year ended June 30, 2022 the Company raised gross proceeds for approximately $1,737,000 and paid commissions of approximately $18,600. However, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

 

Because the Company is not currently generating significant revenues, the Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop the Initial Project and subsequent Projects.

 

As indicated above, the Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more (from debt, equity, joint venture, strategic partnering, etc.) during the next twelve months, some of which may be in the context of joint ventures for the development of one or more large scale projects. We reiterate that there is no assurance, especially in the extremely unsettled capital markets that presently exist for companies such as Bion, that the Company will be able to obtain the funds that it needs to stay in business, finance its Projects and other activities, continue its technology development and/or to successfully develop its business.

 

See Item 2 below and Note 5 (“Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution”) to the Financial Statements included in this report and the Company’s Forms 10-K for the year ended June 30, 2022 (and

the years 2009-2021) for discussion and more details related to the dissolution of PA1, the Pennvest Loan and the

Kreider 1 project.

 

As indicated above, the Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more (from debt, equity, joint venture, strategic partnering, etc.) during the next twelve months, some of which may be in the context of joint ventures for the development of one or more large scale projects. We reiterate that there is no assurance, especially in the extremely unsettled capital markets that presently exist for companies such as Bion, that the Company will be able to obtain the funds that it needs to stay in business, finance its Projects, JVs and other activities, continue its technology development and/or to successfully develop its business.

 

 

42 
 

There is extremely limited likelihood that funds required during the next twelve months or in the periods immediately thereafter will be generated from operations and there is no assurance that those funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company's existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for companies such as Bion.

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

CONTRACTUAL OBLIGATIONS

 

We have the following material contractual obligations (in addition to employment and consulting agreements with management and employees):

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of September 30, 2022:

 

Year ended June 30, 2023  $43,750 
Year ended June 30, 2024   75,000 
Year ended June 30, 2025   31,250 
Undiscounted cash flow   150,000 
Less imputed interest   (17,888)
Total  $132,112 

  

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of September 30, 2022 were 2.33 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

Through 3G1 the Company is in the process of developing the Initial Project. See discussion above and in the Notes to our Financial Statements. 

 

OFF-BALANCE SHEET ARRANGEMENTS

 

The Company does not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures.

 

(a) Evaluation of Disclosure Controls and Procedures.

 

The term "disclosure controls and procedures" is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This term refers to the controls and procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized, and reported within the required time periods. Our Chief Executive Officer and Principal Financial Officer has evaluated the effectiveness of the design and operations of our disclosure controls and procedures as of the end of the period covered by this quarterly report, and has concluded that, as of that date, our disclosure controls and procedures were not effective at ensuring that required information will be disclosed on a timely basis in our reports filed under the Exchange Act, as a result of the material weakness in internal control over financial reporting discussed in Item 9(A) of our Form 10-K for the year ended June 30, 2022.

 

(b) Changes in Internal Control over Financial Reporting.

 

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

43 
 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

The Company is currently involved in no litigation matters except:

 

A:Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations werebeen subject disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

 

44 
 

B: Dissolution of Bion PA1, LLC (“PA1”)

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

 

45 
 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1, since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

Item 1A.  Risk Factors.

Not applicable.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

During the quarter ended September 30, 2022, the Company sold the following restricted securities: a) 100,000 shares of common stock issued pursuant to our 2006 Consolidated Incentive Plan (“Plan”) upon the conversion of debt, b) 50,000 shares issued to entities for services valued at $80,000 c) 74,834 shares of common stock issued pursuant to exercise of 78,834 warrants at $0.75/warrant and the Company received gross proceeds of $56,126 and d) the Company sold 320,000 units at $1.00 per unit consisting of one share of the Company’s restricted common stock and one  warrant to purchase one share of the Company’s restricted common stock at $1.25 until December 31, 2023 and received gross proceeds of $320,000. All of these transactions the Company relied on the exemptions in Section 4(2) of the Securities Act of 1933, as amended, and/or under Rule 506 of Regulation D under the Securities Act of 1933, as amended. See Notes to Financial Statements (included herein) for additional details.

The proceeds were utilized for general corporate purposes.

Item 3.  Defaults Upon Senior Securities.

Not applicable.

Item 4.  Mine Safety Disclosures.

Not applicable.

Item 5.  Other Information.

Not applicable.

Item 6.  Exhibits.

  (a) Exhibits required by Item 601 of Regulation S-K.

 

Exhibit       Incorporated by Reference   Filed/Furnished
No.   Description   Form     Exhibit   Filing Date   Herewith
31.1*   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act                 X
31.2*   Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act                 X
32.1**   Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act                 X
32.2**   Certification of Principal Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act                 X
101.INS*   Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.                 X
101.SCH*   Inline XBRL Taxonomy Extension Schema Document                 X
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document                 X
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document                 X
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document                 X
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document                 X
104*   Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.                 X

 

* Filed herewith.
   
** Furnished herewith.

 

 

46 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    BION ENVIRONMENTAL TECHNOLOGIES, INC.
     
     
Date: November 14, 2022 By: /s/ Mark A. Smith
    Mark A. Smith, President and Chief Financial Officer (Principal Financial and Accounting Officer)
     
     
     
Date:  November 14, 2022 By: /s/ William O’Neill
    William O’Neill, Chief Executive Officer
     
     

 

 

 

47 
 

 

 

 

 

 

 

 

 

 

 

EX-31.1 2 bion_ex31z1.htm EXHIBIT 31.1 Certification

Exhibit 31.1

 


SECTION 302 CERTIFICATION

 


I, William O’Neill, certify that:

 


1.   I have reviewed this quarterly report on Form 10-Q of Bion Environmental Technologies, Inc.;

 


2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 


3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

 


4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 


(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 


(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 


(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 


(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 


5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 


(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 


(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 


Date:  November 14, 2022

 



/s/ William O’Neill

William O’Neill

Chief Executive Officer





EX-31.2 3 bion_ex31z2.htm EXHIBIT 31.2 Certification


Exhibit 31.2


SECTION 302 CERTIFICATION


I, Mark A. Smith, certify that:


1.   I have reviewed this quarterly report on Form 10-Q of Bion Environmental Technologies, Inc.;


2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;


4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:  November 14, 2022




/s/ Mark A. Smith

Mark A. Smith

Executive Chairman, President and Chief Financial Officer




EX-32.1 4 bion_ex32z1.htm EXHIBIT 32.1 Certification


Exhibit 32.1

 


CERTIFICATION OF CEO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Form 10-Q of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the quarter ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), William O’Neill, Chief Executive Officer of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

November 14, 2022 /s/ William O’Neill  
 

William O’Neill

Chief Executive Officer

 

 




This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 


A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 bion_ex32z2.htm EXHIBIT 32.2 Certification


Exhibit 32.2

 


CERTIFICATION OF CFO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 


In connection with the Form 10-Q of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark A. Smith, President (Executive Chairman) and Interim Chief Financial Officer (Principal Financial and  Accounting Officer) of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

       
Date: November 14, 2022   /s/ Mark A. Smith  
   

Mark A. Smith

Executive Chairman, President and

Interim Chief Financial Officer

 
       

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

EX-101.SCH 6 bnet-20220930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDER'S EQUITY (DEFICIT) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DEFERRED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - DEFERRED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bnet-20220930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bnet-20220930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bnet-20220930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series B Preferred Stock [Member] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Subscriptions Receivable [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Counterparty Name [Axis] Ribbonwire [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Ownership [Axis] Centerpoint [Member] Antidilutive Securities [Axis] Warrant [Member] Share-Based Payment Arrangement, Option [Member] Convertible Debt Securities [Member] Convertible Preferred Stock Antidilutive Securities [Member] Long-Lived Tangible Asset [Axis] Property Plant And Equipment Of P A 1 [Member] Title of Individual [Axis] Chief Executive Officer [Member] Bassani [Member] Smith [Member] Consultants [Member] Nature of Expense [Axis] Interest Expense On Deferred Compensation Obligation [Member] Debt Instrument [Axis] Pennvest Loan [Member] Scenario [Axis] Years One Through Five [Member] Years Six Through Maturity [Member] Legal Entity [Axis] P A 1 [Member] The 2020 Convertible Obligations [Member] Long-Term Debt, Type [Axis] Convertible Debt [Member] President [Member] Executive Vice Chairman [Member] Principal [Member] Convertible Obligations 2020 [Member] Award Type [Axis] Common Shares [Member] Warrants [Member] Accrued Interest [Member] Receivable Type [Axis] Secured Promissory Note [Member] September 2015 Convertible Notes [Member] Related Party Transaction [Axis] Bassani Family Trusts [Member] Schafer [Member] Shareholder [Member] Two Consultants [Member] Plan Name [Axis] Equity Incentive Plan [Member] Plan 2006 [Member] Northrop [Member] Financial Instrument [Axis] Options Held [Member] Class of Warrant or Right [Axis] Warrants Issused Subscription Receivable [Member] Smiths [Member] Former Employee [Member] Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member] Extension Bonus [Member] Fy 2016 Extension Agreement [Member] Forecast [Member] Warrants Expiring On December 312025 [Member] Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS  Current assets:  Cash  Prepaid expenses  Deposits and other assets  Total current assets  Operating lease right-of-use asset  Property and equipment, net (Note 3)  Total assets  LIABILITIES AND EQUITY (DEFICIT)  Current liabilities: Accounts payable and accrued expenses Preferred stock  Deferred compensation (Note 4)  Loan payable and accrued interest (Note 5)  Total current liabilities  Operating lease liability  Convertible notes payable - affiliates (Note 6)  Total liabilities  Deficit: Bion's stockholders' equity (deficit): Common stock, no par value, 250,000,000 shares authorized, 44,303,654 and 43,758,820 shares issued, respectively; 43,599,345 and 43,054,511 shares outstanding, respectively Additional paid-in capital Subscription receivable - affiliates (Note 8) Accumulated deficit Total Bion's stockholders’ deficit Noncontrolling interest Total deficit Total liabilities and deficit Preferred stock, par value (in dollars per share) Preferred stock, authorized (in shares) Preferred stock, issued (in shares) Preferred stock, outstanding (in shares) Preferred stock, liquidation Common Stock, Par or Stated Value Per Share Common stock, authorized (in shares) Common Stock, Shares, Issued Common Stock, Value, Outstanding Income Statement [Abstract] Revenue Operating expenses: General and administrative (including stock-based compensation) Depreciation Research and development (including stock-based compensation) Total operating expenses Loss from operations Other (income) expense: Interest income Interest expense Total other expense Net loss Net loss attributable to the noncontrolling interest Net loss applicable to Bion's common stockholders Net loss applicable to Bion's common stockholders per basic and diluted common share Weighted-average number of common shares outstanding: Basic and diluted Beginning balance, value Beginning balance, shares Sale of units Sale of units, shares Warrants exercised for common shares Warrants exercised for common shares , shares Issuance of units for services Issuance of units for services, shares Issuance of warrants for services Commissions on warrant exercises Commissions on warrant exercises , shares Conversion of debt and liabilities Conversion of debt and liabilities, shares Modification of warrants Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Accrued interest on loans payable, deferred compensation and other Stock-based compensation Stock-based compensation for services Decrease (increase) in prepaid expenses Increase (decrease) in accounts payable and accrued expenses Decrease in operating lease assets and liabilities Increase in deferred compensation Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from exercise of warrants Commissions on exercise of warrants Proceeds from sale of units Net cash provided by financing activities Net decrease in cash Cash at beginning of year Cash at end of year Supplemental disclosure of cash flow information: Cash paid for interest Non-cash investing and financing transactions: Conversion of debt and liabilities into notes payable Conversion of deferred compensation to notes payable Conversion of notes payable into shares Capitalized interest in property and equipment Shares issued for warrant exercise commissions Shares issued for accounts payable Purchase of property and equipment for accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Share-Based Payment Arrangement [Abstract] DEFERRED COMPENSATION Debt Disclosure [Abstract] LOANS PAYABLE Convertible Notes Payable - Affiliates CONVERTIBLE NOTES PAYABLE - AFFILIATES Stockholders Equity STOCKHOLDERS' EQUITY Subscription Receivable - Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Principles of consolidation Cash and cash equivalents Property and equipment Patents Stock-based compensation Derivative Financial Instruments Options Warrants Concentrations of credit risk Noncontrolling interests Fair value measurements Lease Accounting Revenue Recognition Income (Loss) per share Use of estimates Recent Accounting Pronouncements Schedule of anti dilutive securities Schedule of earnings per share, basic and diluted Schedule of property and equipment Schedule of option activity Schedule of future minimum lease payments Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Tech wastage Cattle per head Percentage of sustainable Description of kreider 2 poultry project Net Income (loss) Net income Gain on sale of domain Operating loss Working Capital Stockholders deficit Proceeds from Issuance or Sale of Equity Deferred Compensation Liability, Amount Cancelled Capital Required for Capital Adequacy Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Shares issued – beginning of period Shares held by subsidiaries (Note 7) Shares outstanding – beginning of period Weighted average shares issued     during the period Diluted weighted average shares –     end of period Noncontrolling interest, ownership percentage by parent Cash equivalents Machinery and equipment Buildings and structures Computers and office equipment 3G project construction in process  Property and equipment, gross  Less accumulated depreciation  Property and equipment, net  Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Capitalized interest Non cash compensation Impairment of Long-Lived Assets Held-for-use Depreciation expense Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Deferred compensation liability Interest Rate on Deferred Compensation Deferred Compensation Consecutive Trading Days (Day) Deferred Compensation, Convertible to Common Stock Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share) Interest Expense Interest Expense, Related Party Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Construction Loan Accrued Interest and Late Charges Payable Total assets Total liabilities Accounts payable and accrued liabilities Accounts payable Accrued Liabilities, Current Gain on legal dissolution of subsidiary Line of Credit Facility, Maximum Borrowing Capacity Debt Instrument, Interest Rate During Period Debt Instrument, Annual Principal Payment Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Interest Expense, Debt Loans as a liability Debt Instrument, Debt Default, Amount Realized from the asset sale Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage, Quarterly Conversion Price Per Unit (in dollars per share) Original conversion price Convertible Notes Payable, Noncurrent Salary paid Debt conversion value Debt conversion shares, warrants Capitalized amount Financing Receivable, Interest Rate, Stated Percentage Convertible Notes Payable Stockholders Equity - Stock Option Activity Options outstanding, beginning (in shares) Options outstanding, beginning weighted-average exercise price Outstanding, weighted-average remaining contractual life (Year) Outstanding, aggregate intrinsic value beginning Granted Granted, weighted-average exercise price Exercised, options (in shares) Exercised, weighted-average exercise price Forfeited, options (in shares) Forfeited, weighted-average exercise price Expired, options (in shares) Expired, weighted-average exercise price Options outstanding, ending (in shares) Options outstanding, ending weighted-average exercise price Outstanding, aggregate intrinsic value ending Preferred Stock, Shares Outstanding, Ending Balance (in shares) Par value Preferred Stock, Convertible Option Per Share (in dollars per share) Preferred Stock, Dividend Rate, Percentage Preferred Stock, Redemption Price Per Share (in dollars per share) Redemption of convertible Preferred stock Dividends Payable Dividends, Preferred Stock Liability Shares Held by Subsidiaries (in shares) Debt conversion shares Conversion price per share Warrants exercisable per share Class of Warrant or Right, Exercised During Period (in shares) Common Stock Shares Issued upon Exercise of Warrants (in shares) Warrant Exercised for Common Stock Shares issued for consultant services Share price Total value of consultant services Sale of unit, price per unit Share price Number of shares issued Number of shares issued, value Class of Warrant or Right, Outstanding (in shares) Weighted average exercise price Remaining contractual life Issuance of warrants Share-based Payment Arrangement, Plan Modification, Incremental Cost Interest expenses Warrant Exercised for Common Stock Number of shares issued Cancellation of warrants Exercise bonus Stock options, authorized (in shares) Number of shares granted Share-based Compensation, Granted Share-based Compensation, Granted Share-based Payment Arrangement, Expense Fair value of stock options Financing Receivable, after Allowance for Credit Loss, Total Notes receivable interest Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Financing Receivable, Principal Amount Year ended June 30, 2023 Year ended June 30, 2024 Year ended June 30, 2025 Undiscounted cash flow Less imputed interest Total Loss Contingencies [Table] Loss Contingencies [Line Items] Monthly Officers Cash Compensation Compensation increased Cash compensation paid Deferred Compensation, Maximum Convertible Amount Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share) Salaries and wages Additional paid amount Interest bearing secured promissory note Repayments of Long-term Debt, Total Warrants held by trust owned Warrants and Rights Outstanding Debt instrument paid amount Principal, interest Aggregate payment Sale of domain, description Loan related to construction Accrued interest Line of Credit, Current Gain (Loss) on Securitization of Financial Assets Weighted average remaining lease term Discounted rate Subsequent Event [Table] Subsequent Event [Line Items] Sale of units Sale of units, price per unit Sale of units, price per share Expiry date Proceeds from sale of units Assets, Current Common Stock, Share Subscribed but Unissued, Subscriptions Receivable Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Income, Operating Other Nonoperating Income (Expense) Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payments for Repurchase of Warrants Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Payment Arrangement [Policy Text Block] Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Other, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share Price WarrantExercisedForCommonStock Shares, Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Sale of Stock, Number of Shares Issued in Transaction Sale of Stock, Consideration Received Per Transaction EX-101.PRE 10 bnet-20220930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
3 Months Ended
Sep. 30, 2022
Nov. 01, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2022  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --06-30  
Entity File Number 000-19333  
Entity Registrant Name Bion Environmental Technologies, Inc  
Entity Central Index Key 0000875729  
Entity Tax Identification Number 84-1176672  
Entity Incorporation, State or Country Code CO  
Entity Address, Address Line One 9 East Park Court  
Entity Address, City or Town Old Bethpage  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 11804  
City Area Code 516  
Local Phone Number 586-5643  
Title of 12(b) Security Common Stock  
Trading Symbol BNET  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   43,625,575
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Sep. 30, 2022
Jun. 30, 2022
 Current assets:    
 Cash $ 1,897,981 $ 3,160,442
 Prepaid expenses 134,253 157,550
 Deposits and other assets 1,000 1,000
 Total current assets 2,033,234 3,318,992
 Operating lease right-of-use asset 132,881 145,787
 Property and equipment, net (Note 3) 3,248,610 2,895,558
 Total assets 5,414,725 6,360,337
 Current liabilities:    
Accounts payable and accrued expenses 549,425 1,360,644
 Deferred compensation (Note 4) 654,349 594,798
 Loan payable and accrued interest (Note 5)
 Total current liabilities 1,203,774 1,955,442
 Operating lease liability 132,113 128,864
 Convertible notes payable - affiliates (Note 6) 5,212,286 5,170,610
 Total liabilities 6,548,173 7,254,916
Bion's stockholders' equity (deficit):    
Common stock, no par value, 250,000,000 shares authorized, 44,303,654 and 43,758,820 shares issued, respectively; 43,599,345 and 43,054,511 shares outstanding, respectively
Additional paid-in capital 124,300,604 123,620,046
Subscription receivable - affiliates (Note 8) (504,650) (504,650)
Accumulated deficit (124,966,975) (124,047,548)
Total Bion's stockholders’ deficit (1,171,021) (932,152)
Noncontrolling interest 37,573 37,573
Total deficit (1,133,448) (894,579)
Total liabilities and deficit 5,414,725 6,360,337
Series B Preferred Stock [Member]    
 Current liabilities:    
Preferred stock
 Total current liabilities 0  
Series A Preferred Stock [Member]    
 Current liabilities:    
Preferred stock
Bion's stockholders' equity (deficit):    
Total deficit
Series C Preferred Stock [Member]    
 Current liabilities:    
Preferred stock
Bion's stockholders' equity (deficit):    
Total deficit
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Common Stock, Par or Stated Value Per Share   $ 0
Common stock, authorized (in shares) 250,000,000 250,000,000
Common Stock, Shares, Issued 44,303,654 43,758,820
Common Stock, Value, Outstanding $ 43,599,345 $ 43,054,511
Series B Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 50,000 50,000
Preferred stock, issued (in shares) 0 200
Preferred stock, outstanding (in shares) 0 200
Preferred stock, liquidation $ 0 $ 40,000
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 50,000 50,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Series C Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 60,000 60,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue
Operating expenses:    
General and administrative (including stock-based compensation) 866,494 491,133
Depreciation 330 248
Research and development (including stock-based compensation) 28,443 61,809
Total operating expenses 895,267 553,190
Loss from operations (895,267) (553,190)
Other (income) expense:    
Interest income (1,935) (1,494)
Interest expense 26,095 112,180
Total other expense 24,160 110,686
Net loss (919,427) (663,876)
Net loss attributable to the noncontrolling interest 506
Net loss applicable to Bion's common stockholders $ (919,427) $ (663,370)
Net loss applicable to Bion's common stockholders per basic and diluted common share $ (0.02) $ (0.02)
Weighted-average number of common shares outstanding:    
Basic and diluted 43,451,846 40,719,692
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDER'S EQUITY (DEFICIT) (Unaudited) - USD ($)
Series A Preferred Stock [Member]
Series C Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscriptions Receivable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Jun. 30, 2021 $ 121,399,067 $ (504,650) $ (132,339,873) $ 39,117 $ (11,406,339)
Beginning balance, shares at Jun. 30, 2021 41,315,986          
Warrants exercised for common shares 104,500 104,500
Warrants exercised for common shares , shares     139,334          
Commissions on warrant exercises (1,000) (1,000)
Commissions on warrant exercises , shares     10,000          
Conversion of debt and liabilities 5,126 5,126
Conversion of debt and liabilities, shares     10,253          
Net loss (663,370) (506) (663,876)
Ending balance, value at Sep. 30, 2021 121,507,693 (504,650) (133,003,243) 38,611 (11,961,589)
Ending balance, shares at Sep. 30, 2021   41,475,573          
Beginning balance, value at Jun. 30, 2022 123,620,046 (504,650) (124,047,548) 37,573 (894,579)
Beginning balance, shares at Jun. 30, 2022 43,758,820          
Sale of units 320,000 320,000
Sale of units, shares     320,000          
Warrants exercised for common shares 56,125 56,125
Warrants exercised for common shares , shares     74,834          
Issuance of units for services 80,000 80,000
Issuance of units for services, shares     50,000          
Issuance of warrants for services 15,000 15,000
Conversion of debt and liabilities 50,000 50,000
Conversion of debt and liabilities, shares     100,000          
Modification of warrants 159,433 159,433
Net loss (919,427) (919,427)
Ending balance, value at Sep. 30, 2022 $ 124,300,604 $ (504,650) $ (124,966,975) $ 37,573 $ (1,133,448)
Ending balance, shares at Sep. 30, 2022 44,303,654          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (919,427) $ (663,876)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 330 248
Accrued interest on loans payable, deferred compensation and other 26,096 121,111
Stock-based compensation 154,933
Stock-based compensation for services 95,000
Decrease (increase) in prepaid expenses 23,297 33,753
Increase (decrease) in accounts payable and accrued expenses (787,276) 59,367
Decrease in operating lease assets and liabilities 16,155
Increase in deferred compensation 75,000 99,400
Net cash used in operating activities (1,315,892) (349,997)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of property and equipment (322,694) (7,490)
Net cash used in investing activities (322,694) (7,490)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from exercise of warrants 56,125 104,500
Commissions on exercise of warrants (1,000)
Proceeds from sale of units 320,000
Net cash provided by financing activities 376,125 103,500
Net decrease in cash (1,262,461) (253,987)
Cash at beginning of year 3,160,442 4,216,321
Cash at end of year 1,897,981 3,962,334
Supplemental disclosure of cash flow information:    
Cash paid for interest
Non-cash investing and financing transactions:    
Conversion of debt and liabilities into notes payable 23,943
Conversion of deferred compensation to notes payable 20,000
Conversion of notes payable into shares 50,000
Capitalized interest in property and equipment 30,688
Shares issued for warrant exercise commissions 7,500
Shares issued for accounts payable 5,126
Purchase of property and equipment for accounts payable $ 54,800
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS
3 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS

1.  ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to create extraordinary value for our shareholders and employees (all of whom own securities in the Company) while delivering premium, sustainable products to our customers through ventures developing profitable, transparent, and sustainable solutions for livestock agriculture. 

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third-generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste stream ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures s (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3 Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of 2022 Bion began marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2023, Bion announced a letter of intent (“Ribbonwire LOI”) to develop its first large-scale commercial project, a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). The Dalhart Project will be developed to produce blockchain-verified, sustainable beef (with reduced the stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) while remediating the environmental impacts associated usually associated with cattle CAFOs. Bion’s patented technology will refine the waste stream into valuable coproducts that include clean water, renewable natural gas (RNG), photovoltaic solar electricity and organic fertilizer products. We anticipate converting the Ribbonwire LOI into a definitive joint venture agreement with Ribbonwire Ranch and creating distribution agreements with key retailers and food service distributors during the next six months.

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef joint venture projects over the next twelve months while moving forward with the Initial Project (see below) and the Dalhart Project (and/or other Gen3Tech beef joint venture projects) and pursuing other opportunities in the livestock industry enabled by our Gen3 Tech business model.  The Ribbonwire LOI announcement has generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment.

 

During the next six months, the Company intends to construct and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial setting by the end of the 2nd quarter in 2023 and supports development of the Dalhart Project (and/or other Gen3Tech beef joint venture projects) during 2023.  We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion is now focused primarily on: i) development/construction of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) development/construction of the Dalhart Project (and/or other Gen3Tech beef joint venture projects), iii) developing applications and markets for its low carbon organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product while raising sustainable livestock.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During July 2022, the Company entered into a letter of intent with Ribbonwire Ranch (Dalhart, Texas) (“Ribbonwire LOI”) setting forth the parties’ intention to negotiate a joint venture agreement and enter into a joint venture to develop and operate an initial 15,000 head integrated, sustainable beef facility on RWR property (“Dalhart Project”) including:

 

a)innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,
b)‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,
c)a Bion GEN3 Tech module (which will utilize the recycled CO2 to increase ammonium bicarbonate recovery) for the production of ammonium bicarbonate fertilizer for use in organic crop production (plus residual organic solids and clean water),
d)which will produce verifiably sustainable beef products with USDA certified branding.

The Dalhart Project will include expansion capability up to 60,000 head of cattle, in aggregate, located at/around/contiguous to the initial facilities on Ribbonwire property.

The opportunity presented by the Ribbonwire LOI to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation in Dalhart, TX a reality as soon as possible.

 

To place the Ribbonwire LOI and the Dalhart Project in the context of Company’s business plan (and our prior public disclosure), if the contemplated venture moves forward on the timelines set forth in the Ribbonwire LOI, active development of the Dalhart Project will commence early in the second quarter of 2023.

 

Prior to such activity, the Company intends to construct and operate the initial phase of the previously announced Gen3 Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion 3G Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the Dalhart Project). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, intends to utilize anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Construction and related activities of this demonstration project have commenced with main module assembly on site targeted to commence during January 2023 (somewhat delayed due to supply chain constraints) followed by operations through the first half of 2023 to generate the required information. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Company anticipates that it will negotiate additional letters of intent and enter into additional joint ventures related to the development of further commercial-scale sustainable beef projects over the next 6-18 months in addition to the Dalhart Project.

 

As previously disclosed, during late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility will be large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs have delayed likely delivery dates for core modules of the Bion system to the site until sometime during January 2023. 3G1 has been moving forward with the development process of the Initial Project. See Note 3 “Property and Equipment” and Note 10 “Subsequent Events” (for activities since the start of the second quarter of the 2023 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

Specifically, the Initial Project is being developed to provide and/or accomplish the following:

 

  i. Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

  ii. Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

  iii. Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.

 

  iv. Produce sustainable beef products for initial test marketing efforts.

 

The Initial Project will be carried out in stages with phase one focused on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project, (coupled with obtaining organic certifications(s) for our for our solid ammonium bicarbonate fertilizer product line), Bion expects to be ready to move forward with its plans for development of much larger facilities including the Dalhart Project. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 6-12 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the development/construction of the Initial Project with a 2023 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the core modules may be re-located to a subsequent more permanent location to be determined at a later date. The Company is in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3 Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) including innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company is also considering re-locating the core modules of the Initial Project to Dalhart, Texas, where they may be integrated into the first phases of the Dalhart Project. 

 

The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI, the California Department of Food & Agriculture (“CDFA”) and the Iowa Organic Program (“IOP”) and are in the review processes (which are likely to require an extended period of time and multiple procedural steps, in part due to the novel nature of our Gen3Tech in the context of organic certifications). See “Organic Fertilizer Listing/Certification Process” below.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project’ below as an example) in the swine, dairy and poultry industries utilizing our Gen3 Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/ dairy/ egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a certain segment of consumers are choosing seemingly sustainable offering, and are also willing to pay a premium for it. Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef is 63% more expensive today, while pork and chicken, which are now primarily raised in covered barns, at CAFOs with highly integrated supply chains, are 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and have enjoyed steady sales growth. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the only ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy.

 

It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy these concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be first to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in appropriate geographical locations) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

 

Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

Sustainable Organic Beef

 

Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Organic Fertilizer Listing/Certification Process

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of organically listed ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products.

 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line have been filed with OMRI (filed during May 2021), the Iowa Organic Program (“IOP”)(filed during March 2022) and the California Department of Food & Agriculture (“CDFA”)(filed during May 2022) and are each in the review process. The review processes are likely to require an extended period of time and multiple procedural steps with each entity in part due to the novel nature of Bion’s Gen3 Tech and our solid ammonium bicarbonate product in the context of organic certifications. The OMRI application has proceeded through multiple stages of review and rebuttal/appeal without receiving a positive result to date. The Company’s has recently filed responses to the CDFA’s initial set of questions and comments regarding our solid ammonium bicarbonate product line. The Company’s product line is novel in part due to the fact that there is not a formal listing category for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this matter with one or more listings/certifications of this product line well prior to operational dates for the Company’s initial large scale JV Gen3 Tech projects.

 

 Gen3 Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3 Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company has commenced discussions with Kreider Farms regarding updating the JVA to reflect the capabilities of our Gen3 Tech platform and anticipates executing an amended (or new) JVA during the current fiscal year. The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3 Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage, and the Company has additional applications pending and/or planned.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2023 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

 The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

 Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

Going concern and management’s plans:

 

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses of approximately $3,451,000 during the year ended June 30, 2021 and a net income of $8,292,000 for the year ended June 30, 2022. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of PA-1 resulting in a gain of approximately $10,235,000 as well as a one-time gain of $902,490 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. The Company incurred a net loss of $919,000 and $663,000 for the three months ended September 30, 2022 and 2021, respectively. At September 30, 2022, the Company has working capital and a stockholders’ deficit of approximately $1,171,000 and $829,000, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the years ended June 30, 2022 and 2021, the Company received gross proceeds of approximately $1,737,000 and $5,209,000, respectively, from the sale of its debt and equity securities.

 

During the three months ended September 30, 2022, the Company received total proceeds of approximately $376,000 from the sale of its equity securities.

 

During fiscal years 2022 and 2021, the Company has faced less difficulty in raising equity funding (but substantial equity dilution has gone along with the larger amounts of equity financing during the periods) than was experienced in the prior 3 years except that during the first three months of the current fiscal year, the Company has raised equity funds at a rate materially lower than the average rate during fiscal years 2021 and 2022. The Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) portions of their cash compensation and/or are accepting compensation in part in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent relative success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart Project), Integrated Projects and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at September 30, 2022, and the results of operations and cash flows of the Company for the three months ended September 30, 2022 and 2021. Operating results for the three months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of September 30, 2022 and June 30, 2022 there are no cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three months ended September 30, 2022 and 2021, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

        
   September 30,
2022
   September 30,
2021
 
Warrants   19,873,801    21,802,822 
Options   11,201,600    10,471,600 
Convertible debt   10,793,421    10,462,498 
Convertible preferred stock         20,250 

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three months ended September 30, 2022 and 2021:

 

        
   Three months
ended
September 30,
2022
   Three months
Ended
September 30,
2021
 
Shares issued – beginning of period   43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,054,511    40,611,677 
Weighted average shares issued
    during the period
   397,335    108,015 
Diluted weighted average shares –
    end of period
   43,451,846    40,719,692 

 

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT
3 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

3.  PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

 

        
   September 30,
2022
   June 30,
2022
 
Machinery and equipment  $     $   
Buildings and structures            
Computers and office equipment   13,598    13,598 
3G project construction in process   3,245,604    2,892,222 
 Property and equipment, gross    3,259,202    2,905,820 
Less accumulated depreciation   (10,592)   (10,262))
 Property and equipment, net   $3,248,610   $2,895,558 

 

The 3G project began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for 3G construction in process includes $62,688 for capitalized interest and $135,648 in non-cash compensation as of September 30, 2022.

 

Management has reviewed the remaining property and equipment for impairment as of September 30, 2022 and believes that no impairment exists.

 

Depreciation expense was $330 and $248 for the three months ended September 30, 2022 and 2021, respectively.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEFERRED COMPENSATION
3 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
DEFERRED COMPENSATION

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $654,349 and $528,640 as of September 30, 2022 and 2021, respectively. Included in the deferred compensation balances as of September 30, 2022, are $459,627 and $5,000 owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of September 30, 2021 was $436,920 and nil, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $117,222 and $19,220 as of September 30, 2022 and 2021, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 0% to 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing.

Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election.

During the three months ended September 30, 2022, Smith elected to convert $20,000 of deferred compensation into the 2020 Convertible Note.

The Company recorded interest expense of $4,551 ($4,119 with related parties) and $4,032 ($3,949 with related parties) for the three months ended September 30, 2022 and 2021, respectively, related to deferred compensation.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
LOANS PAYABLE
3 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
LOANS PAYABLE

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONVERTIBLE NOTES PAYABLE - AFFILIATES
3 Months Ended
Sep. 30, 2022
Convertible Notes Payable - Affiliates  
CONVERTIBLE NOTES PAYABLE - AFFILIATES

6.       CONVERTIBLE NOTES PAYABLE - AFFILIATES:

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations, which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”.

 

As of September 30, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees), Smith and Edward Schafer (“Schafer”), a director of the Company, were $2,620,941, $1,335,199 and $503,813, respectively. As of September 30, 2021, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $2,526,492, $1,253,335 and $485,658, respectively.

 

During the three months ended September 30, 2022, Smith elected to add $20,000 of his salary to his 2020 Convertible Obligations.

 

During the three months ended September 30, 2022, Smith elected to convert $30,000 in principal of the 2020 Convertible Obligation to 60,000 units (60,000 common shares and 60,000 warrants) and $20,000 of accrued interest of the 2020 Convertible Obligation to 40,000 units (40,000 common shares and 40,000 warrants).

 

The Company recorded interest expense of $41,367 and $40,560 for the three months ended September 30, 2022 and 2021, respectively. The Company capitalized $30,688 and nil related to the 3G project for the three months ended September 30, 2022 and 2021, respectively.

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani (now owned by Bassani Family Trusts), Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of September 30, 2022, including accrued interest owed Bassani Family Trusts, Schafer and Shareholder, are $281,789, $21,009 and $449,535, respectively. The balances of the September 2015 Convertible Notes as of September 30, 2021, including accrued interest, were $172,765, $20,354 and $434,419, respectively.

 

The Company recorded interest expense of $6,366 and $5,366 for the years ended September 30, 2022 and 2021, respectively, on the September 2015 Convertible Notes.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY
3 Months Ended
Sep. 30, 2022
Stockholders Equity  
STOCKHOLDERS' EQUITY

7.       STOCKHOLDERS' EQUITY:

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

During the years ended June 30, 2022, and 2021, the Company declared dividends of $1,000 and $2,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is no liability at September 30, 2022.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

During the three months ended September 30, 2022, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

During the three months ended September 30, 2022, 74,834 warrants were exercised to purchase 74,834 shares of the Company’s common stock at $0.75 per share for total proceeds of $56,125.

During the three months ended September 30, 2022, the Company issued 50,000 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.60 per share for a total value of $80,000.

During the three months ended September 30, 2022, the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 320,000 units for total proceeds of $320,000.

 

Warrants:

 

As of September 30, 2022, the Company had approximately 20.6 million warrants outstanding, with exercise prices from $0.60 to $1.60 and expiring on various dates through November 9, 2026.

 

The weighted-average exercise price for the outstanding warrants is $0.76, and the weighted-average remaining contractual life as of September 30, 2022 is 2.2 years.

 

During the three months ended September 30, 2022, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until three years after the date of conversion.

 

During the three months ended September 30, 2022, the Company approved the issuance of 150,000 warrants, in aggregate, to three new members of its Advisory Group for advisory and/or consulting services of $15,000, in aggregate. The warrants are exercisable at $1.50 to $1.60 and expire in August 2025.

During the three months ended September 30, 2022, the Company approved the modification of existing warrants held by one former consultant and four investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $154,933 and interest expenses of $4,500.

During the three months ended September 30, 2022, 74,834 warrants were exercised to purchase 74,834 shares of the Company’s common stock at $0.75 per share for total proceeds of $56,126.

 

Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

Stock options:

 

On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “Equity Plan”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,

 

On February 11, 2022, the Company granted 10,000 options under the 2006 Plan to one consultant.

 

On April 29, 2022, the Company granted an aggregate of 720,000 options under the 2006 Plan to seven employees/consultants/directors including: i) 50,000 options each to Schafer and Northrop for service as directors, ii) 200,000 options to Bassani (now COO of the Company and formerly CEO) and iii) 200,000 options to Smith, the Company’s President, which new option grants are included in the presentation below.

 

The Company recorded compensation expense related to employee stock options of nil and nil for the three months ended 2022 and 2021, respectively. The Company granted nil options during the three months ended September 30, 2022 and 2021, respectively.

 

A summary of option activity under the 2006 Plan for the three months ended September 30, 2022 is as follows:

                 
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2022    11,201,600   $0.80    2.7   $4,429,263 
   Granted                       
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at September 30, 2022    11,201,600   $0.80    2.48   $5,757,755 

 

 

The total fair value of stock options that vested during the three months ended September 30, 2022 and 2021 was nil. As of September 30, 2022, the Company had no unrecognized compensation cost related to stock options.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSCRIPTION RECEIVABLE - AFFILIATES
3 Months Ended
Sep. 30, 2022
Subscription Receivable - Affiliates  
SUBSCRIPTION RECEIVABLE - AFFILIATES

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of September 30, 2022, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($504,741, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum and are secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

As of September 30, 2022, the Company has an interest bearing, secured promissory note for $30,000 ($34,987 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at 4% per annum, and is secured by $30,000 ($35,361, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

As of September 30, 2022 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($55,472 including interest) from two former employees as consideration to purchase warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

9.       COMMITMENTS AND CONTINGENCIES:

 

Employment and consulting agreements:

 

Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $18,000 until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2022, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $25,000 per month of which $5,000 a month is deferred. For the three months ended September 30, 2022 and 2021, Smith was paid $60,000 and $54,000, respectively, of cash compensation.

 

Since March 31, 2005, the Company has had various agreements with Bassani (and/or Brightcap which provided his services during some of the initial years), now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’), (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which will continue to be accrued in part until there is adequate cash available. Additionally, the Company has agreed to pay him $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of September 30, 2022, the principal and accrued interest was $351,812. For the three months ended September 30, 2022 and 2021, Brightcap was paid $75,000 and $60,000, respectively, of cash compensation.

 

William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s GEN3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13th month) with compensation of $25,000 cash and $10,000 deferred compensation per month. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.  For the three months ended September 30, 2022 and 2021, O’Neill was paid $45,500 and nil, respectively, of cash compensation.

 

Execution/exercise bonuses:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant. These exercise bonuses were subsequently increased to 75%.

 

During the year ended June 30, 2021, the Company added a 75% execution/exercise bonus to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of September 30, 2022, the execution/exercise bonuses ranging from 50-90% were applicable to 10,966,600 of the Company’s outstanding options and 17,612,151 of the Company’s outstanding warrants.

 

Effective May 1, 2022, an entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.

 

Purchase Order Agreement:

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375)) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. On March 21, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next 25% payment ($666,375).  On June 6, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next 25% payment ($666,375) which was paid on July 5, 2022 bringing the aggregate payments to $1,999,125 as of the date of this report. No invoices were received in the quarter ended September 30, 2022. Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete and procurement/fabrication has now been initiated.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, etc.) for work related to the Initial Project.

 

Litigation:

 

A: Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations werebeen subject disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

The Company currently is not involved in any other material litigation or similar events.

 

Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of September 30, 2022:

 

     
Year ended June 30, 2023  $43,750 
Year ended June 30, 2024   75,000 
Year ended June 30, 2025   31,250 
Undiscounted cash flow   150,000 
Less imputed interest   (17,888)
Total  $132,112 

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of September 30, 2022 were 2.33 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSEQUENT EVENTS
3 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

10.        SUBSEQUENT EVENTS:

 

The Company has evaluated events that occurred subsequent to September 30, 2022 for recognition and disclosure in the financial statements and notes to the financial statements.

 

On October 28, 2022 the Company entered into a subscription agreement to sell 26,230 units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024 for total proceeds of $26,230.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Principles of consolidation

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at September 30, 2022, and the results of operations and cash flows of the Company for the three months ended September 30, 2022 and 2021. Operating results for the three months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.

 

Cash and cash equivalents

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of September 30, 2022 and June 30, 2022 there are no cash equivalents.

 

Property and equipment

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three months ended September 30, 2022 and 2021, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

        
   September 30,
2022
   September 30,
2021
 
Warrants   19,873,801    21,802,822 
Options   11,201,600    10,471,600 
Convertible debt   10,793,421    10,462,498 
Convertible preferred stock         20,250 

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three months ended September 30, 2022 and 2021:

 

        
   Three months
ended
September 30,
2022
   Three months
Ended
September 30,
2021
 
Shares issued – beginning of period   43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,054,511    40,611,677 
Weighted average shares issued
    during the period
   397,335    108,015 
Diluted weighted average shares –
    end of period
   43,451,846    40,719,692 

 

Use of estimates

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of anti dilutive securities
        
   September 30,
2022
   September 30,
2021
 
Warrants   19,873,801    21,802,822 
Options   11,201,600    10,471,600 
Convertible debt   10,793,421    10,462,498 
Convertible preferred stock         20,250 
Schedule of earnings per share, basic and diluted
        
   Three months
ended
September 30,
2022
   Three months
Ended
September 30,
2021
 
Shares issued – beginning of period   43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,054,511    40,611,677 
Weighted average shares issued
    during the period
   397,335    108,015 
Diluted weighted average shares –
    end of period
   43,451,846    40,719,692 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Tables)
3 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
        
   September 30,
2022
   June 30,
2022
 
Machinery and equipment  $     $   
Buildings and structures            
Computers and office equipment   13,598    13,598 
3G project construction in process   3,245,604    2,892,222 
 Property and equipment, gross    3,259,202    2,905,820 
Less accumulated depreciation   (10,592)   (10,262))
 Property and equipment, net   $3,248,610   $2,895,558 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY (Tables)
3 Months Ended
Sep. 30, 2022
Stockholders Equity  
Schedule of option activity
                 
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2022    11,201,600   $0.80    2.7   $4,429,263 
   Granted                       
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at September 30, 2022    11,201,600   $0.80    2.48   $5,757,755 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Tables)
3 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of future minimum lease payments
     
Year ended June 30, 2023  $43,750 
Year ended June 30, 2024   75,000 
Year ended June 30, 2025   31,250 
Undiscounted cash flow   150,000 
Less imputed interest   (17,888)
Total  $132,112 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative)
3 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
Decimal
Sep. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2018
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Tech wastage | Decimal 1,500        
Cattle per head | Decimal 300        
Percentage of sustainable 29.50%        
Description of kreider 2 poultry project Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3 Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).        
Net Income (loss)     $ 8,292,000 $ 3,451,000  
Net income     10,235,000    
Gain on sale of domain     902,490    
Operating loss $ 919,000 $ 663,000      
Working Capital 1,171,000        
Stockholders deficit 1,171,021   932,152    
Proceeds from Issuance or Sale of Equity 376,000   $ 1,737,000 $ 5,209,000  
Deferred Compensation Liability, Amount Cancelled         $ 2,404,000
Minimum [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Capital Required for Capital Adequacy 20,000,000        
Maximum [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Capital Required for Capital Adequacy $ 80,000,000        
Ribbonwire [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Tech wastage | Decimal 15,000        
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) - shares
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 19,873,801 21,802,822
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 11,201,600 10,471,600
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 10,793,421 10,462,498
Convertible Preferred Stock Antidilutive Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 20,250
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) - shares
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Accounting Policies [Abstract]    
Shares issued – beginning of period 43,758,820 41,315,986
Shares held by subsidiaries (Note 7) (704,309) (704,309)
Shares outstanding – beginning of period 43,054,511 40,611,677
Weighted average shares issued     during the period 397,335 108,015
Diluted weighted average shares –     end of period 43,451,846 40,719,692
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Cash equivalents $ 0 $ 0
Centerpoint [Member]    
Noncontrolling interest, ownership percentage by parent 58.90%  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT - Property and Equipment (Details) - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Property, Plant and Equipment [Abstract]    
Machinery and equipment
Buildings and structures
Computers and office equipment 13,598 13,598
3G project construction in process 3,245,604 2,892,222
 Property and equipment, gross  3,259,202 2,905,820
Less accumulated depreciation (10,592) (10,262)
 Property and equipment, net  $ 3,248,610 $ 2,895,558
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Property, Plant and Equipment [Line Items]    
Capitalized interest $ 62,688  
Non cash compensation 135,648  
Depreciation expense 330 $ 248
Property Plant And Equipment Of P A 1 [Member]    
Property, Plant and Equipment [Line Items]    
Impairment of Long-Lived Assets Held-for-use $ 0  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEFERRED COMPENSATION (Details Narrative) - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Deferred compensation liability $ 654,349 $ 528,640 $ 594,798
Interest Rate on Deferred Compensation 4.00%    
Deferred Compensation Consecutive Trading Days (Day) 10 days    
Interest Expense $ 26,095 112,180  
Interest Expense On Deferred Compensation Obligation [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Interest Expense 4,551 4,032  
Interest Expense, Related Party 4,119 3,949  
Bassani [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Deferred compensation liability   436,920  
Smith [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Deferred compensation liability   0  
Deferred Compensation, Convertible to Common Stock 20,000    
Chief Executive Officer [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Deferred compensation liability 459,627 5,000  
Deferred Compensation, Convertible to Common Stock $ 300,000    
Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share) $ 0.75    
Consultants [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Deferred compensation liability $ 117,222 $ 19,220  
Interest Rate on Deferred Compensation 0.00% 3.00%  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
LOANS PAYABLE (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 15, 2022
Mar. 21, 2022
Jan. 28, 2022
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 29, 2021
Sep. 25, 2014
Short-Term Debt [Line Items]                  
Total assets       $ 5,414,725 $ 297 $ 6,360,337   $ 0  
Total liabilities       6,548,173 10,154,334 7,254,916   10,234,501  
Accounts payable and accrued liabilities       549,425 9,939,148 1,360,644   10,009,802  
Accounts payable         214,235     212,263  
Accrued Liabilities, Current         950     $ 12,436  
Gain on legal dissolution of subsidiary       10,234,501          
Debt Instrument, Interest Rate During Period   25.00% 25.00%            
Loans as a liability           9,868,495 $ 9,868,495    
P A 1 [Member]                  
Short-Term Debt [Line Items]                  
Debt Instrument, Debt Default, Amount                 $ 8,137,117
Realized from the asset sale $ 104,725                
Pennvest Loan [Member]                  
Short-Term Debt [Line Items]                  
Construction Loan       10,010,000          
Accrued Interest and Late Charges Payable       2,255,802          
Line of Credit Facility, Maximum Borrowing Capacity       7,754,000          
Debt Instrument, Annual Principal Payment       5,886,000          
Long-Term Debt, Maturity, Year Two       846,000          
Long-Term Debt, Maturity, Year Three       873,000          
Long-Term Debt, Maturity, Year Four       149,000          
Interest Expense, Debt       $ 123,444 $ 246,887 $ 123,444 $ 246,887    
Pennvest Loan [Member] | Years One Through Five [Member]                  
Short-Term Debt [Line Items]                  
Debt Instrument, Interest Rate During Period       2.547%          
Pennvest Loan [Member] | Years Six Through Maturity [Member]                  
Short-Term Debt [Line Items]                  
Debt Instrument, Interest Rate During Period       3.184%          
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jan. 28, 2022
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Jan. 01, 2020
Short-Term Debt [Line Items]          
Original conversion price   $ 0.50      
Convertible Notes Payable, Noncurrent   $ 5,212,286   $ 5,170,610  
Debt conversion value $ 2,665,500        
Interest Expense   26,095 $ 112,180    
Capitalized amount   $ 30,688 0    
President [Member] | Secured Promissory Note [Member]          
Short-Term Debt [Line Items]          
Financing Receivable, Interest Rate, Stated Percentage   4.00%      
The 2020 Convertible Obligations [Member]          
Short-Term Debt [Line Items]          
Salary paid   $ 20,000      
The 2020 Convertible Obligations [Member] | Convertible Debt [Member]          
Short-Term Debt [Line Items]          
Debt Instrument, Interest Rate, Stated Percentage         4.00%
Debt Instrument, Interest Rate, Stated Percentage, Quarterly         4.00%
Conversion Price Per Unit (in dollars per share)         $ 0.50
Original conversion price   $ 0.50      
Interest Expense   $ 41,367 40,560    
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Chief Executive Officer [Member]          
Short-Term Debt [Line Items]          
Convertible Notes Payable, Noncurrent   2,620,941 2,526,492    
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | President [Member]          
Short-Term Debt [Line Items]          
Convertible Notes Payable, Noncurrent   1,335,199 1,253,335    
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Executive Vice Chairman [Member]          
Short-Term Debt [Line Items]          
Convertible Notes Payable, Noncurrent   503,813 485,658    
Principal [Member] | Convertible Obligations 2020 [Member]          
Short-Term Debt [Line Items]          
Debt conversion value   $ 30,000      
Debt conversion shares, warrants   60,000      
Principal [Member] | Convertible Obligations 2020 [Member] | Warrants [Member]          
Short-Term Debt [Line Items]          
Debt conversion shares, warrants   60,000      
Principal [Member] | Convertible Obligations 2020 [Member] | Common Shares [Member]          
Short-Term Debt [Line Items]          
Debt conversion shares, warrants   60,000      
Accrued Interest [Member] | Convertible Obligations 2020 [Member]          
Short-Term Debt [Line Items]          
Debt conversion value   $ 20,000      
Debt conversion shares, warrants   40,000      
Accrued Interest [Member] | Convertible Obligations 2020 [Member] | Common Shares [Member]          
Short-Term Debt [Line Items]          
Debt conversion shares, warrants   40,000      
Accrued Interest [Member] | Convertible Obligations 2020 [Member] | Warrants [Member]          
Short-Term Debt [Line Items]          
Debt conversion shares, warrants   40,000      
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member] | Bassani Family Trusts [Member]          
Short-Term Debt [Line Items]          
Convertible Notes Payable   $ 281,789 172,765    
September 2015 Convertible Notes [Member] | Executive Vice Chairman [Member] | Shareholder [Member]          
Short-Term Debt [Line Items]          
Convertible Notes Payable   449,535 434,419    
September 2015 Convertible Notes [Member] | Consultants [Member] | Schafer [Member]          
Short-Term Debt [Line Items]          
Convertible Notes Payable   $ 21,009 20,354    
September 2015 Convertible Notes [Member] | Convertible Debt [Member]          
Short-Term Debt [Line Items]          
Conversion Price Per Unit (in dollars per share)   $ 0.60      
Interest Expense   $ 6,366 $ 5,366    
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY - Stock Option Activity (Details) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2021
Stockholders Equity      
Options outstanding, beginning (in shares) 11,201,600    
Options outstanding, beginning weighted-average exercise price $ 0.80    
Outstanding, weighted-average remaining contractual life (Year) 2 years 5 months 23 days   2 years 8 months 12 days
Outstanding, aggregate intrinsic value beginning $ 4,429,263    
Granted    
Granted, weighted-average exercise price    
Exercised, options (in shares)    
Exercised, weighted-average exercise price    
Forfeited, options (in shares)    
Forfeited, weighted-average exercise price    
Expired, options (in shares)    
Expired, weighted-average exercise price    
Options outstanding, ending (in shares) 11,201,600    
Options outstanding, ending weighted-average exercise price $ 0.80    
Outstanding, aggregate intrinsic value ending $ 5,757,755    
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Feb. 11, 2022
Jul. 01, 2014
Apr. 29, 2022
Jan. 28, 2022
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
May 01, 2022
Jul. 03, 2014
Jul. 02, 2014
Redemption of convertible Preferred stock         $ 41,000          
Liability         $ 1,203,774   $ 1,955,442      
Shares Held by Subsidiaries (in shares)         704,309 704,309        
Debt conversion value       $ 2,665,500            
Conversion price per share         $ 0.50          
Warrants exercisable per share         $ 0.75          
Class of Warrant or Right, Exercised During Period (in shares)         74,834          
Common Stock Shares Issued upon Exercise of Warrants (in shares)         74,834          
Warrant Exercised for Common Stock         $ 56,125          
Share price         $ 1.60          
Total value of consultant services         $ 80,000          
Sale of unit, price per unit         $ 1.00          
Share price         $ 0.75          
Number of shares issued         320,000          
Number of shares issued, value         $ 320,000          
Class of Warrant or Right, Outstanding (in shares)         20,600,000          
Weighted average exercise price         $ 0.80   $ 0.80      
Issuance of warrants         $ 15,000          
Exercise bonus           75.00%        
Number of shares granted                  
Share-based Compensation, Granted     720,000              
Fair value of stock options         $ 0 $ 0        
Options Held [Member]                    
Share-based Compensation, Granted         0 0        
Schafer [Member]                    
Share-based Compensation, Granted     50,000              
Northrop [Member]                    
Share-based Compensation, Granted     50,000              
Bassani [Member]                    
Share-based Compensation, Granted     200,000              
Smith [Member]                    
Share-based Compensation, Granted     200,000              
Plan 2006 [Member]                    
Number of shares granted 10,000                  
Warrants [Member]                    
Weighted average exercise price         $ 0.76          
Remaining contractual life         2 years 2 months 12 days          
Share-Based Payment Arrangement, Option [Member]                    
Stock options, authorized (in shares)         36,000,000          
Share-based Payment Arrangement, Expense         $ 0 $ 0        
Share-Based Payment Arrangement, Option [Member] | Equity Incentive Plan [Member]                    
Stock options, authorized (in shares)         30,000,000          
Minimum [Member]                    
Warrants exercisable per share         $ 0.60          
Exercise bonus         50.00%          
Maximum [Member]                    
Warrants exercisable per share         $ 1.60          
Exercise bonus         90.00%          
Common Stock [Member]                    
Warrants exercisable per share         $ 0.75          
Shares issued for consultant services         50,000          
Total value of consultant services                  
Issuance of warrants                  
Warrant [Member]                    
Warrants exercisable per share         $ 0.75          
Common Stock Shares Issued upon Exercise of Warrants (in shares)         74,834          
Class of Warrant or Right, Outstanding (in shares)         74,834          
Issuance of warrants         $ 15,000          
Share-based Payment Arrangement, Plan Modification, Incremental Cost         154,933          
Interest expenses         4,500          
Warrant Exercised for Common Stock         $ 56,126          
President [Member]                    
Warrants exercisable per share         $ 0.75          
Two Consultants [Member] | Warrant [Member]                    
Class of Warrant or Right, Exercised During Period (in shares)         150,000          
Two Consultants [Member] | Warrant [Member] | Minimum [Member]                    
Warrants exercisable per share         $ 1.50          
Two Consultants [Member] | Warrant [Member] | Maximum [Member]                    
Warrants exercisable per share         $ 1.60          
Chief Executive Officer [Member]                    
Warrants exercisable per share               $ 1.00    
Number of shares issued               1,000,000    
Cancellation of warrants               700,000    
Exercise bonus               75.00%    
The 2020 Convertible Obligations [Member] | Principal [Member] | Warrant [Member]                    
Debt conversion value         $ 30,000          
The 2020 Convertible Obligations [Member] | Accrued Interest [Member] | Warrant [Member]                    
Debt conversion value         $ 20,000          
The 2020 Convertible Obligations [Member] | Convertible Debt [Member]                    
Conversion price per share         $ 0.50          
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Common Stock [Member]                    
Debt conversion shares         100,000          
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Warrant [Member]                    
Debt conversion shares         100,000          
Conversion price per share         $ 0.50          
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Principal [Member]                    
Debt conversion value         $ 30,000          
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Accrued Interest [Member]                    
Debt conversion value         $ 20,000          
Series B Preferred Stock [Member]                    
Preferred Stock, Shares Outstanding, Ending Balance (in shares)         0   200     200
Par value         $ 0.01   $ 0.01     $ 0.01
Preferred Stock, Convertible Option Per Share (in dollars per share)                 $ 2.00  
Preferred Stock, Dividend Rate, Percentage   2.50%                
Preferred Stock, Redemption Price Per Share (in dollars per share)                   $ 100
Dividends Payable         $ 21,000          
Dividends, Preferred Stock         1,000 $ 2,000        
Liability         $ 0          
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) - USD ($)
Sep. 30, 2022
May 01, 2022
Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75    
Secured Promissory Note [Member] | Smiths [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 35,361    
Financing Receivable, Principal Amount $ 30,000    
Chief Executive Officer [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)   $ 1.00  
Chief Executive Officer [Member] | Warrants Issused Subscription Receivable [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 5,565,000    
Chief Executive Officer [Member] | Secured Promissory Note [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 428,250    
Notes receivable interest $ 504,741    
President [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75    
President [Member] | Warrants Issused Subscription Receivable [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)     300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.60    
President [Member] | Secured Promissory Note [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 34,987    
Financing Receivable, Principal Amount $ 30,000    
Financing Receivable, Interest Rate, Stated Percentage 4.00%    
President [Member] | Warrants Issused Subscription Receivable [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 300,000    
Former Employee [Member] | Warrants Issused Subscription Receivable [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 928,000    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75    
Former Employee [Member] | Secured Promissory Note [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 55,472    
Financing Receivable, Principal Amount $ 46,400    
Financing Receivable, Interest Rate, Stated Percentage 4.00%    
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Details)
Sep. 30, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Year ended June 30, 2023 $ 43,750
Year ended June 30, 2024 75,000
Year ended June 30, 2025 31,250
Undiscounted cash flow 150,000
Less imputed interest (17,888)
Total $ 132,112
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 05, 2022
May 01, 2022
Oct. 10, 2016
Feb. 10, 2015
Mar. 31, 2023
Jun. 15, 2022
Mar. 23, 2022
Mar. 21, 2022
Jan. 28, 2022
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 29, 2021
Aug. 01, 2018
Feb. 28, 2018
Apr. 27, 2017
Oct. 31, 2016
Sep. 25, 2014
Loss Contingencies [Line Items]                                        
Warrants exercisable per share                   $ 0.75                    
Compensation increased   $ 25,000                                    
Cash compensation paid                   $ 154,933                  
Exercise bonus                     75.00%                  
Warrants held by trust owned                   3,000,000                    
Warrants and Rights Outstanding                   17,612,151                    
Debt instrument paid amount                 $ 2,665,500                      
Debt Instrument, Interest Rate During Period               25.00% 25.00%                      
Principal, interest               $ 666,375 $ 666,375                      
Aggregate payment $ 1,999,125                                      
Sale of domain, description             the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.                          
Loan related to construction                             $ 10,010,000          
Accrued interest                             2,255,802          
Total assets                   5,414,725 $ 297 $ 6,360,337     0          
Total liabilities                   6,548,173 10,154,334 7,254,916     10,234,501          
Accounts payable and accrued liabilities                   549,425 9,939,148 1,360,644     10,009,802          
Accounts payable                     214,235       212,263          
Accrued Liabilities, Current                     950       $ 12,436          
Gain on legal dissolution of subsidiary                   $ 10,234,501                    
Line of Credit, Current                       9,868,495 $ 9,868,495              
Weighted average remaining lease term                   2 years 3 months 29 days                    
Discounted rate                   10.00%                    
P A 1 [Member]                                        
Loss Contingencies [Line Items]                                        
Debt Instrument, Debt Default, Amount                                       $ 8,137,117
Gain (Loss) on Securitization of Financial Assets           $ 104,725                            
Pennvest Loan [Member]                                        
Loss Contingencies [Line Items]                                        
Line of Credit Facility, Maximum Borrowing Capacity                   $ 7,754,000                    
Debt Instrument, Annual Principal Payment                   5,886,000                    
Long-Term Debt, Maturity, Year Two                   846,000                    
Long-Term Debt, Maturity, Year Three                   873,000                    
Long-Term Debt, Maturity, Year Four                   149,000                    
Interest Expense, Debt                   $ 123,444 246,887 $ 123,444 $ 246,887              
Minimum [Member]                                        
Loss Contingencies [Line Items]                                        
Warrants exercisable per share                   $ 0.60                    
Exercise bonus                   50.00%                    
Maximum [Member]                                        
Loss Contingencies [Line Items]                                        
Warrants exercisable per share                   $ 1.60                    
Exercise bonus                   90.00%                    
Years One Through Five [Member] | Pennvest Loan [Member]                                        
Loss Contingencies [Line Items]                                        
Debt Instrument, Interest Rate During Period                   2.547%                    
Years Six Through Maturity [Member] | Pennvest Loan [Member]                                        
Loss Contingencies [Line Items]                                        
Debt Instrument, Interest Rate During Period                   3.184%                    
Smith [Member]                                        
Loss Contingencies [Line Items]                                        
Cash compensation paid                   $ 60,000 54,000                  
President [Member]                                        
Loss Contingencies [Line Items]                                        
Monthly Officers Cash Compensation     $ 18,000                                  
Warrants exercisable per share                   $ 0.75                    
President [Member] | Extension Bonus [Member] | Fy 2016 Extension Agreement [Member]                                        
Loss Contingencies [Line Items]                                        
Deferred Compensation, Maximum Convertible Amount                                   $ 300,000 $ 125,000  
Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)                                   $ 0.75 $ 0.75  
President [Member] | Warrants Issused Subscription Receivable [Member]                                        
Loss Contingencies [Line Items]                                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                           300,000            
Warrants exercisable per share                   0.60                    
President [Member] | Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member]                                        
Loss Contingencies [Line Items]                                        
Warrants exercisable per share                   $ 0.75                    
Chief Executive Officer [Member]                                        
Loss Contingencies [Line Items]                                        
Monthly Officers Cash Compensation       $ 31,000           $ 25,000                    
Warrants exercisable per share   $ 1.00                                    
Cash compensation paid                   45,500 0                  
Deferred Compensation, Maximum Convertible Amount                   10,000                    
Exercise bonus   75.00%                                    
Number of shares issued   1,000,000                                    
Cancellation of warrants   700,000                                    
Chief Executive Officer [Member] | Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member]                                        
Loss Contingencies [Line Items]                                        
Financing Receivable, after Allowance for Credit Loss, Total                   351,812                    
Repayments of Long-term Debt, Total                   $ 75,000 $ 60,000                  
Chief Executive Officer [Member] | Warrants Issused Subscription Receivable [Member]                                        
Loss Contingencies [Line Items]                                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                   5,565,000                    
Chief Executive Officer [Member] | Warrants Expiring On December 312025 [Member]                                        
Loss Contingencies [Line Items]                                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                               3,000,000        
Bassani [Member]                                        
Loss Contingencies [Line Items]                                        
Salaries and wages                                 $ 31,000      
Additional paid amount                                 $ 2,000      
Bassani [Member] | Forecast [Member]                                        
Loss Contingencies [Line Items]                                        
Interest bearing secured promissory note         $ 300,000                              
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
1 Months Ended
Oct. 28, 2022
Sep. 30, 2022
Subsequent Event [Line Items]    
Sale of units, price per share   $ 1.60
Subsequent Event [Member]    
Subsequent Event [Line Items]    
Sale of units 26,230  
Sale of units, price per unit $ 1.00  
Sale of units, price per share $ 0.75  
Expiry date Dec. 31, 2024  
Proceeds from sale of units $ 26,230  
XML 47 bion_10q-093022_htm.xml IDEA: XBRL DOCUMENT 0000875729 2022-07-01 2022-09-30 0000875729 2022-11-01 0000875729 2022-09-30 0000875729 2022-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2022-09-30 0000875729 us-gaap:SeriesBPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-09-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-09-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-06-30 0000875729 2021-07-01 2021-09-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-06-30 0000875729 us-gaap:CommonStockMember 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-06-30 0000875729 2021-06-30 0000875729 us-gaap:CommonStockMember 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-07-01 2021-09-30 0000875729 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000875729 bnet:SubscriptionsReceivableMember 2021-07-01 2021-09-30 0000875729 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-07-01 2022-09-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-07-01 2022-09-30 0000875729 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000875729 bnet:SubscriptionsReceivableMember 2022-07-01 2022-09-30 0000875729 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-09-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-09-30 0000875729 us-gaap:CommonStockMember 2021-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000875729 bnet:SubscriptionsReceivableMember 2021-09-30 0000875729 us-gaap:RetainedEarningsMember 2021-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-09-30 0000875729 2021-09-30 0000875729 us-gaap:CommonStockMember 2022-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000875729 bnet:SubscriptionsReceivableMember 2022-09-30 0000875729 us-gaap:RetainedEarningsMember 2022-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-09-30 0000875729 bnet:RibbonwireMember 2022-07-01 2022-09-30 0000875729 2020-07-01 2021-06-30 0000875729 2021-07-01 2022-06-30 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2022-09-30 0000875729 srt:MaximumMember 2022-09-30 0000875729 bnet:CenterpointMember 2022-09-30 0000875729 us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 us-gaap:WarrantMember 2021-07-01 2021-09-30 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2022-09-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2021-09-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2022-07-01 2022-09-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2021-07-01 2021-09-30 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2022-07-01 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2021-09-30 0000875729 bnet:BassaniMember 2021-09-30 0000875729 bnet:SmithMember 2021-09-30 0000875729 bnet:ConsultantsMember 2022-09-30 0000875729 bnet:ConsultantsMember 2021-09-30 0000875729 bnet:SmithMember 2022-09-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-07-01 2022-09-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-07-01 2021-09-30 0000875729 bnet:PennvestLoanMember 2022-09-30 0000875729 2021-12-29 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2022-07-01 2022-09-30 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2022-07-01 2022-09-30 0000875729 bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2020-07-01 2021-06-30 0000875729 bnet:PA1Member 2014-09-25 0000875729 bnet:PA1Member 2022-06-01 2022-06-15 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-09-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-09-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-09-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-09-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-09-30 0000875729 bnet:The2020ConvertibleObligationsMember 2022-07-01 2022-09-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2022-09-30 0000875729 bnet:CommonSharesMember bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2022-09-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2022-07-01 2022-09-30 0000875729 bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2022-09-30 0000875729 bnet:CommonSharesMember bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2022-09-30 0000875729 bnet:WarrantsMember bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2022-09-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2022-09-30 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2022-09-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2021-09-30 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2021-09-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2021-09-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-02 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-03 0000875729 us-gaap:SeriesBPreferredStockMember 2014-06-25 2014-07-01 0000875729 us-gaap:SeriesBPreferredStockMember 2022-07-01 2022-09-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-07-01 2021-09-30 0000875729 bnet:PrincipalMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0000875729 bnet:AccruedInterestMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-09-30 0000875729 srt:PresidentMember 2022-09-30 0000875729 bnet:WarrantsMember 2022-09-30 0000875729 bnet:WarrantsMember 2022-07-01 2022-09-30 0000875729 bnet:PrincipalMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 bnet:AccruedInterestMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-09-30 0000875729 us-gaap:WarrantMember 2022-09-30 0000875729 bnet:TwoConsultantsMember us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 us-gaap:WarrantMember 2022-07-01 2022-09-30 0000875729 srt:MinimumMember bnet:TwoConsultantsMember us-gaap:WarrantMember 2022-09-30 0000875729 srt:MaximumMember bnet:TwoConsultantsMember us-gaap:WarrantMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-05-01 0000875729 us-gaap:EmployeeStockOptionMember bnet:EquityIncentivePlanMember 2022-09-30 0000875729 us-gaap:EmployeeStockOptionMember 2022-09-30 0000875729 bnet:Plan2006Member 2022-02-01 2022-02-11 0000875729 2022-04-01 2022-04-29 0000875729 bnet:SchaferMember 2022-04-01 2022-04-29 0000875729 bnet:NorthropMember 2022-04-01 2022-04-29 0000875729 bnet:BassaniMember 2022-04-01 2022-04-29 0000875729 bnet:SmithMember 2022-04-01 2022-04-29 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000875729 us-gaap:OptionMember 2022-07-01 2022-09-30 0000875729 us-gaap:OptionMember 2021-07-01 2021-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteMember 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-09-30 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-09-30 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-09-30 0000875729 bnet:SmithsMember bnet:SecuredPromissoryNoteMember 2022-09-30 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2022-09-30 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-09-30 0000875729 srt:PresidentMember 2016-10-01 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2021-12-31 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2022-09-30 0000875729 2022-04-30 2022-05-01 0000875729 bnet:SmithMember 2022-07-01 2022-09-30 0000875729 bnet:SmithMember 2021-07-01 2021-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 srt:ScenarioForecastMember bnet:BassaniMember 2023-03-01 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-07-01 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-07-01 2021-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-07-01 2022-09-30 0000875729 srt:ChiefExecutiveOfficerMember 2021-07-01 2021-09-30 0000875729 2022-01-01 2022-01-28 0000875729 2022-03-02 2022-03-21 0000875729 2022-07-01 2022-07-05 0000875729 2022-03-02 2022-03-23 0000875729 bnet:PennvestLoanMember 2022-07-01 2022-09-30 0000875729 bnet:PennvestLoanMember 2021-07-01 2021-09-30 0000875729 us-gaap:SubsequentEventMember 2022-10-01 2022-10-28 0000875729 us-gaap:SubsequentEventMember 2022-10-28 iso4217:USD shares iso4217:USD shares pure bnet:Decimal 0000875729 false --06-30 2023 Q1 10-Q true 2022-09-30 false 000-19333 Bion Environmental Technologies, Inc CO 84-1176672 9 East Park Court Old Bethpage NY 11804 516 586-5643 Common Stock BNET Yes Yes Non-accelerated Filer true false false 43625575 1897981 3160442 134253 157550 1000 1000 2033234 3318992 132881 145787 3248610 2895558 5414725 6360337 549425 1360644 0.01 0.01 50000 50000 0 0 200 200 0 40000 654349 594798 1203774 1955442 132113 128864 5212286 5170610 6548173 7254916 0.01 0.01 50000 50000 0 0 0 0 0.01 0.01 60000 60000 0 0 0 0 0 250000000 250000000 44303654 43758820 43599345 43054511 124300604 123620046 504650 504650 -124966975 -124047548 -1171021 -932152 37573 37573 -1133448 -894579 5414725 6360337 866494 491133 330 248 28443 61809 895267 553190 -895267 -553190 1935 1494 26095 112180 -24160 -110686 -919427 -663876 -506 -919427 -663370 -0.02 -0.02 43451846 40719692 41315986 121399067 -504650 -132339873 39117 -11406339 139334 104500 104500 10000 -1000 -1000 10253 5126 5126 -663370 -506 -663876 41475573 121507693 -504650 -133003243 38611 -11961589 43758820 123620046 -504650 -124047548 37573 -894579 320000 320000 320000 74834 56125 56125 50000 80000 80000 15000 15000 100000 50000 50000 159433 159433 -919427 -919427 44303654 124300604 -504650 -124966975 37573 -1133448 -919427 -663876 330 248 26096 121111 154933 95000 -23297 -33753 -787276 59367 16155 75000 99400 -1315892 -349997 322694 7490 -322694 -7490 56125 104500 1000 320000 376125 103500 -1262461 -253987 3160442 4216321 1897981 3962334 23943 20000 50000 30688 7500 5126 54800 <p id="xdx_801_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zHbxJv8Y5Nob" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>1.  <b><span id="xdx_823_z7aoVxQoWLCb">ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS</span>:</b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Organization and nature of business: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to create extraordinary value for our shareholders and employees (all of whom own securities in the Company) while delivering premium, sustainable products to our customers through ventures developing profitable, transparent, and sustainable solutions for livestock agriculture. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third-generation technology and business/technology platform (“Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste stream ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate groundwater, and exacerbate climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s business model and technology platform can create the opportunity for joint ventures s (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s Gen3 Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">During the first half of 2022 Bion began marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2023, Bion announced a letter of intent (“Ribbonwire LOI”) to develop its first large-scale commercial project, a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). The Dalhart Project will be developed to produce blockchain-verified, sustainable beef (with reduced the stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) while remediating the environmental impacts associated usually associated with cattle CAFOs. Bion’s patented technology will refine the waste stream into valuable coproducts that include clean water, renewable natural gas (RNG), photovoltaic solar electricity and organic fertilizer products. We anticipate converting the Ribbonwire LOI into a definitive joint venture agreement with Ribbonwire Ranch and creating distribution agreements with key retailers and food service distributors during the next six months.</p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef joint venture projects over the next twelve months while moving forward with the Initial Project (see below) and the Dalhart Project (and/or other Gen3Tech beef joint venture projects) and pursuing other opportunities in the livestock industry enabled by our Gen3 Tech business model.  The Ribbonwire LOI announcement has generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties). We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the next six months, the Company intends to construct and begin operations of phase 1 of our Initial Project located near Fair Oaks, Indiana. Bion expects the Initial Project to provide data that illustrates the effectiveness of our Gen3Tech in a commercial setting by the end of the 2<sup>nd</sup> quarter in 2023 and supports development of the Dalhart Project (and/or other Gen3Tech beef joint venture projects) during 2023.  We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion is now focused primarily on: i) development/construction of the Initial Project, our initial commercial-scale Gen3Tech installation, ii) development/construction of the Dalhart Project (and/or other Gen3Tech beef joint venture projects), iii) developing applications and markets for its low carbon organic fertilizer products and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed below) (and related projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&amp;D activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><b>HISTORY, BACKGROUND AND CURRENT ACTIVITIES</b></p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product while raising sustainable livestock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a large production/marketing opportunity for Bion. Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During July 2022, the Company entered into a letter of intent with Ribbonwire Ranch (Dalhart, Texas) (“Ribbonwire LOI”) setting forth the parties’ intention to negotiate a joint venture agreement and enter into a joint venture to develop and operate an initial <span id="xdx_90C_ecustom--Techwastage_uDecimal_c20220701__20220930__srt--CounterpartyNameAxis__custom--RibbonwireMember_zTyjW84CeOi4" title="Tech Wastage">15,000</span> head integrated, sustainable beef facility on RWR property (“Dalhart Project”) including:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt/107% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in"><span style="font-size: 10pt">a)</span></td><td><span style="font-size: 10pt">innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt/107% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in"><span style="font-size: 10pt">b)</span></td><td><span style="font-size: 10pt">‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt/107% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in"><span style="font-size: 10pt">c)</span></td><td><span style="font-size: 10pt">a Bion GEN3 Tech module (which will utilize the recycled CO2 to increase ammonium bicarbonate recovery) for the production of ammonium bicarbonate fertilizer for use in organic crop production (plus residual organic solids and clean water),</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt/107% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt"><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in"><span style="font-size: 10pt">d)</span></td><td><span style="font-size: 10pt">which will produce verifiably sustainable beef products with USDA certified branding.</span></td></tr></table> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">The Dalhart Project will include expansion capability up to 60,000 head of cattle, in aggregate, located at/around/contiguous to the initial facilities on Ribbonwire property.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The opportunity presented by the Ribbonwire LOI to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation in Dalhart, TX a reality as soon as possible.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To place the Ribbonwire LOI and the Dalhart Project in the context of Company’s business plan (and our prior public disclosure), if the contemplated venture moves forward on the timelines set forth in the Ribbonwire LOI, active development of the Dalhart Project will commence early in the second quarter of 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Prior to such activity, the Company intends to construct and operate the initial phase of the previously announced Gen3 Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion 3G Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the Dalhart Project). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, intends to utilize anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Construction and related activities of this demonstration project have commenced with main module assembly on site targeted to commence during January 2023 (somewhat delayed due to supply chain constraints) followed by operations through the first half of 2023 to generate the required information. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company anticipates that it will negotiate additional letters of intent and enter into additional joint ventures related to the development of further commercial-scale sustainable beef projects over the next 6-18 months in addition to the Dalhart Project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously disclosed, during late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately <span id="xdx_901_ecustom--CattlePerHead_uDecimal_c20220701__20220930_z6L6DxPsant9" title="Cattle per head">300</span> head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately <span id="xdx_902_ecustom--Techwastage_uDecimal_c20220701__20220930_zZGWlBq5j736" title="Tech wastage">1,500</span> head). The facility will be large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs have delayed likely delivery dates for core modules of the Bion system to the site until sometime during January 2023. 3G1 has been moving forward with the development process of the Initial Project. See Note 3 “Property and Equipment” and Note 10 “Subsequent Events” (for activities since the start of the second quarter of the 2023 fiscal year).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Specifically, the Initial Project is being developed to provide and/or accomplish the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">i.</span></td> <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Proof of Gen3Tech platform scalability</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">-</span></td> <td><span style="font-size: 10pt">Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3technology platform.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">-</span></td> <td><span style="font-size: 10pt">Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">ii.</span></td> <td><span style="font-size: 10pt">Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">iii.</span></td> <td><span style="font-size: 10pt">Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) for commercial testing by potential joint venture partners and/or purchasers and for university growth trials.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-size: 10pt">iv.</span></td> <td><span style="font-size: 10pt">Produce sustainable beef products for initial test marketing efforts.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project will be carried out in stages with phase one focused on portions of items i. and iii. set forth above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon completing the primary goals of phase 1 of the Initial Project, (coupled with obtaining organic certifications(s) for our for our solid ammonium bicarbonate fertilizer product line), Bion expects to be ready to move forward with its plans for development of much larger facilities including the Dalhart Project. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 6-12 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the development/construction of the Initial Project with a 2023 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.</p> <p style="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the core modules may be re-located to a subsequent more permanent location to be determined at a later date. The Company is in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3 Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) including innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company is also considering re-locating the core modules of the Initial Project to Dalhart, Texas, where they may be integrated into the first phases of the Dalhart Project. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI, the California Department of Food &amp; Agriculture (“CDFA”) and the Iowa Organic Program (“IOP”) and are in the review processes (which are likely to require an extended period of time and multiple procedural steps, in part due to the novel nature of our Gen3Tech in the context of organic certifications). See “Organic Fertilizer Listing/Certification Process” below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘<b><span style="text-decoration: underline">Gen3Tech Kreider 2 Poultry Project’</span></b> below as an example) in the swine, dairy and poultry industries utilizing our Gen3 Tech.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/ dairy/ egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a certain segment of consumers are choosing seemingly sustainable offering, and are also willing to pay a premium for it. Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is <span id="xdx_902_ecustom--PercentageOfSustainable_dp_c20220701__20220930_zf0gMHWKHqXe" title="Percentage of sustainable">29.5</span> percent on average.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef is 63% more expensive today, while pork and chicken, which are now primarily raised in covered barns, at CAFOs with highly integrated supply chains, are 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. Meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, are being heavily promoted by themselves and the media, and have enjoyed steady sales growth. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have recently entered the plant protein space. In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the only ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy these concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s goal is to be first to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at a Bion facility will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in appropriate geographical locations) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Organic Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Organic Fertilizer Listing/Certification Process</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of organically listed ammonium bicarbonate products. The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line have been filed with OMRI (filed during May 2021), the Iowa Organic Program (“IOP”)(filed during March 2022) and the California Department of Food &amp; Agriculture (“CDFA”)(filed during May 2022) and are each in the review process. The review processes are likely to require an extended period of time and multiple procedural steps with each entity in part due to the novel nature of Bion’s Gen3 Tech and our solid ammonium bicarbonate product in the context of organic certifications. The OMRI application has proceeded through multiple stages of review and rebuttal/appeal without receiving a positive result to date. The Company’s has recently filed responses to the CDFA’s initial set of questions and comments regarding our solid ammonium bicarbonate product line. The Company’s product line is novel in part due to the fact that there is not a formal listing category for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produced it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company anticipates positive resolution of this matter with one or more listings/certifications of this product line well prior to operational dates for the Company’s initial large scale JV Gen3 Tech projects.</p> <p style="font: 10pt/110% Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <b><span style="text-decoration: underline">Gen3 Tech Kreider 2 Poultry Project</span></b></p> <p style="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90F_ecustom--DescriptionOfKreider2PoultryProject_c20220701__20220930_z6wQHfDfPsbj" title="Description of kreider 2 poultry project">Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3 Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).</span> Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company has commenced discussions with Kreider Farms regarding updating the JVA to reflect the capabilities of our Gen3 Tech platform and anticipates executing an amended (or new) JVA during the current fiscal year. The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3 Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.</p> <p style="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Technology Deployment: Bion Gen3Tech</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage, and the Company has additional applications pending and/or planned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2023 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <b><span style="text-decoration: underline">The Livestock Problem</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going concern and management’s plans:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses of approximately $<span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20200701__20210630_zFrIukM5MWe7" title="Net Income (loss)">3,451,000</span> during the year ended June 30, 2021 and a net income of $<span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210701__20220630_zqCRg9uTJdT1" title="Net Income (loss)">8,292,000</span> for the year ended June 30, 2022. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of PA-1 resulting in a gain of approximately $<span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperations_pp0p0_c20210701__20220630_zHtnYeVhM3o5" title="Net income">10,235,000</span> as well as a one-time gain of $<span id="xdx_901_ecustom--GainOnSaleOfDomainAmount_c20210701__20220630_z9bqHPHEAnVb" title="Gain on sale of domain">902,490</span> from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. The Company incurred a net loss of $<span id="xdx_909_ecustom--OperatingLoss_c20220701__20220930_zIMOdoitlaPg" title="Operating loss">919,000</span> and $<span id="xdx_90E_ecustom--OperatingLoss_c20210701__20210930_zzt4wDu99srk" title="Operating loss">663,000</span> for the three months ended September 30, 2022 and 2021, respectively. At September 30, 2022, the Company has working capital and a stockholders’ deficit of approximately $<span id="xdx_90C_ecustom--WorkingCapital_c20220930_z39NPwsoK5Q4" title="Working Capital">1,171,000</span> and $829,000, <span id="xdx_90A_eus-gaap--StockholdersEquity_iNI_pp0p0_di_c20220930_zMmuhITTnrDj" style="display: none" title="Stockholders deficit">1,171,021</span> respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2022 and 2021, the Company received gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210701__20220630_zpTFOhYV72Rl" title="Proceeds from Issuance or Sale of Equity">1,737,000</span> and $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20200701__20210630_z3SXq5aCBjva" title="Proceeds from Issuance or Sale of Equity">5,209,000</span>, respectively, from the sale of its debt and equity securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended September 30, 2022, the Company received total proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220701__20220930_z3NXokpfOnq5" title="Proceeds from Issuance or Sale of Equity">376,000</span> from the sale of its equity securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal years 2022 and 2021, the Company has faced less difficulty in raising equity funding (but substantial equity dilution has gone along with the larger amounts of equity financing during the periods) than was experienced in the prior 3 years except that during the first three months of the current fiscal year, the Company has raised equity funds at a rate materially lower than the average rate during fiscal years 2021 and 2022. The Company anticipates substantial increases in demands for capital and operating expenditures as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management challenges due to limited capital resources and working capital constraints which have only recently begun to be alleviated. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) portions of their cash compensation and/or are accepting compensation in part in the form of securities of the Company and/or converting portions of their compensation and deferred compensation to securities of the Company (Notes 5 and 7) and members of the Company’s senior management have made loans to the Company from time to time. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $<span id="xdx_907_ecustom--DeferredCompensationLiabilityAmountCancelled_c20170701__20180630_zi0ziSppktda" title="Deferred Compensation Liability, Amount Cancelled">2,404,000</span>. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to continue its recent relative success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and curtailment of ongoing activities including research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart Project), Integrated Projects and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $<span id="xdx_903_eus-gaap--CapitalRequiredForCapitalAdequacy_iI_pp0p0_c20220930__srt--RangeAxis__srt--MinimumMember_z9VJemxB9wEe" title="Capital Required for Capital Adequacy">20,000,000</span> to $<span id="xdx_90C_eus-gaap--CapitalRequiredForCapitalAdequacy_iI_pp0p0_c20220930__srt--RangeAxis__srt--MaximumMember_zKIiW44PMxeg" title="Capital Required for Capital Adequacy">80,000,000</span> or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Covid-19 pandemic related matters:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 15000 300 1500 0.295 Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3 Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). 3451000 8292000 10235000 902490 919000 663000 1171000 -1171021 1737000 5209000 376000 2404000 20000000 80000000 <p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zDiRYvXzB1Ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2.       <span id="xdx_826_zBH7xFCSs3Y">SIGNIFICANT ACCOUNTING POLICIES</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_znQqXbHdNPBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_866_zF5lcfmDJJK6">Principles of consolidation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its <span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20220930__srt--OwnershipAxis__custom--CenterpointMember_z4e85GSOmuaf" title="Noncontrolling interest, ownership percentage by parent">58.9</span>% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at September 30, 2022, and the results of operations and cash flows of the Company for the three months ended September 30, 2022 and 2021. Operating results for the three months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBZcnlHwNvL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zrF99QdW4Sad">Cash and cash equivalents</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of September 30, 2022 and June 30, 2022 there are <span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20220930_zh7aR6oGBIwk" title="Cash equivalents"><span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20220630_zet6tVan5221" title="Cash equivalents">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zf4mz99qgEyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span id="xdx_868_zcesmvX5P0yk">Property and equipment</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_z15QVxe0RdI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zWg51YEkymE9">Patents</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zYf7jvnnvWq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_866_zSREs7OfJzhg">Stock-based compensation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zRFAW25hR422" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_868_zwWZsIRWsHq8">Derivative Financial Instruments</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_zpxMf8JuVxy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zcUrS0smXLH9">Options</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zMu5exCVpyRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zHb4V003dLa1">Warrants</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zhCldYSRz2Ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zXyeBee8OZx4">Concentrations of credit risk</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_ecustom--MinorityInterestPolicyPolicyTextBlock_zEnEiGjUtVba" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_z4dyJbsyYyeg">Noncontrolling interests</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zNmeGYkfpGHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zo022mKpglT2">Fair value measurements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--LessorLeasesPolicyTextBlock_zNESGU5Jg83" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zcuWKux85l77">Lease Accounting</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zcZnarhozDZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zTyDepeOnFtd">Revenue Recognition</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zCqeYryqajMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_znvnzPEC386j">Income (Loss) per share</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three months ended September 30, 2022 and 2021, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBcSbC3P7l04" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span id="xdx_8B5_zbYFxtmO7fH4" style="display: none">Schedule of anti dilutive securities</span></td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>September 30, <br/> 2022</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>September 30, <br/> 2021</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Warrants</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">19,873,801</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">21,802,822</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Options</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,471,600</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Convertible debt</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,793,421</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,462,498</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Convertible preferred stock</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0636">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">20,250</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zQvq5Bn3Z723" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three months ended September 30, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zCsaAuIr2TM" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span id="xdx_8BA_zNhJYW2UiWvg" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td colspan="2" id="xdx_492_20220701__20220930_znJ9RhvoQe5a" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_492_20210701__20210930_z1dkLu9MHebg" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>ended <br/>September 30, <br/>2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>Ended <br/>September 30, <br/>2021</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr id="xdx_406_ecustom--SharesIssuedBeginningOfPeriod_z9acJssNVupa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">43,758,820</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">41,315,986</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--SharesHeldBySubsidiaries_iN_di_zejoFH00Azo5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_zTCiqlWgZqm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,054,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,611,677</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--WeightedAverageSharesIssuedDuringPeriod_zjL839YN2NMb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">397,335</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">108,015</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zelxqmf7mtec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,451,846</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">40,719,692</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zVbauxVDOXyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p id="xdx_84C_eus-gaap--UseOfEstimates_z3EaJNUzrHZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zPoK3X2XOqZd">Use of estimates</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1ojBlKGN1Mj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zrokbKqHKG72">Recent Accounting Pronouncements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_znQqXbHdNPBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_866_zF5lcfmDJJK6">Principles of consolidation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its <span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20220930__srt--OwnershipAxis__custom--CenterpointMember_z4e85GSOmuaf" title="Noncontrolling interest, ownership percentage by parent">58.9</span>% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at September 30, 2022, and the results of operations and cash flows of the Company for the three months ended September 30, 2022 and 2021. Operating results for the three months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0.589 <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBZcnlHwNvL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zrF99QdW4Sad">Cash and cash equivalents</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of September 30, 2022 and June 30, 2022 there are <span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20220930_zh7aR6oGBIwk" title="Cash equivalents"><span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20220630_zet6tVan5221" title="Cash equivalents">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 0 0 <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zf4mz99qgEyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span id="xdx_868_zcesmvX5P0yk">Property and equipment</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_z15QVxe0RdI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zWg51YEkymE9">Patents</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zYf7jvnnvWq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_866_zSREs7OfJzhg">Stock-based compensation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zRFAW25hR422" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_868_zwWZsIRWsHq8">Derivative Financial Instruments</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_zpxMf8JuVxy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zcUrS0smXLH9">Options</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zMu5exCVpyRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zHb4V003dLa1">Warrants</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zhCldYSRz2Ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_864_zXyeBee8OZx4">Concentrations of credit risk</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_ecustom--MinorityInterestPolicyPolicyTextBlock_zEnEiGjUtVba" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_z4dyJbsyYyeg">Noncontrolling interests</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zNmeGYkfpGHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zo022mKpglT2">Fair value measurements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--LessorLeasesPolicyTextBlock_zNESGU5Jg83" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zcuWKux85l77">Lease Accounting</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zcZnarhozDZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zTyDepeOnFtd">Revenue Recognition</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zCqeYryqajMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_znvnzPEC386j">Income (Loss) per share</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three months ended September 30, 2022 and 2021, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBcSbC3P7l04" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span id="xdx_8B5_zbYFxtmO7fH4" style="display: none">Schedule of anti dilutive securities</span></td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>September 30, <br/> 2022</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>September 30, <br/> 2021</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Warrants</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">19,873,801</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">21,802,822</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Options</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,471,600</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Convertible debt</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,793,421</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,462,498</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Convertible preferred stock</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0636">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">20,250</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zQvq5Bn3Z723" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three months ended September 30, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zCsaAuIr2TM" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span id="xdx_8BA_zNhJYW2UiWvg" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td colspan="2" id="xdx_492_20220701__20220930_znJ9RhvoQe5a" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_492_20210701__20210930_z1dkLu9MHebg" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>ended <br/>September 30, <br/>2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>Ended <br/>September 30, <br/>2021</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr id="xdx_406_ecustom--SharesIssuedBeginningOfPeriod_z9acJssNVupa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">43,758,820</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">41,315,986</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--SharesHeldBySubsidiaries_iN_di_zejoFH00Azo5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_zTCiqlWgZqm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,054,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,611,677</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--WeightedAverageSharesIssuedDuringPeriod_zjL839YN2NMb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">397,335</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">108,015</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zelxqmf7mtec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,451,846</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">40,719,692</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zVbauxVDOXyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBcSbC3P7l04" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span id="xdx_8B5_zbYFxtmO7fH4" style="display: none">Schedule of anti dilutive securities</span></td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>September 30, <br/> 2022</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>September 30, <br/> 2021</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Warrants</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">19,873,801</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">21,802,822</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Options</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,471,600</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Convertible debt</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,793,421</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">10,462,498</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Convertible preferred stock</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0636">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font-size: 10pt; text-align: right" title="Antidilutive securities">20,250</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> 19873801 21802822 11201600 10471600 10793421 10462498 20250 <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zCsaAuIr2TM" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span id="xdx_8BA_zNhJYW2UiWvg" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td> </td> <td colspan="2" id="xdx_492_20220701__20220930_znJ9RhvoQe5a" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_492_20210701__20210930_z1dkLu9MHebg" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>ended <br/>September 30, <br/>2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Three months <br/>Ended <br/>September 30, <br/>2021</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr id="xdx_406_ecustom--SharesIssuedBeginningOfPeriod_z9acJssNVupa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">43,758,820</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">41,315,986</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--SharesHeldBySubsidiaries_iN_di_zejoFH00Azo5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_zTCiqlWgZqm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,054,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,611,677</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--WeightedAverageSharesIssuedDuringPeriod_zjL839YN2NMb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">397,335</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">108,015</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zelxqmf7mtec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,451,846</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">40,719,692</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 43758820 41315986 704309 704309 43054511 40611677 397335 108015 43451846 40719692 <p id="xdx_84C_eus-gaap--UseOfEstimates_z3EaJNUzrHZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zPoK3X2XOqZd">Use of estimates</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z1ojBlKGN1Mj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_zrokbKqHKG72">Recent Accounting Pronouncements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z6KndtQ0V8B3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>3.  <span id="xdx_828_zJEs0YoDqdQ7">PROPERTY AND EQUIPMENT</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zu3iQMMsJB01" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zGfF5GWSfP3i" style="display: none">Schedule of property and equipment</span></td><td style="font-size: 10pt"> </td> <td colspan="2" id="xdx_491_20220930_zL5PzxTeEUwh" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" id="xdx_495_20220630_zELyXyLLIxAe" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>September 30, <br/>2022</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>June 30, <br/>2022</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr id="xdx_40C_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGztBB_zqNTJ3LdnMI" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Machinery and equipment</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0668">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--BuildingsAndImprovementsGross_iI_pp0p0_maPPAEGztBB_zDX0y3hlSVY3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Buildings and structures</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0670">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ComputersAndOfficeEquipment_iI_pp0p0_maPPAEGztBB_zYmPWk8uE3Yb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Computers and office equipment</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right">13,598</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right">13,598</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAEGztBB_z2oIwVXfuvUf" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">3G project construction in process</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,245,604</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,892,222</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGztBB_maPPAEOzbot_zSxqP3jWzPx6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255)"> Property and equipment, gross </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">3,259,202</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,905,820</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAEOzbot_z6EeNFG9cru3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,592</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,262</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">))</td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentOtherNet_iTI_pp0p0_mtPPAEOzbot_zBnR6tjumJ0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255); padding-bottom: 2.5pt"> Property and equipment, net </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,248,610</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,895,558</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 3G project began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for 3G construction in process includes $<span id="xdx_903_eus-gaap--InterestCostsCapitalized_c20220701__20220930_pp0p0" title="Capitalized interest">62,688</span> for capitalized interest and $<span id="xdx_906_ecustom--NonCashCompensation_c20220701__20220930_zZcILvrZXSV8" title="Non cash compensation">135,648</span> in non-cash compensation as of September 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has reviewed the remaining property and equipment for impairment as of September 30, 2022 and believes that <span id="xdx_901_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20220701__20220930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--PropertyPlantAndEquipmentOfPA1Member_zsjZ8agc2C0e" title="Impairment of Long-Lived Assets Held-for-use">no</span> impairment exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense was $<span id="xdx_902_eus-gaap--Depreciation_c20220701__20220930_pp0p0" title="Depreciation expense">330</span> and $<span id="xdx_904_eus-gaap--Depreciation_c20210701__20210930_pp0p0" title="Depreciation expense">248</span> for the three months ended September 30, 2022 and 2021, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zu3iQMMsJB01" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zGfF5GWSfP3i" style="display: none">Schedule of property and equipment</span></td><td style="font-size: 10pt"> </td> <td colspan="2" id="xdx_491_20220930_zL5PzxTeEUwh" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" id="xdx_495_20220630_zELyXyLLIxAe" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>September 30, <br/>2022</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>June 30, <br/>2022</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr id="xdx_40C_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGztBB_zqNTJ3LdnMI" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Machinery and equipment</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0668">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--BuildingsAndImprovementsGross_iI_pp0p0_maPPAEGztBB_zDX0y3hlSVY3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Buildings and structures</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0670">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ComputersAndOfficeEquipment_iI_pp0p0_maPPAEGztBB_zYmPWk8uE3Yb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Computers and office equipment</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right">13,598</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right">13,598</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAEGztBB_z2oIwVXfuvUf" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">3G project construction in process</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,245,604</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,892,222</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGztBB_maPPAEOzbot_zSxqP3jWzPx6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255)"> Property and equipment, gross </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">3,259,202</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,905,820</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAEOzbot_z6EeNFG9cru3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,592</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,262</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">))</td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentOtherNet_iTI_pp0p0_mtPPAEOzbot_zBnR6tjumJ0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255); padding-bottom: 2.5pt"> Property and equipment, net </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,248,610</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,895,558</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 13598 13598 3245604 2892222 3259202 2905820 10592 10262 3248610 2895558 62688 135648 0 330 248 <p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zb9Xnxa61q8i" style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-indent: 20pt; text-align: justify"><b>4.       <span id="xdx_827_zIeQdNz37W67">DEFERRED COMPENSATION</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company owes deferred compensation to various employees, former employees and consultants totaling $<span id="xdx_90E_eus-gaap--DeferredCompensationLiabilityCurrent_c20220930_pp0p0" title="Deferred compensation liability">654,349</span> and $<span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20210930_z2eMSxJmi4Fa" title="Deferred compensation liability">528,640</span> as of September 30, 2022 and 2021, respectively. Included in the deferred compensation balances as of September 30, 2022, are $<span id="xdx_90F_eus-gaap--DeferredCompensationLiabilityCurrent_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Deferred compensation liability">459,627</span> and $<span id="xdx_90D_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20210930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOYvrw1iOsWl" title="Deferred compensation liability">5,000</span> owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at <span id="xdx_900_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20220930_zOJhzyGWvbjf" title="Interest Rate on Deferred Compensation">4</span>% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last <span id="xdx_909_ecustom--DeferredCompensationConsecutiveTradingDays_dtD_c20220701__20220930_zN0PJ457ZcEk" title="Deferred Compensation Consecutive Trading Days (Day)">10</span> trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of September 30, 2021 was $<span id="xdx_900_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20210930__srt--CounterpartyNameAxis__custom--BassaniMember_zRhIg8IxpGH7" title="Deferred compensation liability">436,920</span> and <span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20210930__srt--CounterpartyNameAxis__custom--SmithMember_zo0JsCON1HZ" style="display: none" title="Deferred compensation liability">0</span> nil, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $<span id="xdx_90F_eus-gaap--DeferredCompensationLiabilityCurrent_c20220930__srt--TitleOfIndividualAxis__custom--ConsultantsMember_pp0p0" title="Deferred compensation liability">117,222</span> and $<span id="xdx_90E_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20210930__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zokDckR7SEu" title="Deferred compensation liability">19,220</span> as of September 30, 2022 and 2021, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at <span id="xdx_90A_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20220930__srt--TitleOfIndividualAxis__custom--ConsultantsMember_znEd78CCMuvd" title="Interest Rate on Deferred Compensation">0</span>% to <span id="xdx_904_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20210930__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zKUEU26yM6R" title="Interest Rate on Deferred Compensation">3</span>% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">Bassani and Smith have each been granted the right to convert up to $<span id="xdx_904_ecustom--DeferredCompensationConvertibleToCommonStock_iI_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zYDLSdFrwPAa" title="Deferred Compensation, Convertible to Common Stock">300,000</span> of deferred compensation balances at a price of $<span id="xdx_906_ecustom--DeferredCompensationConvertibleToCommonStockPricePerShare_iI_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z62YuXl1PFqh" title="Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share)">0.75</span> per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended September 30, 2022, Smith elected to convert $<span id="xdx_90E_ecustom--DeferredCompensationConvertibleToCommonStock_iI_c20220930__srt--CounterpartyNameAxis__custom--SmithMember_zS02g8upWQ05" title="Deferred Compensation, Convertible to Common Stock">20,000</span> of deferred compensation into the 2020 Convertible Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_904_eus-gaap--InterestExpense_c20220701__20220930__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense">4,551</span> ($<span id="xdx_903_eus-gaap--InterestExpenseRelatedParty_c20220701__20220930__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense, Related Party">4,119</span> with related parties) and $<span id="xdx_90A_eus-gaap--InterestExpense_c20210701__20210930__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense">4,032</span> ($<span id="xdx_901_eus-gaap--InterestExpenseRelatedParty_c20210701__20210930__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense, Related Party">3,949</span> with related parties) for the three months ended September 30, 2022 and 2021, respectively, related to deferred compensation.</p> 654349 528640 459627 5000 0.04 P10D 436920 0 117222 19220 0 0.03 300000 0.75 20000 4551 4119 4032 3949 <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_zVePx2Lbqaie" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>5.       <span id="xdx_828_zB5fGsSSPCId">LOANS PAYABLE</span>:</b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $<span id="xdx_909_eus-gaap--ConstructionLoan_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Construction Loan">10,010,000</span> under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_901_ecustom--AccruedInterestAndLateChargesPayable_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zmvu6902IpZc" title="Accrued Interest and Late Charges Payable">2,255,802</span> as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $<span id="xdx_905_eus-gaap--Assets_c20210930_pp0p0" title="Total assets">297</span> and its total liabilities were $<span id="xdx_90F_eus-gaap--Liabilities_c20210930_pp0p0" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_909_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_c20210930_pp0p0" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_901_eus-gaap--AccountsPayableCurrent_c20210930_pp0p0" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_904_eus-gaap--AccruedLiabilitiesCurrent_c20210930_pp0p0" title="Accrued Liabilities, Current">950</span>) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil <span id="xdx_90C_eus-gaap--Assets_iI_pp0p0_c20211229_zZTpr4BtgUje" style="display: none" title="Total assets">0</span> and its total liabilities were $<span id="xdx_909_eus-gaap--Liabilities_c20211229_pp0p0" title="Total liabilities">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_904_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_c20211229_pp0p0" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $<span id="xdx_903_eus-gaap--AccountsPayableCurrent_c20211229_pp0p0" title="Accounts payable">212,263</span> and accrued liabilities of $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_c20211229_pp0p0" title="Accrued Liabilities, Current">12,436</span>. The net amount of $<span id="xdx_902_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20220701__20220930_pp0p0" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As background, the terms of the Pennvest Loan provided for funding of up to $<span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Line of Credit Facility, Maximum Borrowing Capacity">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20220930__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zPfVmhGice3h" title="Debt Instrument, Interest Rate During Period">2.547</span>% per annum for years 1 through 5 and <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20220930__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zI2rJ4ATS4M3" title="Debt Instrument, Interest Rate During Period">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_903_eus-gaap--DebtInstrumentAnnualPrincipalPayment_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Debt Instrument, Annual Principal Payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_90C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Two">846,000</span> in fiscal year 2022, $<span id="xdx_901_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Three">873,000</span> in fiscal year 2023 and $<span id="xdx_90C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Long-Term Debt, Maturity, Year Four">149,000</span> in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_pp0p0_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zP2IyXfiDM6h" title="Interest Expense, Debt">123,444</span> and $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pp0p0_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z74zkRSMmz2g" title="Interest Expense, Debt">246,887</span> for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $<span id="xdx_90F_eus-gaap--LinesOfCreditCurrent_iI_pp0p0_c20210630_zD8KIoR8fpD6" title="Loans as a liability">9,868,495</span> despite the fact that the obligation (if any) was solely an obligation of PA1<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtAmount_c20140925__dei--LegalEntityAxis__custom--PA1Member_pp0p0" title="Debt Instrument, Debt Default, Amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $<span id="xdx_90F_eus-gaap--GainLossOnSecuritizationOfFinancialAssets_c20220601__20220615__dei--LegalEntityAxis__custom--PA1Member_pp0p0" title="Realized from the asset sale">104,725</span> was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 10010000 2255802 297 10154334 9939148 214235 950 0 10234501 10009802 212263 12436 10234501 7754000 0.02547 0.03184 5886000 846000 873000 149000 123444 246887 9868495 8137117 104725 <p id="xdx_803_ecustom--ConvertibleDebtTextBlock_zcFW6pHvbuDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>6.       <span id="xdx_82B_zrOA8oncd3lh">CONVERTIBLE NOTES PAYABLE - AFFILIATES</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2020 Convertible Obligations </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2020 Convertible Obligations, which accrue interest at either <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z61z9TRr8UOd" title="Debt Instrument, Interest Rate, Stated Percentage">4</span>% per annum or <span id="xdx_905_ecustom--DebtInstrumentInterestRateStatedPercentageQuarterly_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zsQw7aKzyOpa" title="Debt Instrument, Interest Rate, Stated Percentage, Quarterly">4</span>% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $<span id="xdx_907_ecustom--ConversionPricePerUnit_iI_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_ztE29X3x4mY1" title="Conversion Price Per Unit (in dollars per share)">0.50</span> per Unit until July 1, 2024. The original conversion price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220930_zGfky96CmPug" title="Original conversion price">0.50</span> per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees), Smith and Edward Schafer (“Schafer”), a director of the Company, were $<span id="xdx_903_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zdQGExmWbZwg" title="Convertible Notes Payable, Noncurrent">2,620,941</span>, $<span id="xdx_90C_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__srt--PresidentMember_zuCNlBoxZfWc" title="Convertible Notes Payable, Noncurrent">1,335,199</span> and $<span id="xdx_90F_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember_z4Mz33vqkCz" title="Convertible Notes Payable, Noncurrent">503,813</span>, respectively. As of September 30, 2021, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $<span id="xdx_90B_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zjNaQcqLgbj" title="Convertible Notes Payable, Noncurrent">2,526,492</span>, $<span id="xdx_906_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__srt--PresidentMember_zZIPxjvoJHta" title="Convertible Notes Payable, Noncurrent">1,253,335</span> and $<span id="xdx_902_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember_zg4zE0gxaOtj" title="Convertible Notes Payable, Noncurrent">485,658</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30, 2022, Smith elected to add $<span id="xdx_908_eus-gaap--SalariesAndWages_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zZVkri92IZag" title="Salary paid">20,000</span> of his salary to his 2020 Convertible Obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30, 2022, Smith elected to convert $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zOc9u0qD2fnh" title="Debt conversion value">30,000</span> in principal of the 2020 Convertible Obligation to <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zvSVnO6gMDE5" title="Debt conversion shares">60,000</span> units (<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember_z6xLnxybnSqc" title="Debt conversion shares, common shares">60,000</span> common shares and <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zD9A79ySyW1a" title="Debt conversion shares, warrants">60,000</span> warrants) and $<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zAiXz2V6Kloh" title="Debt conversion value">20,000</span> of accrued interest of the 2020 Convertible Obligation to <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zIrtOrfo35u2" title="Debt conversion shares">40,000</span> units (<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember_zMpeJlNIfU2c" title="Debt conversion shares, common shares">40,000</span> common shares and <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--WarrantsMember_z4LP8F8PhhIh" title="Debt conversion shares, warrants">40,000</span> warrants).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_90B_eus-gaap--InterestExpense_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zPKl8e25M0J9" title="Interest Expense">41,367</span> and $<span id="xdx_90C_eus-gaap--InterestExpense_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zgreQqrvwlbl" title="Interest Expense">40,560</span> for the three months ended September 30, 2022 and 2021, respectively. The Company capitalized $<span id="xdx_90B_eus-gaap--CostsIncurredDevelopmentCosts_c20220701__20220930_zB2EjuLlFL36" title="Capitalized amount">30,688</span> and nil <span id="xdx_902_eus-gaap--CostsIncurredDevelopmentCosts_c20210701__20210930_zVQSmcuuss5c" style="display: none" title="Capitalized amount">0</span> related to the 3G project for the three months ended September 30, 2022 and 2021, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>September 2015 Convertible Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani (now owned by Bassani Family Trusts), Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at <span id="xdx_903_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20220930__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zqP7gOCkJFki" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_908_ecustom--ConversionPricePerUnit_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zhhSi7SgGFj1" title="Conversion Price Per Unit (in dollars per share)">0.60</span> per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balances of the September 2015 Convertible Notes as of September 30, 2022, including accrued interest owed Bassani Family Trusts, Schafer and Shareholder, are $<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_zwEZ1oY3tSkl" title="Convertible Notes Payable">281,789</span>, $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20220930__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_zcfg84fIMvCk" title="Convertible Notes Payable">21,009</span> and $<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_c20220930__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ShareholderMember_zngRm8LUEhN1" title="Convertible Notes Payable">449,535</span>, respectively. The balances of the September 2015 Convertible Notes as of September 30, 2021, including accrued interest, were $<span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_c20210930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_ziJu56wrrLsf" title="Convertible Notes Payable">172,765</span>, $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20210930__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_zE4irQ0tMzn6" title="Convertible Notes Payable">20,354</span> and $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20210930__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ShareholderMember_zxt40pum2T01" title="Convertible Notes Payable">434,419</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_90F_eus-gaap--InterestExpense_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zY7rUQPoa144" title="Interest Expense">6,366</span> and $<span id="xdx_90A_eus-gaap--InterestExpense_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zFaozJcs8VTc" title="Interest Expense">5,366</span> for the years ended September 30, 2022 and 2021, respectively, on the September 2015 Convertible Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0.04 0.04 0.50 0.50 2620941 1335199 503813 2526492 1253335 485658 20000 30000 60000 60000 60000 20000 40000 40000 40000 41367 40560 30688 0 0.04 0.60 281789 21009 449535 172765 20354 434419 6366 5366 <p id="xdx_807_ecustom--SockholdersEquityNoteDisclosureTextBlock_zIhc4LpNS33" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>7.       <span id="xdx_82E_zHwiOsWEitE1">STOCKHOLDERS' EQUITY</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Series B Preferred stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since July 1, 2014, the Company had <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Outstanding, Ending Balance (in shares)">200</span> shares of Series B redeemable convertible Preferred stock outstanding with a par value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Par value">0.01</span> per share, convertible at the option of the holder at $<span id="xdx_904_ecustom--PreferredStockConvertibleOptionPerShare_iI_c20140703__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBLhnbIN1oCl" title="Preferred Stock, Convertible Option Per Share (in dollars per share)">2.00</span> per share, with dividends accrued and payable at <span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_dp_c20140625__20140701__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zF4xH0Clc5nb" title="Preferred Stock, Dividend Rate, Percentage">2.5</span>% per quarter. The Series B Preferred stock is mandatorily redeemable at $<span id="xdx_901_eus-gaap--PreferredStockRedemptionPricePerShare_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Redemption Price Per Share (in dollars per share)">100</span> per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. 200 shares of Series B redeemable convertible Preferred stock were redeemed for $<span id="xdx_909_ecustom--RedemptionOfConvertiblePreferredStock_c20220701__20220930_zpmAJdrubef2" title="Redemption of convertible Preferred stock">41,000</span>, which included the $<span id="xdx_905_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5jZr0O1O4Vc" title="Dividends Payable">21,000</span> in accrued dividend payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2022, and 2021, the Company declared dividends of $<span id="xdx_909_eus-gaap--DividendsPreferredStock_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pp0p0" title="Dividends, Preferred Stock">1,000</span> and $<span id="xdx_90B_eus-gaap--DividendsPreferredStock_c20210701__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pp0p0" title="Dividends, Preferred Stock">2,000</span> respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is <span id="xdx_90A_eus-gaap--LiabilitiesCurrent_iI_do_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJCJqNRYA4Zf" title="Liability">no</span> liability at September 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Centerpoint holds <span id="xdx_901_ecustom--SharesHeldBySubsidiaries_c20220701__20220930_zxC2xU5wsAUk" title="Shares Held by Subsidiaries (in shares)">704,309</span> shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30, 2022, Smith elected to convert $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__custom--PrincipalMember_z4FOhyYovNNi" title="Debt conversion value">30,000</span> in principal and $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__custom--AccruedInterestMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zMg0VDclxWog" title="Debt conversion value">20,000</span> in accrued interest from the 2020 Convertible Obligation to <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwGT2VeqXtL" title="Debt conversion value">100,000</span> units at $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zmYdDHivwcY6" title="Conversion price per share">.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__srt--TitleOfIndividualAxis__srt--PresidentMember_z5LvixlL1M7g" title="Warrants exercisable per share">0.75</span> per share until December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the three months ended September 30, 2022, <span id="xdx_903_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20220701__20220930_zwqI2paqPNMi" title="Class of Warrant or Right, Exercised During Period (in shares)">74,834</span> warrants were exercised to purchase <span id="xdx_903_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20220701__20220930_z6HKsvX4MNj6" title="Common Stock Shares Issued upon Exercise of Warrants (in shares)">74,834</span> shares of the Company’s common stock at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH7yHAte4ON4" title="Warrants exercisable per share">0.75</span> per share for total proceeds of $<span id="xdx_90E_ecustom--WarrantsExercisedForCommonStock_c20220701__20220930_zy9Kimt7t9Ec" title="Warrant Exercised for Common Stock">56,125</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the three months ended September 30, 2022, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGXL84dzxpT3" title="Shares issued for consultant services">50,000</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220930_zhV1Nfnemyek" title="Share price">1.60</span> per share for a total value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220701__20220930_zip6qhAR1Z3" title="Total value of consultant services">80,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30, 2022, the Company entered into subscription agreements to sell units for $<span id="xdx_907_ecustom--SaleOfUnitPricePerUnit_iI_c20220930_zq1vBnsTLDq9" title="Sale of unit, price per unit">1.00</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_904_eus-gaap--SharePrice_iI_c20220930_zfCriHEWXFmd" title="Share price">0.75</span> per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20220930_zDodwy2Vjig2" title="Number of shares issued">320,000</span> units for total proceeds of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220701__20220930_zj4hD1EBg5w7" title="Number of shares issued, value">320,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Warrants:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, the Company had approximately <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pn3n3_dm_c20220930_zkSiCnabRBPl" title="Warrant outstanding">20.6</span> million warrants outstanding, with exercise prices from $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__srt--RangeAxis__srt--MinimumMember_zXzNzZYZREkh" title="Warrants exercise price per share">0.60</span> to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__srt--RangeAxis__srt--MaximumMember_zqqhJxf4mRoi" title="Warrants exercise price per share">1.60</span> and expiring on various dates through November 9, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted-average exercise price for the outstanding warrants is $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220930__us-gaap--AwardTypeAxis__custom--WarrantsMember_zgWPn4FLlaa5" title="Weighted average exercise price">0.76</span>, and the weighted-average remaining contractual life as of September 30, 2022 is <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20220930__us-gaap--AwardTypeAxis__custom--WarrantsMember_z0eqDTCPAV12" title="Remaining contractual life">2.2</span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30, 2022, Smith elected to convert $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__srt--TitleOfIndividualAxis__custom--PrincipalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSTE42Ucynph" title="Debt conversion value">30,000</span> in principal and $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20220930__srt--TitleOfIndividualAxis__custom--AccruedInterestMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zwKifSnxy7Da" title="Debt conversion value">20,000</span> in accrued interest from the 2020 Convertible Obligation to <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcUEGUnSnHoc" title="Debt conversion shares">100,000</span> units at $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuNCqjZqlw4g" title="Conversion price per share">.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqzLW4I6afU5" title="Warrants exercisable per share">0.75</span> per share until three years after the date of conversion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the three months ended September 30, 2022, the Company approved the issuance of <span id="xdx_900_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20220701__20220930__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIzUXXMSUA8l" title="Class of Warrant or Right, Exercised During Period (in shares)">150,000</span> warrants, in aggregate, to three new members of its Advisory Group for advisory and/or consulting services of $<span id="xdx_907_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2mEy6UkI69k" title="Issuance of warrants">15,000</span>, in aggregate. The warrants are exercisable at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zq2mKUHwLdd9" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.50</span> to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zU57yTXCsn11" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.60</span> and expire in August 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">During the three months ended September 30, 2022, the Company approved the modification of existing warrants held by one former consultant and four investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Share-based Payment Arrangement, Plan Modification, Incremental Cost">154,933</span> and interest expenses of $<span id="xdx_906_ecustom--InterestExpenses_pp0p0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z59yXQWHwfNi" title="Interest expenses">4,500</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30, 2022, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2OEpJ4p15Hg" title="Class of Warrant or Right, Outstanding (in shares)">74,834</span> warrants were exercised to purchase <span id="xdx_90C_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSsFos3X5x7e" title="Common Stock Shares Issued upon Exercise of Warrants (in shares)">74,834</span> shares of the Company’s common stock at $0.75 per share for total proceeds of $<span id="xdx_906_ecustom--WarrantExercisedForCommonStock_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z22iBugFUHq3" title="Warrant Exercised for Common Stock">56,126</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued <span id="xdx_907_eus-gaap--SharesIssued_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Number of shares issued">1,000,000</span> Incentive Warrants exercisable at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Warrants exercisable per share">1.00</span> per share until April 30, 2026 of which up to <span id="xdx_901_ecustom--CancellationOfWarrants_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zavjJvWfEt81" title="Cancellation of warrants">700,000</span> Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a <span id="xdx_907_ecustom--ExerciseBonus_iI_dp_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJ1NKRgan2ph" title="Exercise bonus">75</span>% exercise bonus if the terms set forth therein are met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Stock options: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “<span style="text-decoration: underline">Equity Plan</span>”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_pdd" title="Stock options, authorized (in shares)">30,000,000</span> shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock options, authorized (in shares)">36,000,000</span> shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 11, 2022, the Company granted <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220201__20220211__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" title="Number of shares granted">10,000</span> options under the 2006 Plan to one consultant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 29, 2022, the Company granted an aggregate of <span id="xdx_901_ecustom--SharebasedCompensationGranted_c20220401__20220429_zMvc4hvb7tq5" title="Share-based Compensation, Granted">720,000</span> options under the 2006 Plan to seven employees/consultants/directors including: i) <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--SchaferMember_pdd" title="Share-based Compensation, Granted"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--NorthropMember_pdd" title="Share-based Compensation, Granted">50,000</span></span> options each to Schafer and Northrop for service as directors, ii) <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--BassaniMember_pdd" title="Share-based Compensation, Granted">200,000</span> options to Bassani (now COO of the Company and formerly CEO) and iii) <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220401__20220429__srt--CounterpartyNameAxis__custom--SmithMember_pdd" title="Share-based Compensation, Granted">200,000</span> options to Smith, the Company’s President, which new option grants are included in the presentation below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded compensation expense related to employee stock options of nil <span id="xdx_904_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="display: none" title="Share-based Payment Arrangement, Expense">0</span> and nil <span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="display: none" title="Share-based Payment Arrangement, Expense">0</span> for the three months ended 2022 and 2021, respectively. The Company granted nil <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20220930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_ziw9NYUkYnb3" title="Share-based Compensation, Granted"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_pdd" style="display: none" title="Share-based Compensation, Granted">0</span></span> options during the three months ended September 30, 2022 and 2021, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt">A summary of option activity under the 2006 Plan for the three months ended September 30, 2022 is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOURnfIAyhP8" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left"><span id="xdx_8BC_zvGSkSZHsgW9" style="display: none">Schedule of option activity</span></td><td> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Weighted- <br/> Average <br/> Exercise <br/> Price</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Aggregate <br/> Intrinsic <br/> Value</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 24%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at July 1, 2022</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20220930_zzICCq4nQVAk" style="width: 16%; font-size: 10pt; text-align: right" title="Options outstanding, beginning (in shares)">11,201,600</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220701__20220930_zhfpnsaEwGx3" style="width: 16%; font-size: 10pt; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.80</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 15%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630_zIP76QUwWghj" title="Outstanding, weighted-average remaining contractual life (Year)">2.7</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220701__20220930_zHE1r3ZT2jq8" style="width: 15%; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value beginning">4,429,263</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Granted, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1009">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Exercised, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1011">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1013">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Forfeited, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1015">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1017">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Expired, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1019">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1021">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at September 30, 2022</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220701__20220930_zHcLXKUVSoEh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending (in shares)">11,201,600</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220701__20220930_zrswR9VACfq7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending weighted-average exercise price">0.80</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20220930_zEc4o91hNa7" title="Outstanding, weighted-average remaining contractual life (Year)">2.48</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220701__20220930_zMRzrWOY5UQ" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value ending">5,757,755</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total fair value of stock options that vested during the three months ended September 30, 2022 and 2021 was <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220701__20220930_pp0p0" title="Fair value of stock options"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20210701__20210930_z8jthfjJCkRl" style="display: none" title="Fair value of stock options">0</span></span> nil. As of September 30, 2022, the Company had no unrecognized compensation cost related to stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> 200 0.01 2.00 0.025 100 41000 21000 1000 2000 0 704309 30000 20000 100000 0.50 0.75 74834 74834 0.75 56125 50000 1.60 80000 1.00 0.75 320000 320000 20600000 0.60 1.60 0.76 P2Y2M12D 30000 20000 100000 0.50 0.75 150000 15000 1.50 1.60 154933 4500 74834 74834 56126 1000000 1.00 700000 0.75 30000000 36000000 10000 720000 50000 50000 200000 200000 0 0 0 0 <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zOURnfIAyhP8" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details)"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left"><span id="xdx_8BC_zvGSkSZHsgW9" style="display: none">Schedule of option activity</span></td><td> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Options</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Weighted- <br/> Average <br/> Exercise <br/> Price</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 8pt"><b>Aggregate <br/> Intrinsic <br/> Value</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 24%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at July 1, 2022</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20220930_zzICCq4nQVAk" style="width: 16%; font-size: 10pt; text-align: right" title="Options outstanding, beginning (in shares)">11,201,600</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220701__20220930_zhfpnsaEwGx3" style="width: 16%; font-size: 10pt; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.80</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 15%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630_zIP76QUwWghj" title="Outstanding, weighted-average remaining contractual life (Year)">2.7</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220701__20220930_zHE1r3ZT2jq8" style="width: 15%; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value beginning">4,429,263</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Granted, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1009">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Exercised, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1011">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1013">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Forfeited, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1015">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1017">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Expired, options (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1019">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20210930_pdd" style="font-size: 10pt; text-align: right" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1021">—</span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at September 30, 2022</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220701__20220930_zHcLXKUVSoEh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending (in shares)">11,201,600</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220701__20220930_zrswR9VACfq7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending weighted-average exercise price">0.80</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20220930_zEc4o91hNa7" title="Outstanding, weighted-average remaining contractual life (Year)">2.48</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220701__20220930_zMRzrWOY5UQ" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value ending">5,757,755</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 11201600 0.80 P2Y8M12D 4429263 11201600 0.80 P2Y5M23D 5757755 0 0 <p id="xdx_803_ecustom--SubscriptionReceivableTextBlock_zKoHfSgiaB0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>8.       <span id="xdx_821_zNG64DHlNby7">SUBSCRIPTION RECEIVABLE - AFFILIATES</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_903_eus-gaap--NotesReceivableNet_iI_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_z6otYhmDIR3f" title="Financing Receivable, after Allowance for Credit Loss, Total">428,250</span> ($<span id="xdx_90D_ecustom--NotesReceivableInterest_iI_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zn5eNwDpNGo9" title="Notes receivable interest">504,741</span>, including interest) from Bassani which were received as consideration for purchases of warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_z0ivDUhaW962" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">5,565,000</span> shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930_zAGIKan4TNre" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> and have expiry dates ranging from December 31, 2024 to December 31, 2025. The promissory notes bear interest at 4% per annum and are secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, the Company has an interest bearing, secured promissory note for $<span id="xdx_908_ecustom--FinancingReceivablePrincipalAmount_iI_c20220930__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zpd2SXmlXNh2" title="Financing Receivable, Principal Amount">30,000</span> ($<span id="xdx_908_eus-gaap--NotesReceivableNet_iI_c20220930__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zEK0KgyZBDPa" title="Financing Receivable, after Allowance for Credit Loss, Total">34,987</span> including interest) from Smith as consideration to purchase warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220930__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zJUQz5PnSMGd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zJqe7B4eBEU3" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.60</span> and have expiry dates of December 31, 2024. The warrants have a 75% exercise bonus and the promissory note bears interest at <span id="xdx_900_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20220930__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_z6xyaTiED5xj" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, and is secured by $<span id="xdx_902_ecustom--FinancingReceivablePrincipalAmount_iI_c20220930__srt--CounterpartyNameAxis__custom--SmithsMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zuK3cDe1Okfg" title="Financing Receivable, Principal Amount">30,000</span> ($<span id="xdx_90A_eus-gaap--NotesReceivableNet_iI_c20220930__srt--CounterpartyNameAxis__custom--SmithsMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zMkDMSpwGGO2" title="Financing Receivable, after Allowance for Credit Loss, Total">35,361</span>, including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">As of September 30, 2022 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_90F_ecustom--FinancingReceivablePrincipalAmount_iI_c20220930__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_z8OD6ZHF7lPd" title="Financing Receivable, Principal Amount">46,400</span> ($<span id="xdx_905_eus-gaap--NotesReceivableNet_iI_c20220930__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_z8GTcfcWuVFd" title="Financing Receivable, after Allowance for Credit Loss, Total">55,472</span> including interest) from two former employees as consideration to purchase warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220930__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zC2uk8ZDg0Zc" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">928,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_z3ttnquGoOWl" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> and have expiry dates of December 31, 2024. These warrants have a 90% exercise bonus. The promissory notes bear interest at <span id="xdx_902_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20220930__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zZUnj7bWae49" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.</p> 428250 504741 5565000 0.75 30000 34987 300000 0.60 0.04 30000 35361 46400 55472 928000 0.75 0.04 <p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zPIrxbwgGdGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9.       <span id="xdx_822_zYWAXfdvvNuf">COMMITMENTS AND CONTINGENCIES</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employment and consulting agreements:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly salary of $<span id="xdx_90D_ecustom--MonthlyOfficersCashCompensation_c20161001__20161010__srt--TitleOfIndividualAxis__srt--PresidentMember_zIFZ4kxzmdIj" title="Monthly Officers Cash Compensation">18,000</span> until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20211231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220930__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember_pdd" title="Warrants exercisable per share">0.75</span> per share, until December 31, 2022, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $<span id="xdx_909_ecustom--CompensationIncreased_c20220430__20220501_zTxLeHwvNO86" title="Compensation increased">25,000</span> per month of which $5,000 a month is deferred. For the three months ended September 30, 2022 and 2021, Smith was paid $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20220701__20220930__srt--CounterpartyNameAxis__custom--SmithMember_pp0p0" title="Cash compensation paid">60,000</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20210701__20210930__srt--CounterpartyNameAxis__custom--SmithMember_pp0p0" title="Cash compensation paid">54,000</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Since March 31, 2005, the Company has had various agreements with Bassani (and/or Brightcap which provided his services during some of the initial years), now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’), (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($<span id="xdx_90E_ecustom--MonthlyOfficersCashCompensation_c20150203__20150210__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zhLb3LCw6wuk" title="Monthly officers cash compensation">31,000</span> per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During October 2016 Bassani was granted the right to convert up to $<span id="xdx_90B_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zZ88IoiK2hL1" title="Deferred Compensation, Maximum Convertible Amount">125,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_904_ecustom--DeferredCompensationStockConversionPricePerShare_iI_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zgxvCpPriaRc" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)">0.75</span> per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $<span id="xdx_909_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zjLat0EbOANh" title="Deferred Compensation, Maximum Convertible Amount">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_902_ecustom--DeferredCompensationStockConversionPricePerShare_iI_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zBPfbv7ZrtTg" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)">0.75</span> per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $<span id="xdx_90C_eus-gaap--AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent_iI_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_z3xVZSVfYIEb" title="Salaries and wages">31,000</span> per month, which will continue to be accrued in part until there is adequate cash available. Additionally, the Company has agreed to pay him $<span id="xdx_90D_eus-gaap--OtherAdditionalCapital_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_pp0p0" title="Additional paid amount">2,000</span> per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $<span id="xdx_905_ecustom--InterestBearingSecuredPromissoryNote_c20230301__20230331__srt--TitleOfIndividualAxis__custom--BassaniMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zLirDFRhZDy1" title="Interest bearing secured promissory note">300,000</span> from Bassani as consideration to purchase warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20180801__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsExpiringOnDecember312025Member_pdd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">3,000,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of September 30, 2022, the principal and accrued interest was $<span id="xdx_901_eus-gaap--NotesReceivableNet_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_pp0p0" title="Financing Receivable, after Allowance for Credit Loss, Total">351,812</span>. For the three months ended September 30, 2022 and 2021, Brightcap was paid $<span id="xdx_909_eus-gaap--RepaymentsOfLongTermDebt_c20220701__20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_pp0p0" title="Repayments of Long-term Debt, Total">75,000</span> and $<span id="xdx_90B_eus-gaap--RepaymentsOfLongTermDebt_c20210701__20210930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_pp0p0" title="Repayments of Long-term Debt, Total">60,000</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s GEN3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13th month) with compensation of $<span id="xdx_903_ecustom--MonthlyOfficersCashCompensation_c20220701__20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z60EeoXCkIt2" title="Monthly Officers Cash Compensation">25,000</span> cash and $<span id="xdx_904_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_c20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zSwt2KgUG8w2" title="Deferred Compensation, Maximum Convertible Amount">10,000</span> deferred compensation per month. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise bonus if the terms set forth therein are met.  For the three months ended September 30, 2022 and 2021, O’Neill was paid $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zP4YKqf6tGGb" title="Cash compensation paid">45,500</span> and <span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20210701__20210930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zs1xBMdAHmYd" style="display: none" title="Cash compensation paid">0</span> nil, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Execution/exercise bonuses:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant. These exercise bonuses were subsequently increased to 75%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, the Company added a <span id="xdx_906_ecustom--ExerciseBonus_iI_dp_c20210930_zCY3IrXcvBig" title="Exercise bonus">75</span>% execution/exercise bonus to the terms of <span id="xdx_900_ecustom--WarrantsHeldByTrustOwned_c20220701__20220930_zrCxTGrcJlc2" title="Warrants held by trust owned">3,000,000</span> warrants held by a trust owned by Bassani.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2022, the execution/exercise bonuses ranging from <span id="xdx_90F_ecustom--ExerciseBonus_iI_dp_c20220930__srt--RangeAxis__srt--MinimumMember_zumBnJZwQ1dh" title="Exercise bonus">50</span>-<span id="xdx_90A_ecustom--ExerciseBonus_iI_dp_c20220930__srt--RangeAxis__srt--MaximumMember_zHM44evVlvo2" title="Exercise bonus">90</span>% were applicable to 10,966,600 of the Company’s outstanding options and <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_c20220930_pp0p0" title="Warrants and Rights Outstanding">17,612,151</span> of the Company’s outstanding warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 1, 2022, an entity affiliated with O’Neill was issued <span id="xdx_903_eus-gaap--SharesIssued_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z6QFzBDLBOjd" title="Number of shares issued">1,000,000</span> Incentive Warrants exercisable at $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zeeY9saXaR83" title="Warrants exercisable per share">1.00</span> per share until April 30, 2026 of which up to <span id="xdx_900_ecustom--CancellationOfWarrants_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zhx6Zjt2buub" title="Cancellation of warrants">700,000</span> Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a <span id="xdx_904_ecustom--ExerciseBonus_iI_dp_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zqX9L0KgZeQg" title="Exercise bonus">75</span>% exercise bonus if the terms set forth therein are met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Purchase Order Agreement:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220101__20220128_pp0p0" title="Debt instrument paid amount">2,665,500</span> (and made the initial <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220101__20220128_zzsKSqOiXKy1" title="Debt Instrument, Interest Rate During Period">25</span>% payment ($<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20220128_pp0p0" title="Principal, interest">666,375</span>)) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. On March 21, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220302__20220321_zwb1gHulHu12" title="Debt Instrument, Interest Rate During Period">25</span>% payment ($<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20220302__20220321_pp0p0" title="Principal, interest">666,375</span>).  On June 6, 2022 the Company received progress notice re: completion of certain work in process and an invoice from Buflovak for the next 25% payment ($666,375) which was paid on July 5, 2022 bringing the aggregate payments to $<span id="xdx_908_ecustom--AggregatePayment_c20220701__20220705_zg5VpRnn2WR5" title="Aggregate payment">1,999,125</span> as of the date of this report. No invoices were received in the quarter ended September 30, 2022. Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete and procurement/fabrication has now been initiated.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, etc.) for work related to the Initial Project.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Litigation:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222"><b><span style="text-decoration: underline">A: Website: Domain Sale/Resolved Litigation/Hacking/Theft</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"> </p> <p style="font: 10pt/12.6pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> On March 23, 2022 <span id="xdx_901_ecustom--SaleOfDomainDescription_c20220302__20220323_z0m8M2SZOW0g" title="Sale of domain, description">the Company entered into an agreement to sell domain name &lt;biontech.com&gt; and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.</span> The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name &lt;biontech.com&gt; no longer represented a core asset of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the &lt;biontech.com&gt; domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name &lt;biontech.com&gt; ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name &lt;biontech.com&gt; to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations werebeen subject disruption and expenses were incurred related to the matter including legal fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222"><b><span style="text-decoration: underline">B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $<span id="xdx_90A_eus-gaap--LongTermConstructionLoanCurrent_c20211229_pp0p0" title="Loan related to construction">10,010,000</span> under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_90A_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_c20211229_pp0p0" title="Accrued interest">2,255,802</span> as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $<span id="xdx_905_eus-gaap--Assets_iI_pp0p0_c20210930_zcXsd8YHfv2i" title="Total assets">297</span> and its total liabilities were $<span id="xdx_909_eus-gaap--Liabilities_iI_pp0p0_c20210930_z20pdZ4Vokj" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_909_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zpX2KQLUOri6" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_90C_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20210930_zhCrnHgHZM2c" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_90C_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20210930_z8Wy2qENARJ5" title="Accrued Liabilities, Current">950</span>) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil <span id="xdx_903_eus-gaap--Assets_c20211229_pp0p0" style="display: none" title="Total assets">0</span> and its total liabilities were $<span id="xdx_906_eus-gaap--Liabilities_iI_pp0p0_c20211229_z6uUb0Q6tebk" title="Total liabilities">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_907_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20211229_zvVi3DoozRW7" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $<span id="xdx_909_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20211229_z7ngojHO8QAj" title="Accounts payable">212,263</span> and accrued liabilities of $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20211229_z8PWrLKx391k" title="Accrued Liabilities, Current">12,436</span>. The net amount of $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20220701__20220930_zelCuZvc8BFg" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As background, the terms of the Pennvest Loan provided for funding of up to $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zV82Dp0zLoVg" title="Line of Credit Facility, Maximum Borrowing Capacity">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20220930__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zas5FYer7KHl" title="Debt Instrument, Interest Rate During Period">2.547</span>% per annum for years 1 through 5 and <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20220930__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zNvg7nEpDOw5" title="Debt Instrument, Interest Rate During Period">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_900_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zwx5J6mpDUR8" title="Debt Instrument, Annual Principal Payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_905_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zOeNLo2nza9j" title="Long-Term Debt, Maturity, Year Two">846,000</span> in fiscal year 2022, $<span id="xdx_90A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zALMYToZ7Lih" title="Long-Term Debt, Maturity, Year Three">873,000</span> in fiscal year 2023 and $<span id="xdx_90C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z9PoHxV8R2Fb" title="Long-Term Debt, Maturity, Year Four">149,000</span> in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0p0_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zORmMjQfpHLa" title="Interest Expense, Debt">123,444</span> and $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_pp0p0_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zLIaYobJmjc" title="Interest Expense, Debt">246,887</span> for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $<span id="xdx_901_eus-gaap--LinesOfCreditCurrent_iI_pp0p0_c20220630_zZHGodtyVkt7" title="Line of Credit, Current">9,868,495</span> despite the fact that the obligation (if any) was solely an obligation of PA1<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_90F_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pp0p0_c20140925__dei--LegalEntityAxis__custom--PA1Member_zjLX6BwwSpOj" title="Debt Instrument, Debt Default, Amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $<span id="xdx_906_eus-gaap--GainLossOnSecuritizationOfFinancialAssets_pp0p0_c20220601__20220615__dei--LegalEntityAxis__custom--PA1Member_ztDBamZPF81h" title="Gain (Loss) on Securitization of Financial Assets">104,725</span> was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company currently is not involved in any other material litigation or similar events.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Lease:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The future minimum lease payment under noncancelable operating lease with terms greater than one year as of September 30, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_zN8MwrLUJFLc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BF_zUctgLFQDXmk" style="display: none">Schedule of future minimum lease payments</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20220930_zViEcbutX907" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Year ended June 30, 2023</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">43,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td>Year ended June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInFourYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended June 30, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,250</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--UndiscountedCashFlow_iI_pp0p0_zrE2xPxPqLs5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Undiscounted cash flow</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--LessImputedInterest_iI_pp0p0_z80uf6hzDdsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(17,888</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CapitalLeasesContingentRentalPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">132,112</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of September 30, 2022 were <span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220930_zkF6t6BZcrB9" title="Weighted average remaining lease term">2.33</span> years and <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20220930_zJ9FqAU7NRJ8" title="Discounted rate">10</span>%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> 18000 300000 0.75 25000 60000 54000 31000 125000 0.75 300000 0.75 31000 2000 300000 3000000 351812 75000 60000 25000 10000 45500 0 0.75 3000000 0.50 0.90 17612151 1000000 1.00 700000 0.75 2665500 0.25 666375 0.25 666375 1999125 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. 10010000 2255802 297 10154334 9939148 214235 950 0 10234501 10009802 212263 12436 10234501 7754000 0.02547 0.03184 5886000 846000 873000 149000 123444 246887 9868495 8137117 104725 <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_zN8MwrLUJFLc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BF_zUctgLFQDXmk" style="display: none">Schedule of future minimum lease payments</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20220930_zViEcbutX907" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Year ended June 30, 2023</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">43,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td>Year ended June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeasesFutureMinimumPaymentsReceivableInFourYears_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended June 30, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,250</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--UndiscountedCashFlow_iI_pp0p0_zrE2xPxPqLs5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Undiscounted cash flow</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--LessImputedInterest_iI_pp0p0_z80uf6hzDdsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(17,888</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CapitalLeasesContingentRentalPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">132,112</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 43750 75000 31250 150000 -17888 132112 P2Y3M29D 0.10 <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_za5PiukdUUD" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>10.        <span id="xdx_82D_zWA4Li4WHTWc">SUBSEQUENT EVENTS</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated events that occurred subsequent to September 30, 2022 for recognition and disclosure in the financial statements and notes to the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 28, 2022 the Company entered into a subscription agreement to sell <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20221001__20221028__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziG3sbcmitth" title="Sale of units">26,230</span> units for $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20221028__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAEFMRCHmi8k" title="Sale of units, price per unit">1.00</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20221028__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9itl5MiYpH" title="Sale of units, price per share">0.75</span> per share with an expiry date of <span id="xdx_90E_eus-gaap--StockRepurchaseProgramExpirationDate_dd_c20221001__20221028__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbNzyR6fgXNl" title="Expiry date">December 31, 2024</span> for total proceeds of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20221001__20221028__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8b7UJwLJZ33" title="Proceeds from sale of units">26,230</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 26230 1.00 0.75 2024-12-31 26230 EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 176 275 1 false 63 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://biontech.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://biontech.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://biontech.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDER'S EQUITY (DEFICIT) (Unaudited) Sheet http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDER'S EQUITY (DEFICIT) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://biontech.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS Notes 7 false false R8.htm 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://biontech.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://biontech.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 9 false false R10.htm 00000010 - Disclosure - DEFERRED COMPENSATION Sheet http://biontech.com/role/DeferredCompensation DEFERRED COMPENSATION Notes 10 false false R11.htm 00000011 - Disclosure - LOANS PAYABLE Sheet http://biontech.com/role/LoansPayable LOANS PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES Notes http://biontech.com/role/ConvertibleNotesPayable-Affiliates CONVERTIBLE NOTES PAYABLE - AFFILIATES Notes 12 false false R13.htm 00000013 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://biontech.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES Sheet http://biontech.com/role/SubscriptionReceivable-Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES Notes 14 false false R15.htm 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://biontech.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 00000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://biontech.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://biontech.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biontech.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://biontech.com/role/SignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://biontech.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://biontech.com/role/PropertyAndEquipment 19 false false R20.htm 00000020 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://biontech.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://biontech.com/role/StockholdersEquity 20 false false R21.htm 00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://biontech.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://biontech.com/role/CommitmentsAndContingencies 21 false false R22.htm 00000022 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Details http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans 22 false false R23.htm 00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Details 23 false false R24.htm 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Details 24 false false R25.htm 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://biontech.com/role/SignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) Sheet http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT - Property and Equipment (Details) Details 26 false false R27.htm 00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://biontech.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://biontech.com/role/PropertyAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - DEFERRED COMPENSATION (Details Narrative) Sheet http://biontech.com/role/DeferredCompensationDetailsNarrative DEFERRED COMPENSATION (Details Narrative) Details http://biontech.com/role/DeferredCompensation 28 false false R29.htm 00000029 - Disclosure - LOANS PAYABLE (Details Narrative) Sheet http://biontech.com/role/LoansPayableDetailsNarrative LOANS PAYABLE (Details Narrative) Details http://biontech.com/role/LoansPayable 29 false false R30.htm 00000030 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) Notes http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) Details http://biontech.com/role/ConvertibleNotesPayable-Affiliates 30 false false R31.htm 00000031 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details) Sheet http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails STOCKHOLDERS' EQUITY - Stock Option Activity (Details) Details 31 false false R32.htm 00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://biontech.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://biontech.com/role/StockholdersEquityTables 32 false false R33.htm 00000033 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) Sheet http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) Details http://biontech.com/role/SubscriptionReceivable-Affiliates 33 false false R34.htm 00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://biontech.com/role/CommitmentsAndContingenciesTables 34 false false R35.htm 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://biontech.com/role/CommitmentsAndContingenciesTables 35 false false R36.htm 00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://biontech.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://biontech.com/role/SubsequentEvents 36 false false All Reports Book All Reports bion_10q-093022.htm bion_ex31z1.htm bion_ex31z2.htm bion_ex32z1.htm bion_ex32z2.htm bnet-20220930.xsd bnet-20220930_cal.xml bnet-20220930_def.xml bnet-20220930_lab.xml bnet-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bion_10q-093022.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 176, "dts": { "calculationLink": { "local": [ "bnet-20220930_cal.xml" ] }, "definitionLink": { "local": [ "bnet-20220930_def.xml" ] }, "inline": { "local": [ "bion_10q-093022.htm" ] }, "labelLink": { "local": [ "bnet-20220930_lab.xml" ] }, "presentationLink": { "local": [ "bnet-20220930_pre.xml" ] }, "schema": { "local": [ "bnet-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 446, "entityCount": 1, "hidden": { "http://biontech.com/20220930": 38, "http://fasb.org/us-gaap/2022": 87, "http://xbrl.sec.gov/dei/2022": 5, "total": 130 }, "keyCustom": 66, "keyStandard": 209, "memberCustom": 37, "memberStandard": 18, "nsprefix": "bnet", "nsuri": "http://biontech.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://biontech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - DEFERRED COMPENSATION", "role": "http://biontech.com/role/DeferredCompensation", "shortName": "DEFERRED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - LOANS PAYABLE", "role": "http://biontech.com/role/LoansPayable", "shortName": "LOANS PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES", "role": "http://biontech.com/role/ConvertibleNotesPayable-Affiliates", "shortName": "CONVERTIBLE NOTES PAYABLE - AFFILIATES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:ConvertibleDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:SockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://biontech.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:SockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:SubscriptionReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES", "role": "http://biontech.com/role/SubscriptionReceivable-Affiliates", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "bnet:SubscriptionReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://biontech.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS", "role": "http://biontech.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://biontech.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://biontech.com/role/SignificantAccountingPoliciesTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://biontech.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://biontech.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "bnet:SockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://biontech.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "bnet:SockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://biontech.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "bnet:Techwastage", "reportCount": 1, "unique": true, "unitRef": "Decimal", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "bnet:Techwastage", "reportCount": 1, "unique": true, "unitRef": "Decimal", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-012022-09-30_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "role": "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-012022-09-30_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "bnet:SharesIssuedBeginningOfPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "role": "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "bnet:SharesIssuedBeginningOfPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "bnet:ComputersAndOfficeEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "role": "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "bnet:ComputersAndOfficeEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestCostsCapitalized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestCostsCapitalized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - DEFERRED COMPENSATION (Details Narrative)", "role": "http://biontech.com/role/DeferredCompensationDetailsNarrative", "shortName": "DEFERRED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:DeferredCompensationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - LOANS PAYABLE (Details Narrative)", "role": "http://biontech.com/role/LoansPayableDetailsNarrative", "shortName": "LOANS PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30_custom_PennvestLoanMember", "decimals": "0", "lang": null, "name": "us-gaap:ConstructionLoan", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative)", "role": "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "lang": null, "name": "us-gaap:CostsIncurredDevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "bnet:SockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details)", "role": "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails", "shortName": "STOCKHOLDERS' EQUITY - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "bnet:SockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:SockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "bnet:RedemptionOfConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)", "role": "http://biontech.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS' EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bnet:SockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "bnet:RedemptionOfConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative)", "role": "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30_custom_SmithsMember_custom_SecuredPromissoryNoteMember", "decimals": "0", "lang": null, "name": "us-gaap:NotesReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://biontech.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-04-302022-05-01", "decimals": "0", "lang": null, "name": "bnet:CompensationIncreased", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "bnet:SockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://biontech.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-10-012022-10-28_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://biontech.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDER'S EQUITY (DEFICIT) (Unaudited)", "role": "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDER'S EQUITY (DEFICIT) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS", "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://biontech.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://biontech.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bion_10q-093022.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 63, "tag": { "bnet_AccruedInterestAndLateChargesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued Interest and Late Charges Payable" } } }, "localname": "AccruedInterestAndLateChargesPayable", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_AccruedInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Interest [Member]" } } }, "localname": "AccruedInterestMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_AdjustmentToAdditionalPaidInCapitalModificationOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Modification of warrants" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalModificationOfWarrants", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_AggregatePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate payment" } } }, "localname": "AggregatePayment", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_BassaniFamilyTrustsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bassani Family Trusts [Member]" } } }, "localname": "BassaniFamilyTrustsMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_BassaniMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bassani [Member]" } } }, "localname": "BassaniMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_CancellationOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cancellation of warrants" } } }, "localname": "CancellationOfWarrants", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CapitalizedInterestInPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Capitalized interest in property and equipment" } } }, "localname": "CapitalizedInterestInPropertyAndEquipment", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_CattlePerHead": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cattle per head" } } }, "localname": "CattlePerHead", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "decimalItemType" }, "bnet_CenterpointMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Centerpoint [Member]" } } }, "localname": "CenterpointMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ClassOfWarrantOrRightExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercised During Period (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CommissionsOnWarrantExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Commissions on warrant exercises" } } }, "localname": "CommissionsOnWarrantExercises", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_CommissionsOnWarrantExercisesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commissions on warrant exercises , shares" } } }, "localname": "CommissionsOnWarrantExercisesShares", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bnet_CommonSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Shares [Member]" } } }, "localname": "CommonSharesMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_CommonStockSharesIssuedUponExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Shares Issued upon Exercise of Warrants (in shares)" } } }, "localname": "CommonStockSharesIssuedUponExerciseOfWarrants", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_CompensationIncreased": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Compensation increased" } } }, "localname": "CompensationIncreased", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_ComputersAndOfficeEquipment": { "auth_ref": [], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Computers and office equipment" } } }, "localname": "ComputersAndOfficeEquipment", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "bnet_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ConversionOfDebtAndLiabilitiesIntoNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities into notes payable" } } }, "localname": "ConversionOfDebtAndLiabilitiesIntoNotesPayable", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ConversionOfDeferredCompensationToNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of deferred compensation to notes payable" } } }, "localname": "ConversionOfDeferredCompensationToNotesPayable", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ConversionOfNotesPayableIntoShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of notes payable into shares" } } }, "localname": "ConversionOfNotesPayableIntoShares", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_ConversionPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion Price Per Unit (in dollars per share)" } } }, "localname": "ConversionPricePerUnit", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_ConvertibleDebtTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE - AFFILIATES" } } }, "localname": "ConvertibleDebtTextBlock", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-Affiliates" ], "xbrltype": "textBlockItemType" }, "bnet_ConvertibleObligations2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Obligations 2020 [Member]" } } }, "localname": "ConvertibleObligations2020Member", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ConvertiblePreferredStockAntidilutiveSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock Antidilutive Securities [Member]" } } }, "localname": "ConvertiblePreferredStockAntidilutiveSecuritiesMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "bnet_DebtInstrumentInterestRateStatedPercentageQuarterly": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage, Quarterly" } } }, "localname": "DebtInstrumentInterestRateStatedPercentageQuarterly", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_DeferredCompensationConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Compensation Consecutive Trading Days (Day)" } } }, "localname": "DeferredCompensationConsecutiveTradingDays", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "bnet_DeferredCompensationConvertibleToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Compensation, Convertible to Common Stock" } } }, "localname": "DeferredCompensationConvertibleToCommonStock", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationConvertibleToCommonStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share)" } } }, "localname": "DeferredCompensationConvertibleToCommonStockPricePerShare", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_DeferredCompensationLiabilityAmountCancelled": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred Compensation Liability, Amount Cancelled" } } }, "localname": "DeferredCompensationLiabilityAmountCancelled", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationMaximumConvertibleAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Compensation, Maximum Convertible Amount" } } }, "localname": "DeferredCompensationMaximumConvertibleAmount", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_DeferredCompensationStockConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)" } } }, "localname": "DeferredCompensationStockConversionPricePerShare", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_DeficitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deficit:" } } }, "localname": "DeficitAbstract", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "bnet_DescriptionOfKreider2PoultryProject": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of kreider 2 poultry project" } } }, "localname": "DescriptionOfKreider2PoultryProject", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "bnet_DisclosureConvertibleNotesPayableAffiliatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable - Affiliates" } } }, "localname": "DisclosureConvertibleNotesPayableAffiliatesAbstract", "nsuri": "http://biontech.com/20220930", "xbrltype": "stringItemType" }, "bnet_DisclosureStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity", "verboseLabel": "Stockholders Equity - Stock Option Activity" } } }, "localname": "DisclosureStockholdersEquityAbstract", "nsuri": "http://biontech.com/20220930", "xbrltype": "stringItemType" }, "bnet_DisclosureSubscriptionReceivableAffiliatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subscription Receivable - Affiliates" } } }, "localname": "DisclosureSubscriptionReceivableAffiliatesAbstract", "nsuri": "http://biontech.com/20220930", "xbrltype": "stringItemType" }, "bnet_EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan [Member]" } } }, "localname": "EquityIncentivePlanMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_EquityIssuancesWarrantsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "EquityIssuancesWarrantsPolicyPolicyTextBlock", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bnet_ExecutiveViceChairmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Executive Vice Chairman [Member]" } } }, "localname": "ExecutiveViceChairmanMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ExerciseBonus": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise bonus" } } }, "localname": "ExerciseBonus", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_ExtensionBonusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Extension Bonus [Member]" } } }, "localname": "ExtensionBonusMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_FinancingReceivableInterestRateStatedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing Receivable, Interest Rate, Stated Percentage" } } }, "localname": "FinancingReceivableInterestRateStatedPercentage", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_FinancingReceivablePrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Financing Receivable, Principal Amount" } } }, "localname": "FinancingReceivablePrincipalAmount", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_FormerEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Former Employee [Member]" } } }, "localname": "FormerEmployeeMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_Fy2016ExtensionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fy 2016 Extension Agreement [Member]" } } }, "localname": "Fy2016ExtensionAgreementMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_GainOnSaleOfDomainAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain on sale of domain" } } }, "localname": "GainOnSaleOfDomainAmount", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_InterestBearingSecuredPromissoryNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest bearing secured promissory note" } } }, "localname": "InterestBearingSecuredPromissoryNote", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_InterestExpenseOnDeferredCompensationObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Expense On Deferred Compensation Obligation [Member]" } } }, "localname": "InterestExpenseOnDeferredCompensationObligationMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_InterestExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest expenses" } } }, "localname": "InterestExpenses", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_InterestRateOnDeferredCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Rate on Deferred Compensation" } } }, "localname": "InterestRateOnDeferredCompensation", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_LessImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Less imputed interest" } } }, "localname": "LessImputedInterest", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_MinorityInterestPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling interests" } } }, "localname": "MinorityInterestPolicyPolicyTextBlock", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bnet_MonthlyOfficersCashCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Monthly Officers Cash Compensation" } } }, "localname": "MonthlyOfficersCashCompensation", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_NetIncomeLossApplicableToBionsCommonStockholdersPerBasicAndDilutedCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss applicable to Bion's common stockholders per basic and diluted common share" } } }, "localname": "NetIncomeLossApplicableToBionsCommonStockholdersPerBasicAndDilutedCommonShare", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "bnet_NonCashCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non cash compensation" } } }, "localname": "NonCashCompensation", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_NorthropMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Northrop [Member]" } } }, "localname": "NorthropMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_NotesReceivableInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Notes receivable interest" } } }, "localname": "NotesReceivableInterest", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_OperatingLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Operating loss" } } }, "localname": "OperatingLoss", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_PA1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "P A 1 [Member]" } } }, "localname": "PA1Member", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PennvestLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pennvest Loan [Member]" } } }, "localname": "PennvestLoanMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PercentageOfSustainable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of sustainable" } } }, "localname": "PercentageOfSustainable", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "percentItemType" }, "bnet_Plan2006Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Plan 2006 [Member]" } } }, "localname": "Plan2006Member", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PreferredStockConvertibleOptionPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock, Convertible Option Per Share (in dollars per share)" } } }, "localname": "PreferredStockConvertibleOptionPerShare", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_PrincipalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Principal [Member]" } } }, "localname": "PrincipalMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_ProceedsFromSaleOfUnits": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from sale of units" } } }, "localname": "ProceedsFromSaleOfUnits", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_PropertyPlantAndEquipmentOfPA1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment Of P A 1 [Member]" } } }, "localname": "PropertyPlantAndEquipmentOfPA1Member", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_PurchaseOfPropertyAndEquipmentForAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Purchase of property and equipment for accounts payable" } } }, "localname": "PurchaseOfPropertyAndEquipmentForAccountsPayable", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_RedemptionOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemption of convertible Preferred stock" } } }, "localname": "RedemptionOfConvertiblePreferredStock", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_RibbonwireMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ribbonwire [Member]" } } }, "localname": "RibbonwireMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SaleOfDomainDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale of domain, description" } } }, "localname": "SaleOfDomainDescription", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "bnet_SaleOfUnitPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale of unit, price per unit" } } }, "localname": "SaleOfUnitPricePerUnit", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "bnet_SaleOfUnitsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale of units, shares" } } }, "localname": "SaleOfUnitsShares", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bnet_SaleOfUnitsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Sale of units" } } }, "localname": "SaleOfUnitsValue", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_SchaferMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schafer [Member]" } } }, "localname": "SchaferMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member]" } } }, "localname": "SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secured Promissory Note [Member]" } } }, "localname": "SecuredPromissoryNoteMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_September2015ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September 2015 Convertible Notes [Member]" } } }, "localname": "September2015ConvertibleNotesMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SharebasedCompensationGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Granted" } } }, "localname": "SharebasedCompensationGranted", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_ShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder [Member]" } } }, "localname": "ShareholderMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SharesHeldBySubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Held by Subsidiaries (in shares)", "negatedLabel": "Shares held by subsidiaries (Note 7)" } } }, "localname": "SharesHeldBySubsidiaries", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bnet_SharesIssuedBeginningOfPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued \u2013 beginning of period" } } }, "localname": "SharesIssuedBeginningOfPeriod", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_SharesIssuedForAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shares issued for accounts payable" } } }, "localname": "SharesIssuedForAccountsPayable", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_SharesIssuedForWarrantExerciseCommissions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued for warrant exercise commissions" } } }, "localname": "SharesIssuedForWarrantExerciseCommissions", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bnet_SharesOutstandingBeginningOfPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares outstanding \u2013 beginning of period" } } }, "localname": "SharesOutstandingBeginningOfPeriod", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_SmithMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Smith [Member]" } } }, "localname": "SmithMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SmithsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Smiths [Member]" } } }, "localname": "SmithsMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_SockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "SockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "bnet_SubscriptionReceivableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSCRIPTION RECEIVABLE - AFFILIATES" } } }, "localname": "SubscriptionReceivableTextBlock", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-Affiliates" ], "xbrltype": "textBlockItemType" }, "bnet_SubscriptionsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subscriptions Receivable [Member]" } } }, "localname": "SubscriptionsReceivableMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "bnet_Techwastage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tech wastage" } } }, "localname": "Techwastage", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "decimalItemType" }, "bnet_The2020ConvertibleObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The 2020 Convertible Obligations [Member]" } } }, "localname": "The2020ConvertibleObligationsMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_TwoConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Consultants [Member]" } } }, "localname": "TwoConsultantsMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_UndiscountedCashFlow": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Undiscounted cash flow" } } }, "localname": "UndiscountedCashFlow", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantExercisedForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "WarrantExercisedForCommonStock", "verboseLabel": "Warrant Exercised for Common Stock" } } }, "localname": "WarrantExercisedForCommonStock", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsExercisedForCommonShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares" } } }, "localname": "WarrantsExercisedForCommonShares", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsExercisedForCommonSharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares , shares" } } }, "localname": "WarrantsExercisedForCommonSharesShares", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bnet_WarrantsExercisedForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrant Exercised for Common Stock" } } }, "localname": "WarrantsExercisedForCommonStock", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsExpiringOnDecember312025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Expiring On December 312025 [Member]" } } }, "localname": "WarrantsExpiringOnDecember312025Member", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsHeldByTrustOwned": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Warrants held by trust owned" } } }, "localname": "WarrantsHeldByTrustOwned", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member]" } } }, "localname": "WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsIssusedSubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Issused Subscription Receivable [Member]" } } }, "localname": "WarrantsIssusedSubscriptionReceivableMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_WeightedAverageSharesIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares issued \u00a0\u00a0\u00a0\u00a0during the period" } } }, "localname": "WeightedAverageSharesIssuedDuringPeriod", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "bnet_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Working Capital" } } }, "localname": "WorkingCapital", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bnet_YearsOneThroughFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Years One Through Five [Member]" } } }, "localname": "YearsOneThroughFiveMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "bnet_YearsSixThroughMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Years Six Through Maturity [Member]" } } }, "localname": "YearsSixThroughMaturityMember", "nsuri": "http://biontech.com/20220930", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r480", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biontech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r40", "r42", "r86", "r87", "r213", "r250" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r186", "r188", "r189", "r190", "r212", "r249", "r268", "r270", "r396", "r397", "r398", "r399", "r400", "r401", "r420", "r452", "r453", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r186", "r188", "r189", "r190", "r212", "r249", "r268", "r270", "r396", "r397", "r398", "r399", "r400", "r401", "r420", "r452", "r453", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_PresidentMember": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "label": "President [Member]" } } }, "localname": "PresidentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r179", "r186", "r188", "r189", "r190", "r212", "r249", "r265", "r268", "r270", "r301", "r302", "r303", "r396", "r397", "r398", "r399", "r400", "r401", "r420", "r452", "r453", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r179", "r186", "r188", "r189", "r190", "r212", "r249", "r265", "r268", "r270", "r301", "r302", "r303", "r396", "r397", "r398", "r399", "r400", "r401", "r420", "r452", "r453", "r466", "r467" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r41", "r42", "r86", "r87", "r213", "r250" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r99", "r269" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r99", "r103", "r184", "r269" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r99", "r103", "r184", "r269", "r388" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r149", "r381" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26", "r385" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to underwriters, promoters, and employees excluding salaries, wages and amount to related party, classified as current.", "label": "Salaries and wages" } } }, "localname": "AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r430", "r449" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued interest" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r9", "r175" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r385" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r91", "r92", "r93", "r310", "r311", "r312", "r349" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r208", "r254", "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Issuance of warrants for services", "verboseLabel": "Issuance of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r10", "r85", "r135", "r138", "r144", "r157", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r329", "r335", "r351", "r383", "r385", "r424", "r442" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r25", "r85", "r157", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r329", "r335", "r351", "r383", "r385" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Options" } } }, "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r273", "r274", "r275", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r297", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r174" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and structures" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesContingentRentalPaymentsDue": { "auth_ref": [ "r367" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount due based upon the occurrence of an event specified in the contractual terms.", "label": "Total" } } }, "localname": "CapitalLeasesContingentRentalPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalRequiredForCapitalAdequacy": { "auth_ref": [ "r438", "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum total risk-based capital required for capital adequacy as defined by regulatory framework.", "label": "Capital Required for Capital Adequacy" } } }, "localname": "CapitalRequiredForCapitalAdequacy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r7", "r385", "r459", "r460" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r66", "r72", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of year", "periodStartLabel": "Cash at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r66", "r352" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net decrease in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r7" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r15", "r16", "r17", "r83", "r85", "r107", "r108", "r113", "r116", "r117", "r121", "r122", "r123", "r157", "r196", "r200", "r201", "r202", "r205", "r206", "r247", "r248", "r251", "r252", "r254", "r351", "r485" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r258", "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercisable per share", "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r180", "r181", "r182", "r191", "r462" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r91", "r92", "r349" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": { "auth_ref": [ "r17" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription receivable from investors who have been allocated common stock.", "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable", "negatedLabel": "Subscription receivable - affiliates (Note 8)" } } }, "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r385" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, no par value, 250,000,000 shares authorized, 44,303,654 and 43,758,820 shares issued, respectively; 43,599,345 and 43,054,511 shares outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r126", "r440" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r79", "r331" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r174" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "3G project construction in process" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionLoan": { "auth_ref": [ "r11" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans.", "label": "Construction Loan" } } }, "localname": "ConstructionLoan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r207", "r209", "r210", "r212", "r222", "r223", "r224", "r228", "r229", "r230", "r231", "r232", "r239", "r240", "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r34" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable - affiliates (Note 6)", "verboseLabel": "Convertible Notes Payable, Noncurrent" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r13", "r427", "r444", "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsIncurredDevelopmentCosts": { "auth_ref": [ "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities.", "label": "Capitalized amount" } } }, "localname": "CostsIncurredDevelopmentCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r75", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion value", "verboseLabel": "Debt instrument paid amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt conversion shares, warrants", "verboseLabel": "Debt conversion shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "Debt Instrument, Debt Default, Amount" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r82", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r226", "r233", "r234", "r236", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "LOANS PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/LoansPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r13" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Debt Instrument, Annual Principal Payment" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r11", "r12", "r13", "r84", "r89", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r222", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r239", "r240", "r241", "r242", "r364", "r425", "r427", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r211", "r237" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Original conversion price", "verboseLabel": "Conversion price per share" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r33", "r229", "r362" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r33", "r210" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r34", "r84", "r89", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r222", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r232", "r239", "r240", "r241", "r242", "r364" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r34", "r437" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Principal, interest" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r262", "r264" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred compensation (Note 4)", "verboseLabel": "Deferred compensation liability" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits and other assets" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r70", "r173" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations", "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r70", "r173" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r88", "r342", "r343", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r272", "r273", "r305", "r306", "r308", "r314" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "DEFERRED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r12", "r14", "r426", "r443" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r257", "r436" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Share-based Payment Arrangement, Expense" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r46", "r47", "r48", "r91", "r92", "r93", "r95", "r100", "r102", "r120", "r158", "r254", "r257", "r310", "r311", "r312", "r322", "r323", "r349", "r353", "r354", "r355", "r356", "r357", "r358", "r378", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r152", "r153", "r154", "r155", "r156", "r159", "r160", "r161", "r162", "r164", "r165", "r166", "r167", "r168", "r235", "r253", "r348", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r485", "r486", "r487", "r488", "r489", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnSecuritizationOfFinancialAssets": { "auth_ref": [ "r52", "r53", "r70", "r392", "r431", "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A gain (loss) realized on a transfer, accounted for as a sale, of all or a portion of financial assets in which the transferor surrenders control and receives consideration other than a beneficial interest in the assets transferred. Reflects the amount of sales proceeds in excess of, or deficient from, the sum of the carrying amounts of transferred financial assets plus transaction costs.", "label": "Realized from the asset sale", "verboseLabel": "Gain (Loss) on Securitization of Financial Assets" } } }, "localname": "GainLossOnSecuritizationOfFinancialAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r70", "r243", "r244" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on legal dissolution of subsidiary" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative (including stock-based compensation)" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Patents" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r70", "r172", "r177" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r55", "r71", "r96", "r97", "r98", "r99", "r114", "r117", "r327" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Net income" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r45", "r316", "r317", "r318", "r319", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income (Loss) per share" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r69" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (decrease) in accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r69" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase in deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r69", "r371" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Decrease in operating lease assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r69" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Decrease (increase) in prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCostsCapitalized": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest capitalized during the period.", "label": "Capitalized interest" } } }, "localname": "InterestCostsCapitalized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r49", "r134", "r360", "r363", "r433" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense", "verboseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r57", "r230", "r238", "r241", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r54" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "negatedLabel": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r64", "r67", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r70" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Stock-based compensation for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Discounted rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r374", "r375", "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lease Accounting" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r30", "r85", "r139", "r157", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r330", "r335", "r336", "r351", "r383", "r384" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r85", "r157", "r351", "r385", "r429", "r447" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r6", "r32", "r85", "r157", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r330", "r335", "r336", "r351", "r383", "r384", "r385" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liability", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r11", "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Loans as a liability", "verboseLabel": "Line of Credit, Current" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loan payable and accrued interest (Note 5)" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermConstructionLoanCurrent": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the current portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.", "label": "Loan related to construction" } } }, "localname": "LongTermConstructionLoanCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r89", "r194", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r89", "r194", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r89", "r194", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r34", "r195" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r183", "r185", "r186", "r187", "r188", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r174" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r39", "r85", "r157", "r196", "r200", "r201", "r202", "r205", "r206", "r351", "r428", "r446" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling interest, ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r66" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r66" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r66", "r68", "r71" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r43", "r44", "r48", "r50", "r71", "r85", "r94", "r96", "r97", "r98", "r99", "r101", "r102", "r114", "r135", "r137", "r140", "r143", "r145", "r157", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r350", "r351", "r432", "r450" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r43", "r44", "r48", "r101", "r102", "r333", "r338" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to the noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r96", "r97", "r98", "r99", "r104", "r105", "r115", "r117", "r135", "r137", "r140", "r143", "r145" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss applicable to Bion's common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r106", "r109", "r110", "r111", "r112", "r115", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing transactions:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r91", "r92", "r93", "r257", "r325" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r150", "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "Financing Receivable, after Allowance for Credit Loss, Total" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r135", "r137", "r140", "r143", "r145" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r369" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r368" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInFourYears": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the fourth year from the balance sheet date under an operating lease.", "label": "Year ended June 30, 2025" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInFourYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the third year from the balance sheet date under an operating lease.", "label": "Year ended June 30, 2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Future rental payments receivable within the second year from the balance sheet date under an operating lease.", "label": "Year ended June 30, 2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r340" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r38", "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "Additional paid amount" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r71" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Accrued interest on loans payable, deferred compensation and other" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (income) expense:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "auth_ref": [ "r62" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.", "label": "Payments for Repurchase of Warrants", "negatedLabel": "Commissions on exercise of warrants" } } }, "localname": "PaymentsForRepurchaseOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r273", "r274", "r275", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r297", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r273", "r274", "r275", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r297", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r83", "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred stock, liquidation" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r247" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)", "verboseLabel": "Par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r246", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Preferred Stock, Redemption Price Per Share (in dollars per share)" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r247" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding (in shares)", "verboseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16", "r385" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r23", "r169", "r170" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r61" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r43", "r44", "r48", "r65", "r85", "r94", "r101", "r102", "r135", "r137", "r140", "r143", "r145", "r157", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r328", "r332", "r334", "r338", "r339", "r350", "r351", "r434" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r178", "r463", "r464", "r465" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r8", "r174" ], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r176", "r385", "r435", "r448" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net (Note 3)" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherNet": { "auth_ref": [], "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other, Net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentOtherNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r176", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r267", "r379", "r380", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt, Total" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r315", "r421", "r468" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development (including stock-based compensation)" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r257", "r385", "r445", "r457", "r458" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r91", "r92", "r93", "r95", "r100", "r102", "r158", "r310", "r311", "r312", "r322", "r323", "r349", "r454", "r456" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r132", "r133", "r136", "r141", "r142", "r146", "r147", "r148", "r259", "r260", "r422" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary paid" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Sale of Stock, Consideration Received Per Transaction", "verboseLabel": "Proceeds from sale of units" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "verboseLabel": "Sale of units" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of units, price per unit" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of anti dilutive securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r261", "r263" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.", "label": "Schedule of future minimum lease payments" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r277", "r292", "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r15", "r16", "r254" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r15", "r16", "r254" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r15", "r16", "r254" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r69" ], "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation", "verboseLabel": "Cash compensation paid" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Stock options, authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Expired, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Forfeited, options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Granted", "verboseLabel": "Number of shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Share-based Compensation, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r309" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Outstanding, aggregate intrinsic value ending", "periodStartLabel": "Outstanding, aggregate intrinsic value beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding, ending (in shares)", "periodStartLabel": "Options outstanding, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Weighted average exercise price", "periodEndLabel": "Options outstanding, ending weighted-average exercise price", "periodStartLabel": "Options outstanding, beginning weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r273", "r274", "r275", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r297", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r276", "r298", "r299", "r300", "r301", "r304", "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "verboseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted-average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Fair value of stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "verboseLabel": "Number of shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Share price", "verboseLabel": "Sale of units, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r78", "r90" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r16", "r17", "r83", "r85", "r107", "r108", "r113", "r116", "r117", "r121", "r122", "r123", "r157", "r196", "r200", "r201", "r202", "r205", "r206", "r247", "r248", "r251", "r252", "r254", "r351", "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r36", "r46", "r47", "r48", "r91", "r92", "r93", "r95", "r100", "r102", "r120", "r158", "r254", "r257", "r310", "r311", "r312", "r322", "r323", "r349", "r353", "r354", "r355", "r356", "r357", "r358", "r378", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r91", "r92", "r93", "r120", "r422" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r35", "r227", "r254", "r255", "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of debt and liabilities, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of units for services, shares", "verboseLabel": "Shares issued for consultant services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r254", "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r254", "r257", "r283" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercised, options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r36", "r254", "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of debt and liabilities" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of units for services", "verboseLabel": "Total value of consultant services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r254", "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Number of shares issued, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format.", "label": "Expiry date" } } }, "localname": "StockRepurchaseProgramExpirationDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r20", "r21", "r85", "r151", "r157", "r351", "r385" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "negatedLabel": "Stockholders deficit", "totalLabel": "Total Bion's stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bion's stockholders' equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r47", "r85", "r91", "r92", "r93", "r95", "r100", "r157", "r158", "r257", "r310", "r311", "r312", "r322", "r323", "r325", "r326", "r337", "r349", "r351", "r353", "r354", "r358", "r378", "r455", "r456" ], "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r359", "r387" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r359", "r387" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r359", "r387" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r359", "r387" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r386", "r389" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r152", "r153", "r154", "r155", "r156", "r235", "r253", "r348", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r485", "r486", "r487", "r488", "r489", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r124", "r125", "r127", "r128", "r129", "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r106", "r117" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted weighted average shares \u2013 \u00a0\u00a0\u00a0\u00a0end of period" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The average number of limited partnership and general partnership units issued and outstanding that are used in calculating basic and diluted earnings per limited partnership and general partnership unit.", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e639-108305" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=6435544&loc=d3e41834-113960" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r389": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62014-109447" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)(1)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958570-112826" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r469": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r470": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r471": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r472": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r473": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r474": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r475": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r476": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r477": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r478": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r479": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r480": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r481": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r482": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r483": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r484": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r485": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r486": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r487": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r488": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r489": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r490": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r491": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r492": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r493": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r494": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r495": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.T)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868742-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" } }, "version": "2.1" } ZIP 54 0001079973-22-001425-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-22-001425-xbrl.zip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end